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ABSTRACT 
 
 Herpes simplex virus type 1 (HSV-1) is a DNA virus that is a ubiquitous pathogen of 
humans. The hallmark of the HSV-lifecycle is infection of a mucosal surface with spread 
to sensory neurons where the virus establishes a latent infection with periodic recurrences 
for the life of the host. The most common course of symptomatic disease with HSV-1 is 
the typical mucocutaneous lesion that is self-limiting. HSV-1 can also cause acute 
encephalitis and ocular pathology on reactivation.  Both of these manifestations of the 
disease have severe consequences. Although ocular infection is less frequent, the 
extensive prevalence of HSV makes it one of the most common infectious causes of 
blindness in developed countries. Herpetic encephalitis causes significant morbidity and 
mortality, particularly in the immunosuppressed or untreated individual. HSV-1 specifies 
at least 11 glycoproteins that are expressed in the infected cells. The viral glycoproteins 
are the first interface of the virus with a host cell and are therefore vitally important to 
virus pathogenesis. Glycoproteins B, C, D, H, and L have been extensively studied and 
found to be involved in initial attachment, fusion, and entry of the virus into a host cell.  
Recent work in this laboratory has shown that glycoprotein K (gK) is also involved in the 
fusion machinery of the virus, however, little was known about the role of gK in the 
pathogenesis of the virus. To assess the role of gK in pathogenesis, mutant viruses were 
used an experimental infection in a mouse eye model. In this investigation, gK was found 
to have a critical role in the pathogenesis of the virus in the eye as well as in spread of the 
infection to neurons and subsequent development of latency. Following this work, a 
primary neuronal culture system was established to further define the role that gK played 
in neuronal infection and transport. Using this system, gK was found to be a critical 
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determinant for neuronal transport and pathology. Since gK deficient viruses appear 
unable to infect neurons, defining this phenotype may assist in the eventual development 









STATEMENT OF PROBLEM AND HYPOTHESIS 
 
Herpes Simplex Viruses (HSV) are ubiquitous and represent the etiologic agents 
responsible for a multitude of human ailments including mucocutaneous oral and genital 
diseases, ocular disease, and viral encephalitis.  The hallmark of the HSV-lifecycle is 
infection of a mucosal surface with spread to sensory neurons where the virus establishes 
a latent infection with periodic recurrences for the life of the host (Whitley, Kimberlin et 
al. 1998a). The most common course of symptomatic disease with HSV-1 is the typical 
oral mucocutaneous lesion that is self-limiting.  Disease with HSV-1 is often considered a 
quality of life issue rather than a potentially severe infection.  However, HSV-1 can also 
cause acute encephalitis and ocular pathology on reactivation and the impact of HSV can 
be significant on healthy individuals as well as immunosuppressed people (Whitley 
2001b).  Although ocular infection is less frequent than mucocutaneous infection, the 
marked prevalence of HSV in the population makes it one of the most common infectious 
causes of blindness in developed countries (Liesegang, Melton et al. 1989a; Liesegang 
2001). During the life cycle of HSV in its host, there are a number of distinct events 
including initial attachment of the virus to a host cell membrane, fusion and entry of the 
virus, viral protein and DNA production, assembly of capsids and DNA packaging of the 




cell.  Many of these individual facets of the virus life cycle are areas of intense 
investigation. In many cases the constituents of this process are known.  Herpes simplex 
virus has a relatively large genome, for a virus, with approximately 152,000 bases (Kieff, 
Bachenheimer et al. 1971).  This allows HSV-1 to encode approximately 90 known gene 
products and at least 84 transcriptional units participating in the production of proteins 
(Roizman, Knipe et al. 2007).  
In particular, HSV-1 specifies at least 11 glycoproteins that are expressed in the 
infected cells (Roizman and Knipe 2001a).  The viral glycoproteins are the first interface 
of the virus with a host cell and are therefore vitally important to virus pathogenesis. 
Glycoproteins B, C, D, H, and L have been extensively studied and found to be involved 
in initial attachment, fusion, and entry of the virus into a host cell (Furth, Whitbeck et al. 
1997; Whitbeck, Peng et al. 1997; Laquerre, Argnani et al. 1998; Warner, Geraghty et al. 
1998; Krummenacher, Rux et al. 1999; Whitbeck, Muggeridge et al. 1999). These 
proteins can control host cell range and even species range of infection.  
The dogma often encountered with viruses with large genomes and many encoded 
proteins is one of, one protein equals one function or one area of function, such as virion 
attachment, entry, assembly, or egress.  However, smaller viruses with smaller genomes 
often have multifunctional proteins.   In HSV, glycoprotein K (gK) appears to be 
multifunctional. Glycoprotein K has been shown to have roles in virion egress, 
envelopment, and viral fusion and syncytia formation (Ruyechan, Morse et al. 1979; 
Bond and Person 1984; Pogue-Geile, Lee et al. 1984; Debroy, Pederson et al. 1985; 
Jayachandra, Baghian et al. 1997; Laquerre, Argnani et al. 1998; Foster, Melancon et al. 




2010; Chouljenko, Kim et al. 2012).  Recent work in this laboratory (cited above) has 
shown that glycoprotein K (gK) is also involved in the fusion machinery of the virus, 
however, little was known about the role of gK in the pathogenesis of the virus.  The 
overall hypothesis of the investigations described in this thesis, has been that gK plays a 
significant role in viral pathogenesis.  This hypothesis predicts that due to its many and 
varied effects in the virus, a virus lacking gK will have a significant negative impact on 
the pathogenesis of the virus in neurons and by extension ocular disease.  
 
STATEMENT OF RESEARCH OBJECTIVES 
 
The goal of this research was to investigate the role of Herpes Simplex Virus Type 1  
glycoprotein K (gK) in relation to viral pathogenesis in the eye, nervous system and 
individual neurons.  The specific aims of this research were: 
 
1. To assess the virulence and replication characteristics of gK-null viruses in 
cell culture and the mouse eye model.  
2. To develop a reproducible primary cell culture system amenable to 
examination via microscopy and molecular techniques such as PCR.  
3. To use the system developed in aim 2 to examine specific role of gK in 
neuronal infection and anterograde and retrograde transport in neurons 






Overall, the results obtained from this research indicate that: 
1.  Glycoprotein K is critical to spread in the eye and for spread, 
neuroinvasiveness, and the establishment of latency in an animal. 
2.  Glycoprotein K is a critical determinant in the infection of neurons at the level 
of the axonal terminus. 
3.  Glycoprotein K is necessary for spread of the virus from a neuron to epithelial 
cells in an anterograde manner.  
 
The work is presented in individual chapters in a manuscript format having a specific title 
for the central theme of each chapter. 
 
Chapter 2: The Herpes Simplex Virus Type-1(HSV-1) Glycoprotein K(gK) is Essential 
for Viral Corneal Spread and Neuroinvasiveness. 
Chapter 3: A Mutant Herpes Simplex Virus Type-1 (HSV-1) McKrae Lacking the Glycoprotein 





History of Herpesviruses 
Herpes was possibly first described in descriptions of lesions as early as the third 
millennium BCE in a Sumerian tablet and the Ebers papyrus, 1500 BCE (Whitley 2001a).  




crawls along the skin (Wildy 1973) and Pliny (the Elder) mentioned a syndrome that 
could likely be shingles and called this syndrome “zoster” (Beswick 1962).  These lesions 
could have been the result of herpesvirus, other cutaneous infections or even cutaneous 
neoplasms; however, herpes has been part of the human experience since prior to 
recorded history.  The three primary subfamilies of mammalian herpesviruses are 
projected to have arisen about 200 million years ago and the two types of simplex virus 
diverged as much as eight to ten million years ago, yet Homo sapiens sapiens are only 
approximately 200,000 years old (McGeoch, Dolan et al. 1985; Gentry, Rana et al. 1988). 
Herodotus is credited with realizing the association of fever and cutaneous lesions 
in HSV (Whitley 2001a).  While the Greek physician Galen recognized that recurrent 
HSV lesions develop at the same sites in the second century A.D. (Whitley 2001a).  By 
the 18th century, study of the virus had progressed and the first description of genital 
disease associated with herpes virus was published in De Morbis Veneris by John Astruc, 
physician for King Louis XIV of France, after studying French prostitutes (Puellae 
publicae) (Astruc 1736).  In 1814, Bateman accurately describes both herpes labialis and 
herpes preputialis as vesicular to ulcerative diseases often with heat, tingling, and pain 
associated with the vesicles and spontaneous resolution and reoccurrence of the disease 
(Bateman 1814).  In the late 19th century, Vidal demonstrated that inocula from lesions 
could transmit vesicular lesions from patient-to-patient and from one anatomic area to 
another on the same patient, thereby proving the infectious nature of the virus (Vidal 
1873; Longson 1978).  Gruter, using rabbit studies, rather than human, showed that HSV 
could be transmitted from one rabbit to another in likely the first use of an animal model 




by most of the virology community.  In 1930, Andrewes and Carmichael showed that 
recurrent disease could occur in people with significant levels of neutralizing antibodies, 
which was contrary to popular beliefs in virology at the time (Andrewes 1928; Andrewes 
1929; Andrewes and A. 1930). 
By 1939, Burnet and Williams had resolved much of the current view on herpetic 
latency; that the virus remains latent but various stimuli may awaken it from the latent 
state to cause recurrence and lesions (Burnet 1939).  As tissue culture techniques 
emerged and evolved, isolation of other families of human herpesviruses became 
possible. During the 1950’s, Varicella Zoster Virus (VZV, chickenpox) and 
Cytomegalovirus (CMV) were isolated (Weller and Stoddard 1952; Rowe, Hartley et al. 
1956; Craig, Macauley et al. 1957).  By the end of the 1990’s T-cell lymphocyte culture 
allowed the isolation of Human Herpesviruses 6A, 6B and 7 and Representational 
Differential Analysis allowed the isolation of Human Herpesvirus 8 (Salahuddin, Ablashi 
et al. 1986; Lopez, Pellett et al. 1988; Frenkel, Schirmer et al. 1990; Chang, Cesarman et 
al. 1994). In 1962, Schneweiss demonstrated two distinct serotypes of Human 
Herpesvirus (Schneweiss 1962).  In 1971, the first International Committee on Taxonomy 
of Viruses (ICTV) established the genus of Herpesvirus and by 1979 the committee had 
elevated the herpesviruses to a family (Herpesviridae) and established the two serotypes 
of herpes simplex virus (HSV) as Human Herpesvirus 1 and 2 (Davison 2010). 
 
Taxonomy of Herpesviridae 
Initially, identification of viruses, including Herpesviruses, was based on 




of disease and character of lesions.  Developing technologies have shaped the 
classification of viruses. With electron microscopy, Herpesviruses could be classified on 
the basis of morphology.  Biologic and chemical tests also allowed for characterization of 
a virus based on antigens and biochemical properties.  Therefore, all herpesviruses have 
an icosahedral capsid of 162 capsomeres that surrounds a core filled with DNA and the 
capsid is surrounded by a protein-rich tegument and a lipid envelope (Davison 2010).  
Furthermore, biologic properties, like the establishment of latent infection in the natural 
host, were included in the initial classification of herpesviruses into the Herpesviridae 
family by the ICTV in 1979 (Matthews 1979; Davison 2010).  Features of natural host 
species, cell types infected, reproductive cycle, and antigens were used to further 
subdivide the herpesviruses into the subfamilies of Alpha-, Beta- and 
Gammaherpesvirinae (Roizman 1973; Roizmann, Desrosiers et al. 1992; Van 
Regenmortel, Fauquet et al. 2000).  During this time, a formal system for naming 
herpesviruses was founded with various changes occurring over the following years, but 
maintaining that herpesviruses are named after the family or subfamily to which the 
primary host belongs; with the notable exception that human herpesviruses would 
maintain human as a designation rather than hominid (Roizman 1973; Fenner 1976; 
Matthews 1979; Roizman, Carmichael et al. 1981; Francki, Faquet et al. 1991; 
Roizmann, Desrosiers et al. 1992; Davison 2010).  Since the ancestral Herpesvirinae 
subfamilies are projected to have appeared about 200 million years ago, it is not 
surprising that DNA analysis has found many distantly related species of viruses in 
animals (McGeoch, Dolan et al. 1985).  With the discovery of many new herpesviruses, 




contains three families: Herpesviridae, containing the viruses of mammals, birds and 
reptiles; Alloherpesviridae, containing viruses of bony fish and frogs; and 
Malacoherpesviridae, containing the bivalve herpes virus OsHV1 (Davison 2010).  The 
family Herpesviridae now contains the subfamilies of Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae.  Type 1 simplex virus is an 
alphaherpesvirus.  
 Due to the relatively rapidly mutating nature of viruses a couple definitions are 
helpful to consider when discussing taxonomy of a virus.  The ICTV defines virus 
species as “a polythetic class of viruses that constitutes a replicating lineage and occupies 
a particular ecological niche” (Van Regenmortel 1990).  Herpes viruses are considered a 
distinct species if “(a) their genomes differ in a readily assayable and distinctive manner 
across the entire genome and not merely at a specific site, and (b) if the virus can be 
shown to have distinct epidemiologic and biologic characteristics” (Roizmann, Desrosiers 
et al. 1992).  Members of the Alphaherpesvirinae subfamily have the following features 
in common: variable host range, a generally short reproductive cycle in primary host, 
rapid reproduction and spread in permissive tissue cultures, efficient lysis of infected 
non-neuronal cells, and the ability to establish latent infections in neuronal cells, 
primarily in sensory ganglia. The genera Simplexvirus (including HSV-1), 
Varicellovirus, Marek’s disease-like virus, and Infectious laryngotracheitis-like virus are 
members of the Alphaherpesvirinae subfamily (Roizmann, Desrosiers et al. 1992; Van 
Regenmortel, Fauquet et al. 2000).  Members of the Betaherpesvirinae subfamily have 
the following features in common: a more restricted host range, long reproductive cycle 




(infected cells becoming enlarged) and latency is usually maintained in secretory glands, 
lymphoreticular cells or kidneys.  Cytomegalovirus, Muromegalovirus, and Roseolovirus 
are members of the Betaherpesvirinae subfamily (Van Regenmortel, Fauquet et al. 2000). 
Members of the Gammaherpesvirinae subfamily share the following characteristics:  the 
host range is limited to the family or order of the natural host, these viruses replicate in 
lymphoblastoid cells in cell culture, some members of the subfamily cause lytic infection 
in epithelial and fibroblastic cells, usually specific for either B or T lymphocytes, and 
viral latency is usually maintained in lymphoid tissue. Lymphocryptovirus (EBV-Epstein 
Barr virus), and Rhadinovirus are members of the Gammaherpesvirinae subfamily (Van 
Regenmortel, Fauquet et al. 2000).  Table 1.1 shows the family classification and 
common names of the nine known human herpesviruses (denoted by an *) as well as 
other commonly studies herpesviruses. 
 
Table 1.1:  The taxonomic classification of the nine known human herpesviruses 
(denoted by *) as well as other commonly studied herpesviruses; adapted from 
(Roizmann, Desrosiers et al. 1992; Van Regenmortel, Fauquet et al. 2000). 
 
Table 1.1 Notable members of the Herpesviridae family 
Subfamily Designation Vernacular Name 
Alpha- Human herpesvirus 1 (HHV-1)* Herpes simplex virus type 1 (HSV-1) 
  herpes- Human herpesvirus 2 (HHV-2)* Herpes simplex virus type 2 (HSV-2) 
  virinae Human herpesvirus 3 (HHV-3)* Varicella-zoster virus (VZV), chicken pox, shingles 
 Cercopithecine herpesvirus 1 (CeHV-1) Herpesvirus B, Simian Herpesvirus 
 Gallid herpesvirus 1 (GaHV-1) Infectious laryngotracheitis virus 
 Gallid herpesvirus 2 (GaHV-2) Marek’s disease virus 
 Suid herpesvirus 1 (SuHV-1) Pseudorabies virus, Aujesky’s disease virus 




 Ictalurid herpesvirus 1 (IcHV-1) Channel catfish herpesvirus 
 Bovine herpesvirus 1 (BoHV-1) Infectious bovine rhinotracheitis virus 
 Bovine herpesvirus 2 (BoHV-2) Bovine mammillitis 
 Equid herpesvirus 1 (EHV-1) Equine HV-1, Equine abortion virus 
 Equid herpesvirus 3 (EHV-3) Equine coital exanthema 
 Equid herpesvirus 4 (EHV-4) Equine HV-4, Equine 
rhinopneumonitis virus 
Beta- Human herpesvirus 5 (HHV-5) * Cytomegalovirus (CMV) 
  Herpes- 
  virinae 
Human herpesvirus 6A (HHV-6A) 
* 
 
 Human herpesvirus 6B (HHV-6B) 
* 
Roseolovirus 
 Human herpesvirus 7 (HHV-7) *  
 Murid herpesvirus 1 (MuHV-1) Mouse CMV 
 Murid herpesvirus 2 (MuHV-2) Rat CMV 
 Suid herpesvirus 2 (SuHV-2) Inclusion-body rhinitis virus 
 Cercopithecine herpesvirus 5 
(CeHV-5) 
African green monkey CMV 
 Cercopithecine herpesvirus 8 
(CeHV-8) 
Rhesus monkey CMV 
 Elephantid herpesvirus 1 (ElHV-1) Endotheliotropic elephant 
herpesvirus-1 
Gamma- Human herpesvirus 4 (HHV-4) * Epstein-Barr virus (EBV) 
  Herpes- 
  virinae 
Human herpesvirus 8 (HHV-8) * Kaposi’s sarcoma associated 
herpesvirus (KSHV) 
 Alcelaphine herpesvirus 1 (AlHV-
1) 
Wildebeest herpesvirus, Malignant 
catarrhal fever of European cattle 
 Canid herpesvirus 1 (CaHV-1) Canine herpesvirus 












Organization of the Herpes Viral Genome 
The DNA of herpesviruses is arranged as a linear double strand. Rapidly after 
entry into the nucleoplasm of an infected cell nucleus, the DNA circularizes to form a 
double stranded circle.  Herpesvirus DNA ranges from 120 kilobase pairs (kbp) to 250 
kbp depending on the species of virus (McGeoch, Dalrymple et al. 1988a).  Within 
individual viruses, length of the genome can also vary due to variable copy numbers of 
terminal and internal repeated sequences that can change the length within an individual 
virus by 10 kbp.  Herpes simplex virus DNA is composed of approximately 152,000 
bases with a weight of approximately 100 x 106 Daltons and 67-69% cytosine/guanine 
content (Kieff, Bachenheimer et al. 1971).  Cytosine and guanine content of 
herpesviruses ranges from 31% to 75% across the entire genome (Roizman and Pellett 
2001).  Among the herpesviruses, the architecture of the genome varies in the presence 
and location of reiterated sequences.  In HSV, there are sequences at each terminus of the 
genome that are repeated in an inverted orientation.  These are juxtaposed internally 
within the genome.  The genome is divided into two unique regions, the unique long (UL 
or UL) and unique short (US or US) segments, separated by the apposed internal repeats 
(Fig 1.1) (Roizman, Knipe et al. 2007).  The UL region is approximately 108 kbp and 
encodes at least 56 proteins, while the US region is approximately 13 kbp and encodes 12 
proteins (McGeoch, Dalrymple et al. 1988b).  The repeated segments are designated the 
terminal long and short repeats (TRL and TRS respectively) and the internal long and 
short repeats (IRL and IRS respectively) (Roizman and Pellett 2001).  These four 




isomers that have been demonstrated in infected cells in equivalent populations arranged 
in varying orientations (Roizman and Pellett 2001). 
 
Figure 1.1: Schematic representation of the HSV genome.  Schematic of the typical 
HSV genome showing the relative positions of the terminal repeats designated (TR), the 
unique long and short segments (designated UL and US respectively), and the internal 
repeats both long and short (designated IRL and IRS respectively).  The character of the 
repeats (dotted or full black) denotes the positions of the related repeats. 
 
The structure of most herpesvirus genes is a 50-200 bp promoter region followed 
by a TATA box and an initiation site 20-25 bases downstream from the TATA box. 30-
300 bases later, this is followed by 5’ untranslated leader sequence, a major open reading 
frame, a 3’ untranslated segment 10-30 bases long and a polyadenylation signal with 
flanking sequences (Roizman and Pellett 2001).  Occasionally genes lack the TATA box. 
Most genes in herpesviruses code for a single ORF, however, some have a second in-
frame initiation site (Chou and Roizman 1986; Markovitz, Filatov et al. 1999).  The 
majority of herpesvirus genes are not spliced.  Herpesviruses can also produce noncoding 
RNAs, of which the HSV-1 latency associated transcript (LAT) is an example (Roizman 
and Pellett 2001).  Herpesviruses encode a wide range (from 70-200) genes depending on 
the species of virus, with HSV-1 encoding approximately 90 known gene products and at 
least 84 transcriptional units participating in the production of proteins (Roizman, Knipe 




Herpes Virion Architecture 
Herpes virus virions are composed of four structures: an electron-dense core (that 
contains the DNA), surrounded by an icosadeltahedral capsid composed of proteins, a 
protein-rich zone called the tegument, and an outer lipid envelope that contains 
glycosylated protein spikes (Fig 1.2) (Roizman 1974).  Herpes virions range from 120nm 
to 300nm in diameter with the majority of this variability in size due to the makeup of the 
tegument and the state of the envelope (i.e.; an envelope that is not intact will allow more 
significant changes to the tegument during processing for electron microscopy) (Roizman 
1974).   
 
Figure 1.2: Herpesvirus virion structure. Virions of herpes viruses range from 120nm 
to 300nm in diameter (Roizman and Furlong, 1974).  A virion consists of: an electron-
dense core containing the viral genome, a protein capsid surrounding the core, an 
amorphous, proteinaceous tegument around the capsid, and an envelope derived from 
host cell membranes containing glycoproteins (Roizman and Furlong, 1974).  Figure 







The Core  
The core is the central-most structural component of a herpes virion, visible as an 
electron-dense area in electron micrographs.  This structure is composed of the virus 
DNA packaged in the shape of a torus (doughnut) that has been shown in some herpes 
viruses to be suspended by a proteinaceous spindle that attaches the DNA to the inside 
surface of the capsid and contain a less-dense central cylinder (Falke, Siegert et al. 1959; 
Furlong, Swift et al. 1972; Nazerian 1974).  The toroidal structure is 50 nm high, with an 
inside diameter of 18 nm and an outside diameter of 70 nm (Nazerian 1974).  The 
arrangement of the viral DNA in the torus is unknown.  In a host-cell nucleus, the virus 
DNA is arranged in a double-stranded circle (Roizman and Pellett 2001).  
 
The Capsid 
The capsid of all herpesviruses is composed of 162 capsomere proteins arranged 
in an icosahedron with triangulation symmetry of T=16, icosadeltahedron.  This protein 
shell is approximately 15 nm thick and 126 nm in diameter and contains the DNA.  The 
capsid is made of seven proteins pUL6, pUL17, pUL18, pUL19, pUL25, pUL35 and 
pUL38.  The major capsid protein pUL19 (VP5) is the primary structural subunit of the 
capsid.  This protein is arranged in monomers of 5 or 6 copies, pentons or hexons 
respectively. Of the 162 capsomeres, 150 are identical hexons with a copy of VP26 
attached to the outer face (Baker, Jiang et al. 2006).  Of the remaining 12 capsomeres, 11 
are identical pentons situated at the 5 fold vertices (Zhou, He et al. 1995; Zhou, Chen et 
al. 1999; Newcomb, Thomsen et al. 2003).  The last capsomere is a cylindrical, portal-




This portal functions as the channel for DNA entry into the capsid during encapsidation 
and for DNA release after infection.  This portal is a cylindrical structure composed of 
twelve pUL6 molecules and functions as a channel through which DNA is introduced 
into and released from the capsid.  Capsomeres make direct contact through the base of 
the capsomere.  In addition to the direct contact, there is another component of the capsid, 
a heterotrimeric complex (triplex) that indirectly connects the capsomeres (Newcomb, 
Homa et al. 1999).  The triplex consist of two copies of VP23 and one copy of VP19C 
and acts as a scaffold for the capsid proteins (Spencer, Newcomb et al. 1998).  Another 
protein scaffold for the capsid proteins is pUL26/26.5, however this protein is lost when 
DNA is packaged into the core and is not present in mature virions (Homa and Brown 
1997; Newcomb, Homa et al. 1999). 
Three types of capsids (A, B and C) can be observed by electron microscopy. 
While the outer structures of the capsid are the same, the state of the DNA in the virus 
core and the presence of scaffolding proteins determines the types of capsids observed 
(Homa and Brown 1997).  “A” capsids have a significant lack of DNA and protein in the 
capsid cavity due to failed DNA packaging.  “B” capsids lack viral DNA but have the 
scaffolding proteins.  “C” capsids contain all the viral DNA and scaffolding proteins, 
however, the presence of heterodimers of pUL17 and pUL25 on “C” capsids and not 
mature virions suggests that additional modifications occur during packaging and/or 








The tegument is a proteinaceous region of variable thickness that lies between the 
capsid and envelope. In a mature HSV-1 virion, the tegument contains 24 proteins.  
These proteins are pUL7, pUL11, pUL13, pUL14, pUL16, pUL21, pUL23, pUL36 
(VP1/2), pUL37, pUL41, pUL46 (VP11/12), pUL47 (VP13/14), pUL48 (VP16), pUL49 
(VP22), pUL50, pUL51, pUL55, pUS2, pUS3, pUS10, pUS11, ICP34.5, ICP0, and ICP4 
(Mettenleiter 2004; Loret, Guay et al. 2008; Kelly, Fraefel et al. 2009).  This layer 
appears fibrous on negative staining in electron micrographs and can be asymmetrically 
distributed (Morgan, Rose et al. 1959; Wildy and Watson 1962; Morgan, Rose et al. 
1968).  The asymmetrical distribution and thickness of the tegument appears to be 
dependent on location in the infected cell, with more symmetrical arrangement in peri-
nuclear virions and more asymmetry in virions in cytoplasmic vesicles (Falke, Siegert et 
al. 1959).  Extracellular virions also have asymmetric tegument, however, this may be a 
time-dependent phenomenon with the tegument more symmetrically organized at early 
times after egress (Grunewald, Desai et al. 2003; Newcomb and Brown 2009). 
The tegument proteins are important in multiple stages of the virus life cycle. 
They function in the early stages of infection by recruiting the molecular motors of the 
cell to assist in entry and cellular transport and regulating viral and host gene expression, 
as well as having functions later in infection in virion egress (Kelly, Fraefel et al. 2009). 
The tegument has an ordered density surrounding the pentons of the capsid (Zhou, Chen 
et al. 1999).  This is possibly due to the VP1-3 protein, which is a 336 kDa protein 
involved in nucleocapsid attachment to the nuclear pore and DNA release into the 




et al. 2000).  However, this protein is likely involved in multiple stages of the virus life 
cycle and is not essential for DNA packaging, since null mutants still accumulate DNA-
filled capsids in the cytoplasm of infected cells (Desai 2000).  Only 4 of the 24 tegument 
proteins are essential for growth in cell-culture (pUL36, pUL37, pUL48 and ICP4) 
(Roizman and Knipe 2001b; Mettenleiter 2002b; Loret, Guay et al. 2008; Kelly, Fraefel 
et al. 2009).  Some tegument proteins are expressed in significantly, 1000 fold, greater 
quantities than others and recent investigations of null mutant viruses have shown that 
lack of one protein can often be compensated for by recruitment of other proteins (del 
Rio, DeCoste et al. 2005).  
 
The Envelope 
The envelope is the outer covering of the virus.  The envelope is a lipid bilayer 
composed of altered cellular membranes that have the typical trilaminar appearance of 
lipid bilayers (Falke, Siegert et al. 1959; Armstrong, Pereira et al. 1961; Epstein 1962; 
Morgan, Rose et al. 1968).  The envelope also contains numerous protruding 
glycoprotein spikes as well as non-glycosylated transmembrane proteins and membrane-
associated proteins (Roizman, Knipe et al. 2007).  
HSV-1 specifies at least 11 different glycoproteins, including; gpUL27 (gB), 
gpUL44 (gC), gpUS6 (gD), gpUS8 (gE), gpUS4 (gG), gpUL22 (gH), gpUS7 (gI), gpUS5 
(gJ), gpUL53 (gK), gpUL1 (gL), gpUL10 (gM), and possibly gpUL49A (gN).  These 
glycoproteins are expressed in varying amounts and copy number of a specific 
glycoprotein can exceed 1000 in a single virion.  The glycoproteins form spikes and 
protrusions from the envelope that are variable in length and orientation, however, 




reason for their ordered arrangement (Grunewald, Desai et al. 2003).  The envelope 
glycoproteins gB, gD, gH and gL have been shown to be essential for virion entry into a 
susceptible host cell. Non-glycosylated membrane proteins include pUS9, pUL20 and 
pUL45.  Glycoproteins are important in membrane fusion with susceptible cells and 
mediate interactions with host cell membrane receptors and viral entry (Mettenleiter 
2004).  The envelope proteins interact in a complex manner to determine host-cell 
tropism and initiate entry into host cells.  This is evidenced by the interactions of pUL20 
and gK and subsequent interactions with gB, the primary fusogenic protein (Chouljenko, 
Iyer et al. 2009; Chouljenko, Iyer et al. 2010).  Envelope proteins (notably gC) also play a 
role in modulating the host immune response to infection (Roizman, Knipe et al. 2007). 
Table 1.2:  HSV structual proteins by location in the virion architecture.  




















































The Herpes Simplex Virus Lifecycle 
For the herpesvirus lifecycle, like all biological cycles, circular and stepwise 
progression through the cycle will bring one back to the selected start point.  At its most 
basic, the herpesvirus life cycle starting with a mature viral particle, begins with initial 
attachment to a host cell membrane and is followed by fusion with the host cell 
membrane, entry into the host cell, virion transport to the nucleus, production of viral 
proteins and viral DNA, creation of progeny viruses and release as a mature virion from 
the infected cell (Roizman 1974). For HSV-1 this initial infection is generally contained 
within the oral mucosa.  For the mucosal epithelial infection, this infection follows the 
basic life cycle until cleared by the immune system.  However, HSV-1 or 2 infections, 
may enter the sensory neurons innervating the infected area and start a more complex life 
cycle, involving much more distant transport to the nucleus (retrograde transport) and a 
state of latency not observed in epithelial cell infections (Cunningham, Diefenbach et al. 
2006; Saksena, Wakisaka et al. 2006).  This latent state can result in life-long recurrent 
infections (Whitley, Kimberlin et al. 1998b).  In the next few sections, primarily an 
infection lifecycle as observed in an epithelial cell will be discussed with the differences 
in neuronal infection covered later. 
 
Virus Attachment and Entry 
Entry is a three-stage process involving interactions between the viral membrane proteins 
and host-cell surface receptors.  The gamut of membrane proteins on the surface of a 
herpesvirus can determine the species and cell types that a virus can infect(Roizman and 






Figure 1.3: The Herpes Simplex Virus Life Cycle.  Schematic cartoon of the overall 
herpes virus life cycle showing entry, transport to the nucleus, DNA release, coordinate 
gene expression, DNA replication and packaging, and virion egress.  This schematic 




potential host cell.  The second stage is interaction of cellular membrane receptors with a 
viral protein that initiates the final stage of fusion of the two membranes and entry of the 
viral capsid and tegument into the host cell’s cytoplasm.  
Virus attachment begins with an interaction between viral proteins and the 
glycosaminoglycan (GAG) chains of proteoglycans that are richly distributed on the 
surface of mammalian cells (Spear 2004b).  The viral proteins involved in this interaction 




proteoglycan of choice (Shieh, WuDunn et al. 1992; Spear 2004b).  Interestingly, this 
initial attachment step is reversible and while greatly assisting infection of the host cell, it 
is not essential for virus entry or replication as cells lacking heparan sulfate can be 
infected and gC deficient viruses can infect and replicate albeit at 10 fold lower 
efficiencies than normal (Heine, Honess et al. 1974; Banfield, Leduc et al. 1995).  
This initial attachment, while not essential, aids in the positioning of glycoprotein 
D (gD) to start an irreversible reaction that will lead to virus-cell fusion. Glycoprotein D 
interacts with its cellular receptors and as a result undergoes a conformational change that 
activates the virus membrane-cell membrane fusion machinery.  This fusion complex 
involves multiple viral membrane proteins including: gB, gH/gI and recently discovered 
interactions with gK and UL20 (Cai, Gu et al. 1988; Forrester, Farrell et al. 1992; Roop, 
Hutchinson et al. 1993; Spear 2004b; Chouljenko, Iyer et al. 2009; Chouljenko, Iyer et al. 
2010). 
 
Binding and Entry Receptors 
Cellular receptors of gD include: the herpesvirus entry mediator A (HVEM or 
HveA), nectins, and 3-O-sulfated heparan sulfate (Fig 1.4) (Roizman, Knipe et al. 2007).  
HveA is a member of the tumor necrosis factor (TNF) receptor family.  This receptor is 
present on many mammalian tissues and cell types, including leukocytes, T and B 
lymphocytes, epithelial cells, and fibroblasts (Spear, Eisenberg et al. 2000; Spear 2004b).  
However, this receptor is not present on neurons (Spear 2004b).  The natural ligands for 
this receptor include LIGHT and lymphotoxin-alpha (Mauri, Ebner et al. 1998).  These 




or evasion of, immune cells (Kwon, Kim et al. 2003).  Studies have shown that HveA is 
significantly involved in HSV infection of activated T-cells, however, the T-cell is not 
thought to be a primary target of HSV and HveA has been shown to not be the primary 
mediator of entry in other cells, so the significance of this interaction is uncertain 
(Montgomery, Warner et al. 1996). 
 
  
Figure 1.4: Herpes Simplex Virus entry receptors.  The three classes of cell surface 
receptors for HSV entry: the tumor necrosis factor (TNF) receptor family consisting of 
HVEM, the immunoglobulin superfamily consisting of the nectins, and 3-O-sulfated 
heparin sulfate. Figure from (Melancon, 2003). 
 
 Members of the immunoglobulin superfamily may also serve as receptors. Nectin-
1alpha (α) (HveC), nectin-1beta (β) (Herpesvirus-like Immunoglobulin receptor HIgR, 
and nectin-2α (HveB) are members that can mediate HSV entry.  Nectin-1α and nectin-




human tissue targets of HSV infection (skin, brain, and spinal ganglia), as well as 
hematopoietic cells (Cocchi, Lopez et al. 1998; Cocchi, Menotti et al. 1998; Geraghty, 
Krummenacher et al. 1998).  Nectin-1α and β can mediate entry of all HSV-1 strains, 
HSV-2, Pseudorabies virus (PrV) and bovine herpes virus 1 (BHV-1) (Geraghty, 
Krummenacher et al. 1998).  Nectin-2α can mediate the entry of HSV-2, PrV, and certain 
mutants of HSV-1 but not wild-type HSV-1 (Warner, Geraghty et al. 1998; Lopez, 
Cocchi et al. 2000).  Nectin-1 and nectin-2 are also related to the poliovirus receptor 
(Takai and Nakanishi 2003).  Another member of the immunoglobulin family, the paired 
immunoglobulin-like type 2 receptor PILRα has been shown to bind to gB for fusion of 
the virus (Wang, Fan et al. 2009).  PILRα is expressed on hematopoietic cells and some 
non-hematopoietic cells yet it remains to be determined if this receptor is a significant 
contributor to HSV infection of ocular, epithelial, or neuronal cells (Farooq, Valyi-Nagy 
et al. 2010). 
In the host organism, the nectins are intercellular adhesion molecules localized to 
intercellular junctions (Takahashi, Nakanishi et al. 1999).  The nectins are highly 
conserved throughout mammals and are expressed in the target tissues of herpesviruses, 
namely epithelial cells, fibroblasts and neurons (Takahashi, Nakanishi et al. 1999).  The 
nectins are also similar in respect to structure, function, and the ability to mediate HSV 
entry across many species (Shukla, Dal Canto et al. 2000; Milne, Connolly et al. 2001). 
The distribution of these receptors and importance in intercellular junctions suggests that 
these proteins probably play a role in both virus entry and cell-to-cell spread (Roizman 





3-O-sulfated heparan sulfates may mediate entry of HSV-1 and these 
proteoglycans are broadly distributed on human cells (Shukla, Liu et al. 1999).  In 
addition to direct membrane fusion, HSV-1 may enter a cell by endocytosis depending on 
the cell type.  In non-neuronal cells, endocytosis may occur in a pH-dependent manner 
(Garner 2003; Nicola, McEvoy et al. 2003) or pH-independent manner (Milne, Nicola et 
al. 2005).  However, in neurons entry has been proven only in a pH-independent 
membrane fusion type process (Nicola, Hou et al. 2005). 
 
Virus-to-Cell Fusion 
The final stage of virus entry is fusion of the viral envelope with the host cell 
membrane and release of the capsid and tegument into the host cell cytoplasm (Morgan, 
Rose et al. 1968).  In cell culture, gD, gB and gH/gL are essential for virus-to-cell fusion 
and entry into a host cell (Sarmiento, Haffey et al. 1979; Ligas and Johnson 1988; 
Forrester, Farrell et al. 1992).  Glycoprotein D binding to cellular receptors likely induces 
conformational changes in gB that activate the virus fusion machinery (Heldwein, Lou et 
al. 2006; Roller, Dollery et al. 2008; Atanasiu, Whitbeck et al. 2010). Glycoproteins H, L 
and K as well as the non-glycosylated membrane protein UL20 interact to assist and 
modulate this fusion reaction (Spear 2004a; Chouljenko, Iyer et al. 2009; Chouljenko, 
Iyer et al. 2010).  For entry via an endocytotic pathway, the first stage of endocytosis 
appears to occur independent of a gD receptor, however, the viral glycoproteins gB, gD, 
gH/gL are necessary and low endosomal pH may assist in conformational changes 
contributing to fusion (Nicola, McEvoy et al. 2003; Nicola and Straus 2004; Dollery, 




viral protein constituents, these pathways are spatially distinct. After the fusion of the 
virus and target cell membranes, the viral capsid, containing the viral DNA, and some of 
the tegument is released into the cytoplasm (Maurer, Sodeik et al. 2008). In studies of 
PrV, pUL11, pUL47, pUL48, and pUL49 were lost from the capsid while pUL36, pUL37 
and PUS3 remained with the capsid (Granzow, Klupp et al. 2005; Luxton, Haverlock et 
al. 2005; Antinone, Shubeita et al. 2006; Copeland, Newcomb et al. 2009).  The 
progression of the virus through the cytoplasm to the nucleus may also involve two of 
these remaining tegument proteins, UL36 and UL37 (Krautwald, Fuchs et al. 2009; 
Roberts, Abaitua et al. 2009). 
 
Host Protein Shutoff 
As the virus progresses toward the host cell nucleus, the virus also begins the 
inhibition of host cell protein synthesis.  The virion host shutoff (VHS) comes from a 
structural element of the tegument and does not require protein synthesis in the newly 
infected cell (Nishioka and Silverstein 1977; Fenwick and Walker 1978; Nishioka and 
Silverstein 1978b; Nishioka and Silverstein 1978a).  VHS inhibits the production of host 
cell proteins via two mechanisms; it inhibits synthesis and processing of host mRNA and 
it speeds the degradation of mRNAs.  These effects are applicable to the virus, however, 
once viral protein synthesis is occurring, it is in an overwhelming amount that makes the 
effect of VHS on host cell protein production much more significant (Roizman, Knipe et 
al. 2007).  VHS functions to induce the cleavage of mRNA and cause 5’ degradation of 
mRNA (Elgadi, Hayes et al. 1999; Karr and Read 1999).  VHS also forms a complex 




and Knipe 2001b).  Since VHS activity does not rely on production of de novo synthesis 
of viral proteins, VHS preferentially targets cellular mRNA early in infection and may 
facilitate the transition of viral gene expression through the A, B and C genes as it 
accumulates and shortens the life of viral mRNA (Kwong and Frenkel 1987; Oroskar and 
Read 1987).  Although VHS accumulates late in infection, it does not degrade viral 
mRNA, likely due to an interaction between VP16 and VHS at late times during infection 
that blocks the degradation of RNA by VHS (Lam, Smibert et al. 1996).  It is likely that 
this interaction halts the VHS function so that progeny virions may be assembled and 
released as mature infectious virions.  
 
Virion Transport to the Host Cell Nucleus 
After fusion of the viral envelope and deposition of the capsid and some of the 
tegument into the cytoplasm, the capsid and some of the tegument are transported to the 
cell nucleus.  One of the tegument proteins that does not disassociate from the capsid is 
VP16 (α-tiff).  This tegument protein is actually transported along with the capsid to the 
nucleus.  The capsids are transported to the nuclear pores along microtubules by the 
molecular motors dynein and members of the kinesin protein superfamily (KIFs) (Sodeik, 
Ebersold et al. 1997; Dohner, Wolfstein et al. 2002; Garner 2003; Diefenbach, Miranda-
Saksena et al. 2008b; Lyman, Curanovic et al. 2008).  Some experiments have shown that 
microtubules adjacent to the cell plasma membrane are disrupted following entry, which 
suggests that normal microtubule formations are likely altered by the capsid and 
tegument proteins effects on microtubules (Ward, Avitabile et al. 1998).  Additional 




detailing transport in neurons.  After transport, capsids accumulate at the nuclear pore 
complexes.  Capsid binding to the nuclear pore complexes can be prevented with 
antibodies to parts of the nuclear transport machinery (Ojala, Sodeik et al. 2000).  Once 
close to the nucleus, capsids seem to dock to the nuclear pores and the capsid is 
destabilized and DNA is released, or extruded, from the capsid into the nucleus (Sodeik, 
Ebersold et al. 1997; Ojala, Sodeik et al. 2000).  The tegument protein VP1/2, encoded by 
the UL36, gene is involved in this process through interactions with the nuclear pore 
complex (Batterson, Furlong et al. 1983; Batterson and Roizman 1983; Ojala, Sodeik et 
al. 2000).  Temperature sensitive HSV-1 mutants of UL36 cannot release DNA into the 
host cell nucleus (Knipe, Batterson et al. 1981; Batterson and Roizman 1983). The 
pUL25 capsid protein has been shown to interact with nucleoporins CAN/Nup214 and 
hCG1and also binds to the pUL6 portal protein and the tegument protein pUL36 
(Batterson, Furlong et al. 1983; Cardone, Winkler et al. 2007; Newcomb, Booy et al. 
2007; Jovasevic, Liang et al. 2008; Roberts, Abaitua et al. 2009).  It is likely that these 
proteins play a coordinated role in capsid-nuclear pore binding and viral DNA release 
into the nucleus. 
 
Gene Expression in Infected Cells  
Once the viral DNA has penetrated the host-cell nucleus, the HSV infection 
begins in earnest with the expression of viral proteins and eventual synthesis of viral 
DNA. During the infection, HSV-1 expresses greater than 80 gene products in an 
organized pattern and timing of these proteins.  Proteins can be broken into three groups 




(β), and gamma (γ) (Honess and Roizman 1974).  Transcription of viral DNA occurs in 
the nucleus and the virus uses the host RNA polymerase II for transcription of viral genes 
(Alwine, Steinhart et al. 1974; Costanzo, Campadelli-Fiume et al. 1977).  Upon entry into 
the host cell, the tegument protein VP16 is released from the tegument and binds to the 
host cell factor C1 and this complex enters the nucleus and binds to Oct-1 (Katan, Haigh 
et al. 1990; Kristie and Sharp 1990).  This complex is a transactivator of α genes (La 
Boissiere, Hughes et al. 1999).  Shortly after a cell is infected, HSV-1 DNA enters the 
nucleus and localizes to cellular ND10 structures, where VP16 causes the transactivation 
and transcription of the α genes giving VP16 the name (α-TIF) for the α gene 
transactivating factor (Post, Mackem et al. 1981; Ishov and Maul 1996; Maul, Ishov et al. 
1996).  Viral α gene expression peaks at about 2-4 hours post infection.  There are six α 
genes (ICP0, ICP4, ICP22, ICP27, ICP47 and Us1.5 and five of these can stimulate β 
gene expression (Fig 1.5).  ICP4 is required for all viral gene expression after the α genes 
and it also down regulates some α genes, including self down regulation and ICP0, as 
well as the gene products of ORF P and ORF O, which are pre-α genes (Clements, 
Watson et al. 1977; Dixon and Schaffer 1980; Kristie and Roizman 1984; Faber and 
Wilcox 1986; Godowski and Knipe 1986; Kristie and Roizman 1986; Gelman and 
Silverstein 1987; Muller 1987). ICP0 is a non-specific transactivator that can induce α, β, 
and γ genes (Everett, Orr et al. 1991).  The expression of HSV-1 β genes, whose primary 
functions are viral DNA replication and nucleotide metabolism, peaks from 4-8 hours 
after infection (Roizman and Knipe 2001b).  The β genes are further subdivided by the 
timing of expression into β1 genes, which are expressed directly after α genes, and β2 




group, the γ genes, peak after viral DNA replication has already begun.  These genes 
require the presence of ICP4, ICP27 and ICP8 for efficient transcription.  The γ genes 
predominantly include structural proteins, glycoproteins and tegument (Roizman and 
Knipe 2001b).  The HSV-1 C genes are subdivided similarly to the β genes, with γ1 genes 
being expressed earlier, even as early as during α gene expression (and are sometimes 
therefore called “leaky-late”); however, expression peaks after DNA replication.  The γ2 
genes are not expressed until after DNA replication has begun (Wagner 1985). 
Glycoprotein K is a typical example of the γ2 genes.  
 
Figure 1.5: Map of the complex coordinate gene expression in Herpes Simplex 
Virus. 1) α-TIF, from the tegument activates initial transcription of α genes. 2) 
Autoregulation of gene expression. 3) Activation of β gene expression by α genes. 4) 
Activation of γ gene expression by α and β genes 5) γ genes stop expression of α and β 








Viral DNA Replication 
After entry of the viral DNA into the nucleus, the linear DNA forms a circle using 
the DNA ligase and XRCC4, a DNA repair protein, that then acts as the template for 
DNA synthesis (Strang and Stow 2005; Muylaert and Elias 2007).  DNA replication 
begins after β genes are expressed and translated.  Some of the β gene protein products 
assemble at the ND10 nuclear structures, in punctate prereplicative sites, where the viral 
DNA has already localized (Ishov and Maul 1996; Uprichard and Knipe 1996).  The 
rolling circle of replication starts at the origins of replication using the origin binding 
protein (pUL9) (Elias, O'Donnell et al. 1986; Olivo, Nelson et al. 1988).  UL9 binds to 
the viral DNA replication origin sites, unwinds DNA, and recruits ICP8, the ssDNA 
binding protein.  Then these proteins recruit the remaining proteins in the helicase-
primase complex and the DNA polymerase into a replisome (Muylaert, Tang et al. 2011). 
Then the replication of viral DNA begins, initially as a theta structure, then progresses to 
a rolling circle form by the replisome that generates leading and lagging strands of 
replicated DNA (Skaliter, Makhov et al. 1996) and eventually creates many head-to-tail 
concatamers (Jacob, Morse et al. 1979).  The concatamers of viral DNA are contained in 
replication compartments consisting of viral DNA and replication complexes (Quinlan, 
Chen et al. 1984).  Seven viral proteins are necessary for viral DNA replication: the DNA 
polymerase (UL30), the DNA polymerase accessory protein (UL42), the origin-binding 
protein (UL9), the single-stranded DNA binding protein (ICP8) and the helicase-primase 
complex (composed of UL5, UL8 and UL52) (Purifoy, Lewis et al. 1977; Conley, Knipe 
et al. 1981; Challberg 1986; Wu, Nelson et al. 1988).  It is likely that host cell factors and 




one origin of replication is necessary for the replication of viral DNA, there are three 
possible origins of replication: oriS (present in two copies) and oriL (Frenkel, Locker et 
al. 1976; Locker, Frenkel et al. 1982; Mocarski and Roizman 1982; Stow 1982; Vlazny, 
Kwong et al. 1982; Weller, Spadaro et al. 1985; Knopf, Spies et al. 1986; Lockshon and 
Galloway 1986; Deb and Doelberg 1988). 
 
Capsid Assembly and DNA Packaging 
During DNA replication, the γ genes are transcribed and the proteins are made in 
the cytoplasm of the infected cell.  The capsid components of the virus must be then be 
transported back to the nucleus for assembly.  The triplex proteins (two copies of VP19C 
and one VP23) are brought into the nucleus already assembled in the cytoplasm, since 
VP23 does not transport into the nucleus alone (Nicholson, Addison et al. 1994; Rixon, 
Addison et al. 1996).  The major capsid protein (VP5) is transported into the nucleus with 
the triplexes or a scaffolding protein pre-VP22a (Roizman, Knipe et al. 2007).  The 
UL26/UL26.5 genes are responsible for multiple proteins involved in capsid formation 
and assembly.  These proteins are the result of two overlapping genes and multiple 
cleavage forms of the UL26 gene.  Pre-VP22a, the major scaffolding protein for capsid 
formation is the product of the UL26.5 gene and the UL26 gene is responsible for VP21, 
another scaffolding protein, and VP24, a protease that cleaves the major scaffold protein 
(Roizman, Knipe et al. 2007).  Once the capsid and scaffold proteins are in replication 
compartments in the nucleus, the remainder of capsid assembly occurs.  Assembly likely 
begins at the portal ring, that is made from 12 copies of the pUL6 protein (Newcomb, 




assemble, likely guided by the self-assembling nature of the pre-VP22a and guided by 
alignment with the portal ring.  As more pentons, hexons and triplexes are brought 
together the capsomeres form into a sphere-like procapsid (Newcomb, Homa et al. 1996; 
Baines 2011).  Once this procapsid is formed, the viral DNA is loaded into the procapsids 
by a three-part enzyme, the product of the UL28 gene (Beard, Taus et al. 2002).  This 
enzyme is also responsible for the cleavage of the replicated viral DNA concatamers into 
single unit monomers of the viral DNA ready for packaging into the capsids.  During the 
DNA packaging process, the scaffold is also removed by the protease action of VP24 
which allows the procapsid to assume a more stable and resilient icosahedral shape 
(Newcomb, Homa et al. 1996).  
Three types of capsids have been identified for HSV; A, B, and C capsids.  All 
three capsid types are formed of similar pentons, hexons and triplexes and are 
approximately 120 nm in diameter (Gibson and Roizman 1972; Newcomb, Trus et al. 
1993).  C-capsids are capsids that have gone through maturation fully as described and 
can proceed to become infectious viruses after egress.  B-capsids contain VP21, VP22a, 
and VP24 but do not contain viral DNA (Gibson and Roizman 1972; Newcomb, Trus et 
al. 1993).  A-capsids contain no scaffolding proteins and no DNA and are thought to be 
an aborted attempt at DNA packaging (Sherman and Bachenheimer 1987; Newcomb, 
Homa et al. 1996).  
 
Virion Egress 
To complete maturation of the virus and make an infectious particle, the 




Two models are currently considered for this process.  The first model has the virion 
acquire its final tegument and final envelope as it buds through the nuclear membrane 
and the mature virus particle exits the cell through the secretory pathway.  The alternate 
model involves acquisition of a primary envelope as the encapsidated virion passes 
through the nuclear membrane followed by deenvelopment and final tegumentation and 
envelopment occurs in the trans-golgi network (Roizman, Knipe et al. 2007).  
For either model, two viral proteins appear to be involved in the process of 
primary egress from the nucleus; pUL31, a nuclear phosphoprotein embedded in the 
nuclear membrane of infected cells (Reynolds, Ryckman et al. 2001; Fuchs, Klupp et al. 
2002), and pUL34, a protein in inner and outer nuclear membrane of infected cells that 
uses a C-terminal membrane anchor (Klupp, Granzow et al. 2000).  For both models, the 
first step for virion egress terminates with the virus enveloped and present in the 
perinuclear space between the two nuclear membranes (Vlazny, Kwong et al. 1982). 
Furthermore, the inner nuclear membrane is bound by a protein-rich nuclear lamina and it 
appears that this layer must be disrupted to allow intranuclear capsids access to the inner 
nuclear membrane (Scott and O'Hare 2001).  The viral proteins of UL31 and UL34 can 
bind, reorganize and destabilize lamin A/C, which is the primary component of the 
nuclear lamina (Reynolds, Liang et al. 2004a; Reynolds, Liang et al. 2004b; Simpson-
Holley, Baines et al. 2004).  The UL11 protein has also been shown to increase the 
efficiency of this stage of envelopment, however it does not appear to be essential 
(Baines and Roizman 1992; MacLean, Dolan et al. 1992).  
Once this primary envelopment occurs via budding through the inner nuclear 




this point and, while some maturation may still occur, the virion retains its envelope and 
tegument from this envelopment stage and exits the cell via the secretory pathways 
(Darlington and Moss 1968; Johnson and Spear 1982; Johnson, Webb et al. 2001b; 
Baines, Parsch et al. 2004).  This exit strategy takes advantage of the continuity of the 
perinuclear space with the endoplasmic reticulum and secretory paths.  
In the alternate model, the enveloped virion in the perinuclear space must de-
envelope from its primary envelope as it fuses with the outer nuclear membrane (Fig 1.6). 
The virion is de-enveloped and loses some, or all, of its tegument as the virion enters the 
cytoplasm (Enquist, Husak et al. 1998; Mettenleiter 2000).  Re-envelopment then occurs 
in the cytoplasm, specifically in the trans-Golgi network (TGN), compartments where 
additional tegument is also added (Roizman, Knipe et al. 2007).  This has been termed a 
“de-envelopment, re-envelopment” model.  The majority of evidence currently supports 
the latter model.  By electron microscopy, primary enveloped particles have been shown 
fusing with the outer nuclear membrane and unenveloped, cytoplasmic virions have been 
shown budding into cytoplasmic vesicles (Gershon, Sherman et al. 1994; Granzow, 
Klupp et al. 2001; Mettenleiter 2002b).  The lipid composition and ultrastructural 
appearance of the extracellular virions resembles the cells plasma membrane rather than 
the nuclear membranes (van Genderen, Brandimarti et al. 1994).  Furthermore, UL31 and 
UL34 proteins are present in perinuclear virions, but are not able to be detected in 
extracellular virions.  While, the tegument proteins of UL46 and UL49 genes are present 
in cytoplasmic or extracellular virions but are not found in perinuclear virion particles 





The major argument against the “de-envelopment, re-envelopment” model, 
currently, is the lack of a defined mechanism for de-envelopment.  Glycoproteins 
involved in the fusion machinery of the virus do not affect this pathway, as shown by 
experiments with deletion mutants (Cai, Person et al. 1987; Jayachandra, Baghian et al. 
1997; Steven and Spear 1997; Granzow, Klupp et al. 2001).  Current investigation 
focuses on the possibility of redundant pathways including multiples of the glycoproteins 
or as yet unidentified players in this interaction.  
In the “de-envelopment, re-envelopment” model, capsids acquire tegument 
proteins as they pass through the nucleus and cytoplasm, likely in the manner of protein-
protein interactions with the capsid and other tegument members (Mettenleiter 2002b). 
The tegument is composed of at least 15 different proteins in HSV.  While initially 
thought to be structureless, the tegument has been shown to possess some icosahedral 
structure in its inner-most layer around pUL36, a large tegument protein that interacts 
with the major capsid protein, VP5, (Machtiger, Pancake et al. 1980; McNabb and 
Courtney 1992; Newcomb, Trus et al. 1993; Zhou, Chen et al. 1999; Mettenleiter 2002b).  
The tegument likely plays a structural role, linking the capsid to the envelope, and has 
important functions in the early phase of infection, through the actions of the tegument 
proteins UL41 (vhs), UL48 (α-tiff), and Us3 (a protein kinase) (Mettenleiter 2002b; 
Roizman, Knipe et al. 2007).  While a lack of UL36 or UL37 tegument proteins ceases 
virus maturation, this maturation can proceed without UL13, US3, UL41, UL46, UL47, 
or UL49 (Rafield and Knipe 1984; Purves, Longnecker et al. 1987; Desai 2000; Desai, 
Sexton et al. 2001; Klupp, Granzow et al. 2001; Roizman and Knipe 2001b; Mettenleiter 
2002b).  Therefore in cultured cells, while many tegument components are not necessary, 




The final stage of production of an infectious particle involves acquisition of a 
mature virion envelope and exiting the host cell.  After tegumentation of the virion in the 
“de-envelopment, re-envelopment” pathway, the HSV-1 capsid must bud into the system 
of cytoplasmic vesicles called the Trans-Golgi Network (TGN) (Fig1.6).  This network is 
a collection of Golgi-derived endosomes.  This final envelopment stage is not well 
characterized (Mettenleiter 2002b).  It is likely that this step requires some interactions 
between the outer layer of the tegument and some of the viral membrane proteins that 
will be resident on the mature virion.  Deletion of glycoproteins E (gE) and I (gI) or gM 
does not affect the formation of mature virions in pseudorabies virus (PRV-an 
alphaherpesvirus closely related to HSV) or HSV.  However deletion of all three 
glycoproteins inhibits virus spread (and by extension production of mature virions) in 
PRV but not HSV (Enquist, Husak et al. 1998; Brack, Dijkstra et al. 1999; Browne, Bell 
et al. 2004).  Simultaneous deletion of gD, gE and gI causes an envelopment defect in 
HSV (Farnsworth, Goldsmith et al. 2003).  However, any multiple glycoprotein deletion 
may also destabilize other tegument or envelope interactions that may appear as solely an 
envelopment defect.  
The most dramatic secondary envelopment effects are observed with gK or 
pUL20 deletions, in which there is marked accumulation of unenveloped and aberrantly 
enveloped capsids in the infected cell cytoplasm with corresponding decreases in 
extracellular infectious virus (Jayachandra, Baghian et al. 1997; Foster, Melancon et al. 
2004b).  In the normal course of infection, this final step of envelopment is proposed to  
be followed by final egress of the virus from the host cell via the normal cellular 







Figure 1.6:  Schematic of HSV-1 virion morphogenesis and egress in the de-
envelopment/re-envelopment model.  (I) Mature capsids bud through the inner nuclear 
membrane into the perinuclear space.  (II) De-envelopment of perinuclear virions at the 
outer nuclear membrane.  (III) Re-envelopment of cytoplasmic capsids by budding into 
Trans-Golgi-Network derived cytoplasmic vesicles.  (IV) Final egress to the extracellular 
space.  Figure from (Melancon, Luna et al. 2005). 
 
Latent Infection 
Latent infection is more of an alternate pathway in the virus life cycle rather than 
a stage of the life cycle.  The signals that push a herpes virus into a latent infection rather 
than a typical lytic infection are poorly characterized, however, latency and reactivation 
are well-documented phenomena clinically (Roizman, Knipe et al. 2007).  In herpes 
viruses, latent infection generally follows a primary infection and spread in some tissue 
type with latency occurring in a secondary tissue.  Herpesviruses tend to favor latency in 




infection is generally in a mucocutaneous epithelial tissue with the latent infection 
occurring in the sensory ganglionic neurons that innervate this tissue.  This is followed by 
periodic reactivations and subsequent reoccurrence of clinical symptoms at the tissues of 
initial infection.  Latency in HSV is characterized by the viral DNA being held in the 
host-cell nucleus, in a circular episome form, associated with the nucleosomes and near 
total silencing of gene expression.  The latency-associated transcripts (LATs) are 
expressed giving multiple RNA species through splicing (Roizman, Knipe et al. 2007). 
Reactivation generally occurs following some type of neuronal or primary infected tissue 
stress; including UV radiation, intense heat, trauma or others, or a systemic stress and/or 
immunocompromise to the individual infected.  Once this occurs, the infection cycle 
follows in a manner similar to that described above.  Latency will be covered in greater 
detail later in this chapter in sections pertaining to neuronal infection.  
 
HSV Glycoproteins and Their Putative Functions 
Herpes simplex virus type-1 encodes and uses at least eleven virally encoded 
glycoproteins and possibly a twelfth in the mature, wild type virion: gB, 
gC, gD, gE, gG, gH, gI, gJ, gK, gL, gM, and potentially gN (UL49.5).  HSV-1 also has 
multiple non-glycosylated, but still membrane associated proteins: pUL20, pUS9, 
pUL24, pUL43, and pUL34.  Herpesvirus membrane and membrane-associated proteins 
function in multiple important roles; virus fusion to a potential host cell, virus entry via 
host cell membrane fusion, virion morphogenesis, egress from the nucleus and infected 
cell, cell-to-cell spread and virus-induced fusion of host organism cells (Roizman and 




Spear 2004b).  At least 11 membrane proteins are present on the surface of the virion 
envelope (Roizman, Knipe et al. 2007).  These proteins are vitally important in the virus 
life-cycle as they are the first component of the virus that interacts with the host cell that 
will be infected and can shape the interactions available to the virus both in the already 
infected cell (egress, morphogenesis, and immune interactions) and the prospectively 
infected cell (i.e.: cell tropism, virus-cell fusion and entry). 
 
Glycoprotein B (pUL27) 
Glycoprotein B (gB) is the product of the HSV-1 UL27 gene. This gene encodes a 
904 amino acid (aa) protein that exists in its mature form in the viral envelope as a 
homotrimer.  This glycoprotein has a single cytoplasmic domain of 696 aa that has 
multiple N-glycosylation sites, a short, 69 aa transmembrane domain and a 109 aa 
carboyxterminal cellular domain (Claesson-Welsh and Spear 1986; Claesson-Welsh and 
Spear 1987; Highlander, Goins et al. 1991; Spear 1993; Laquerre, Person et al. 1996; 
Whitley 2001a).  Resolution of the crystal structure has shown that it possesses features 
of class I, in the form of an α-helical coiled-coil core, and class II, in the form of 
extended β hairpins with hydrophobic tips, viral fusion proteins (Heldwein, Lou et al. 
2006).  The β hairpin structures are homologous to the Vesicular stomatitis virus (VSV) 
G fusion protein and studies have shown that the hydrophobic tips of the loops are vital 
for HSV-1 gB function in fusion (Hannah, Heldwein et al. 2007).  Glycoprotein B is 
highly conserved among many herpesviruses and in HSV-1 this protein plays an 
important role in virus induced cell fusion, as the suspected primary virus-cell membrane 




(Cai, Person et al. 1987).  The role of gB in membrane fusion can also be demonstrated 
by amino acid substitution or truncation mutations of the carboxyl terminus that result in 
extensive fusion (Bzik, Fox et al. 1984; Cai, Gu et al. 1988; Cai, Person et al. 1988; 
Baghian, Huang et al. 1993; Gage, Levine et al. 1993).   
Glycoprotein B is part of the four glycoprotein group, gB, gD, gH, and gL, 
necessary for cell fusion in transient co-expression assays and carboxyl truncations of gB 
result in extensive fusion in this system (Foster, Melancon et al. 2001; Haan, Lee et al. 
2001; Klupp, Fuchs et al. 2002; Pertel 2002).  These proteins appear to operate in a 
sequence with gD in Phase I, gH/gL in Phase II, and gB in Phase III f fusion (Gianni, 
Fato et al. 2006; Subramanian and Geraghty 2007).  
 
Glycoprotein C (pUL44) 
Glycoprotein C (gC) is the product of the HSV-1 UL44 gene.  This gene encodes 
a 511 aa protein that is a precursor of gC (Frink, Eisenberg et al. 1983).  This protein has 
a single 453 aa extracellular domain, with a 23 aa transmembrane domain and a short 
cytoplasmic tail of 10 aa (Homa, Purifoy et al. 1986).  In the mature form, found in the 
envelope, gC has heavy N-linked and O-linked glycosylation (Wenske and Courtney 
1983).  While not necessary for infection, gC increases efficiency of infection and can be 
found in over 1000 copies on the virus surface (Ruyechan, Morse et al. 1979). 
Glycoprotein C can cause initial binding of the virus to host cell heparan sulfate at the N-
terminal 120 aa binding site (Tal-Singer, Peng et al. 1995).  HSV-1 gC can increase 
binding by nearly 10-fold to host cells. HSV-1 gC also contributes to the viral infection, 




Eisenberg, Ponce de Leon et al. 1987; Huemer, Larcher et al. 1993; Huemer, Nowotny et 
al. 1995).  This can function to protect the virus from the effects of complement mediated 
neutralization (Lubinski, Wang et al. 1998; Lubinski, Wang et al. 1999).  This is an 
important virulence factor in the natural infection and gC deficient mutants can 
demonstrate 5000 fold titer loss due to the rapid inactivation from complement (Kotwal, 
Isaacs et al. 1990; Isaacs, Kotwal et al. 1992; Friedman, Wang et al. 1996; Sahu, Isaacs et 
al. 1998).  Glycoprotein C also carries a second domain that blocks the complement 
component C5 from binding to C3 providing a second block on the potential complement 
neutralization of HSV (Roizman, Knipe et al. 2007).  
 
Glycoprotein D (pUS6) 
Glycoprotein D (gD) is the product of the HSV-1 US6 gene. This gene encodes a 
394 aa multifunctional protein.  Glycoprotein D has a 315 aa extracellular domain with 
three sites for glycosylation (Watson, Weis et al. 1982; McGeoch, Dolan et al. 1985). 
This protein also has short transmembrane anchoring, 22 aa, and cytoplasmic, 32 aa, 
domains (Minson, Hodgman et al. 1986).  This glycoprotein is very important to 
attachment, and by extension, and fusion/entry of the virus, serving as a ligand for all 
known cellular entry receptors, including HVEM, nectin-1, nectin-2 and others (Spear, 
Eisenberg et al. 2000).  This protein is necessary or virus entry and cell-to-cell fusion. At 
the extracellular N-terminus of the protein, there is an immunoglobulin like hairpin loop 
that contains the binding sites for all entry receptors other than nectin-1 and this small 
area also determines the ability to bind to nectin-2 (Carfi, Willis et al. 2001; Spear and 




that express gD are also resistant to infection by initiating endocytosis and degradation of 
the virus; however gD expression alone in some cells can cause a pH-dependent cellular 
fusion (Campadelli-Fiume, Arsenakis et al. 1988; Campadelli-Fiume, Avitabile et al. 
1988; Johnson, Burke et al. 1990).  
 
Glycoproteins E (pUS8) and I (pUS7) 
Glycoprotein E (gE) and glycoprotein I (gI) are the products of the HSV-1 US8 
and US7 genes, respectively.  The US8 gene encodes a 550 aa protein, while the US7 
gene encodes a 390 aa protein (Lee, Para et al. 1982; Longnecker, Chatterjee et al. 1987). 
In the mature virion, these proteins are present in a heterodimer, containing one copy of 
each protein.  This heterodimer can mediate cell-to-cell fusion in epithelial and neuronal 
tissues; however, neither is necessary for virus entry and infection (Johnson and Feenstra 
1987; Mettenleiter, Schreurs et al. 1987; Neidhardt, Schroder et al. 1987; Johnson, Frame 
et al. 1988; Kudelova, Kostal et al. 1991; Card, Whealy et al. 1992b; Jacobs, Mulder et 
al. 1993a; Whealy, Card et al. 1993; Balan, Davis-Poynter et al. 1994a; Kritas, Pensaert 
et al. 1994; Mulder, Jacobs et al. 1994; Cohen and Nguyen 1997; Tirabassi, Townley et 
al. 1997; Dingwell and Johnson 1998; Kimura, Wang et al. 1998; Tirabassi and Enquist 
1998).  In very permissive cells that do not form tight cell junctions, the heterodimeric 
complex is not necessary for cell-to-cell spread (Mettenleiter, Zsak et al. 1987; Zsak, 
Zuckermann et al. 1992; Dingwell, Brunetti et al. 1994; Dingwell, Doering et al. 1995; 
Tirabassi, Townley et al. 1997; Wisner, Brunetti et al. 2000).  Furthermore, this complex 
is not necessary for infection of the apical surface of a cell by extracellular virus 




necessary for spread in synaptically connected neurons (Whealy, Card et al. 1993; 
Mulder, Jacobs et al. 1994; Dingwell, Doering et al. 1995; Babic, Klupp et al. 1996b; 
Tirabassi, Townley et al. 1997; Tirabassi and Enquist 1998).  
This protein complex appears to be specifically designed to assist in cell-to-cell 
spread at host cellular junctions.  Viruses with the wild-type gE/gI complex preferentially 
sort daughter virions to the lateral cell surfaces and cell junctions of infected cells, while 
gE deletion mutants allow the accumulation of increased numbers of daughter virions in 
the supernatant, infected cell cytoplasm, and infected cell apical surface (Alconada, 
Bauer et al. 1996; Kimura, Wang et al. 1998).  
The gE/gI complex also has a high affinity for the Fc portion of immunoglobulin 
G, which suggests a host immune evasion component to this complex.  In the natural 
infection, this serves as a virulence factor, as this can disrupt antibody-dependent cellular 
cytotoxicity and prevent immune targeting of the virus or infected cell (Eberle, Dubreuil 
et al. 1995). 
 
Glycoprotein G (pUS4) 
Glycoprotein G (gG) is the product of the HSV-1 US4 gene.  The US4 gene 
encodes a 283 aa protein.  The function of gG is not precisely known, however, this 
glycoprotein has been shown to be non-essential for viral entry or infection.  No 
phenotypic abnormalities are recognized in single gG deletion mutants in culture and the 
absence of gG only causes minimal attenuation of the virus in vivo (Atkinson, Barr et al. 
1978).  Using polarized cells in culture and in vivo infection of corneal epithelial cells, 




et al. 2000).  It is possible that this protein is involved marginally or has redundant 
functions to another glycoprotein in assisting the binding and entry of the virus at the site 
of primary infection.  Also, during the infection gG is incorporated in the nuclear and 
cytoplasmic membranes, suggesting a possible role for gG in nuclear egress, however 
deletion mutants are not defective for nuclear egress, suggesting a possible redundancy in 
this instance as well (Frame, Marsden et al. 1986; Sullivan and Smith 1987).  
 
Glycoproteins H (pUL22) and L (pUL1) 
Glycoprotein H (gH) and glycoprotein L (gL) are the products of the HSV-1 
UL22 and UL1 genes, respectively.  The UL22 gene encodes an 838 aa protein, while the 
UL1 gene encodes a 224 aa protein (Roizman, Knipe et al. 2007).  Glycoprotein H has a 
singular 785 aa extracellular domain with 21 aa transmembrane domain and a short, 14 
aa, C-terminal cytoplasmic tail.  In the mature virion, these glycoproteins exist as a 
heterodimer.  Since this complex is essential for viral entry and infection, both of these 
glycoproteins are essential (Roizman, Knipe et al. 2007).  
Glycoprotein L has a unique form in the mature virion, in that it is not embedded 
in the membrane, but instead is dependent on the interaction with gH for incorporation 
into the virion (Dubin and Jiang 1995).  In fact, gH appears similarly dependent on gL for 
its function since gH does not fold or process correctly in the absence of gL and gH 
remains in the endoplasmic reticulum and self-aggregates in cells only transfected with 
gH (Foa-Tomasi, Avitabile et al. 1991; Forrester, Sullivan et al. 1991; Roberts, Ponce de 
Leon et al. 1991).  Furthermore, in cells infected with gL-null virus or gH-null virus, the 




viral envelope (Hutchinson, Browne et al. 1992; Roop, Hutchinson et al. 1993).  The 
formation of the heterodimer requires no other viral proteins, suggesting a likely self-
assembly or possibly the assistance of cellular components, however, gL is secreted into 
the extracellular fluid since it has no membrane targeting sequence (Roop, Hutchinson et 
al. 1993; Dubin and Jiang 1995).  
Viruses lacking gH/gL are unable to enter cells, however, they can attach to the 
cell surface and are essential proteins.  Therefore the gH/gL complex appears to be 
essential for later virus-cell membrane fusion and virus entry into cells. 
 
Glycoprotein J (pUS5) 
Glycoprotein J (gJ) is the product of the HSV-1 US5 gene.  The US5 gene 
encodes a 92 aa protein with a predicted signal peptide and a transmembrane domain 
(Ghiasi, Nesburn et al. 1998).  The precise function of gJ for the virus is not well known. 
Deletion of gJ causes no observable changes in virus growth or phenotype in vivo or in 
vitro and gJ deletion does not impair replication at the primary infection site or 
progression to the nervous system in mice (Balan, Davis-Poynter et al. 1994a).  In viruses 
without gD or gJ, apoptosis of infected cells was not blocked as it would normally be in 
an infected cell (Roizman, Knipe et al. 2007).  The UL27.5 gene encodes a protein that 
cross reacts to antibodies to gJ (Chang, Menotti et al. 1998).  This protein accumulates in  
the cytoplasm of infected cells but its function is also uncertain (Roizman, Knipe et al. 






Glycoprotein K (pUL53) 
Glycoprotein K (gK) is the product of the HSV-1 UL53 gene. The UL53 gene 
consists of 1017 bases and encodes the 338 aa protein precursor to gK (Debroy, Pederson 
et al. 1985; Pertel and Spear 1996).  Glycoprotein K has two sites for N-linked mannose 
glycosylation and is extremely hydrophobic (Hutchinson, Goldsmith et al. 1992; 
Ramaswamy and Holland 1992).  Glycoprotein K has been plagued with difficulty in 
determining its form and function.  
Previous experiments have suggested two forms for gK.  The predicted forms 
were a protein with four membrane-spanning domains with the N and C termini on the 
extracellular side of the membrane or a protein with three membrane-spanning domains 
and the C terminus located intracellularly (Debroy, Pederson et al. 1985; Ramaswamy 
and Holland 1992; Mo and Holland 1997).  More recent experiments in this laboratory, 
Kousoulas laboratory LSU-SVM, have confirmed the four membrane spanning form of 
the protein as the overwhelmingly likely mature form of the protein (Fig 1.7) (Foster, 
Alvarez et al. 2003).  
Originally, gK was determined to be necessary for viral replication in vivo, 
however, that has since been shown to be incorrect although gK null viruses have a 
greatly reduced ability to reproduce, due in large part to spread defects (MacLean, 
Efstathiou et al. 1991; David, Baghian et al. 2008).  One attempt at producing a gK 
deletion mutant actually produced an insertion-deletion mutant with the N-terminal 112 
aa of gK retained.  The result was a syncytial phenotype with many aberrant 
particles and and naked capsids trapped in the cytoplasm, which lead to the assumption 




Hutchinson, Roop-Beauchamp et al. 1995). Later, a more precise deletion of gK provided 
an actual gK null virus.  This virus displayed a phenotype of severely impaired egress, 
however, syncytia formation was not a noticeable feature of the gK-null phenotype 





Figure 1.8: Schematic of the expected structure of gK situated in the membrane. 
Schematic shows locations of discrete domains and many characterized mutations.  
Figure and mutation characteristics from (Dolter, Ramaswamy et al. 1994; Foster, Kraus 
et al. 2003; Chouljenko, Iyer et al. 2009) 
  
Some syncytial mutations are present in the non-glycosylated membrane protein 
UL20 (Baines, Ward et al. 1991; MacLean, Efstathiou et al. 1991), the membrane protein 
glycoprotein B (Bzik, Fox et al. 1984; Pellett, Kousoulas et al. 1985) and UL24 (Sanders, 




mutations (especially those involving a minimum of deletions or substitutions) are 
contained within gK (Ruyechan, Morse et al. 1979; Bond and Person 1984; Pogue-Geile, 
Lee et al. 1984; Debroy, Pederson et al. 1985).  The phenotype of syncytia formation 
would strongly indicate the presence of gK in the membrane as either a binding protein or 
a modulator of the primary fusion protein, gB.  
A study of gK localization in the infected cell suggested that gK was located only 
in the perinuclear space and only contained unprocessed carbohydrates, compatible with 
a protein that does not pass through a Golgi-mediated maturation process or reach the 
surface of the cell membrane (Hutchinson, Roop-Beauchamp et al. 1995).  Many of the 
earlier studies of the function of gK have occurred in transiently transfected cells and the 
phenotype observed for mutations of gK are aberrant, with gK retained in the perinuclear 
space or golgi, unless pUL20 is also transfected (Dietz, Klupp et al. 2000).  It was later 
shown that pUL20 and gK are dependent on one another for transport through the Golgi 
network in a manner typical of wild-type virus (Fig 1.8) (Foster, Melancon et al. 2004b; 
Melancon, Fulmer et al. 2007).  As shown for PRV and later HSV, gK appears to rely on 
the cotransfection of UL20 to restore processing of both proteins and to display their true 
phenotype (Foster, Alvarez et al. 2003).  The interactions between gK and gB were later 
confirmed by the Kousoulas laboratory, showing that the amino terminus of gK, 
particularly amino acids 31-68, modulates gB mediated, virus-induced cell fusion and 
virion egress (Melancon, Luna et al. 2005; Chouljenko, Iyer et al. 2009).  
Later glycoprotein K was shown to form a functional protein complex with the 
non-glycosylated membrane protein UL20 that interacted physically with gB 




also been shown to prevent viral entry into otherwise permissible cells (Jambunathan, 
Chowdhury et al. 2011).  Glycoprotein K along with its membrane partner pUL20 have 
been demonstrated to participate in a hierarchical relationship with a protein complex of 
the viral envelope that affects virion egress and envelopment (Chouljenko, Kim et al. 
2012).  It appears that gK and UL20 are intricately linked in the maturation and 
development of the virus and gK appears to be involved in many aspects of the virus life-
cycle including; envelopment, morphogenesis, entry and cell fusion. 
 
 
Figure 1.8:  Schematic of HSV-1 virion morphogenesis and egress hilighting the 
areas of gK and UL20 function.  Red arrows indicate the stages where gK and UL20 






Glycoproteins M (pUL10) and N (pUL49.5) 
Glycoprotein M (gM) and glycoprotein N (gN) are the products of the HSV-1 
UL10 and UL49.5 (or UL49A) genes, respectively.  The UL10 gene encodes a 473 aa 
protein, while the UL49.5 gene encodes a 91 aa protein (Baines and Roizman 1993).  In 
the mature virion, gM is an integral membrane protein with eight predicted, hydrophobic 
transmembrane domains (Baines and Roizman 1993; MacLean, Robertson et al. 1993; 
Babic, Klupp et al. 1996b).  In cell culture, gM deficient viruses replicated at 10 to 20 
fold lower titers with smaller plaque morphology than wild-type (MacLean, Efstathiou et 
al. 1991; MacLean, Robertson et al. 1993).  For gN, there are potential sites of O-linked 
glycosylation and for the homolog of gN in Pseudorabies (PRV), an α-herpesvirus related 
to HSV, the protein has been shown to be glycosylated in the mature virion (Jons, 
Granzow et al. 1996).  
For HSV, gN has been shown to be present in the virion and linked to the 
tegument, however, it has not been shown to by glycosylated (Adams, Cunningham et al. 
1998).  Deletion of gN has shown that this protein is not essential for virus infection or 
replication, with only a two-fold reduction in titers and no phenotypic plaque differences 
in null mutants (Adams, Cunningham et al. 1998).  Interestingly though neither protein is 
necessary for the life cycle of the virus, both proteins are highly conserved though the 
alpha-, beta-, and gammaherpesviruses and in many of these they form a dimeric 
complex (Jons, Dijkstra et al. 1998; Lake, Molesworth et al. 1998; Wu, Zhu et al. 1998; 
Mach, Kropff et al. 2000; Koyano, Mar et al. 2003).  This may indicate redundancy or 
partial redundancy in the functions of these proteins, requiring knock-out of multiple 




While the exact mechanism of action is unknown, it appears that gM and gN work 
together to inhibit virus induced cell fusion.  It also appears that these proteins must work 
together to cause this phenotype.  In cellular fusion assays, gM and gN cause a decrease 
in cell-cell fusion in experiments with the following: PRV gB, gD, and gH/gL, bovine 
respiratory syncytial virus F protein, or with HSV-1 gB, gD, and gH/gL or Moloney 
murine leukemia virus envelope protein.  In these studies, the transfection of both gM and 
gN reduced fusion while the transfection of only gM did not (Klupp, Nixdorf et al. 2000; 
Koyano, Mar et al. 2003).  This phenotype has even been shown to occur with human 
herpesvirus 8 (Koyano, Mar et al. 2003).  
Glycoprotein M has also been shown to be located in the nuclear membranes and 
to be added to the viral particle as it passes through the nuclear membranes, possibly 
indicating a role for gM in nuclear egress and/or increasing pathogenesis of virions 
released during cell lysis, or those that do not undergo full transport through the Golgi 
network (Baines, Wills et al. 2007). 
 
Membrane Protein UL20 (pUL20) 
The UL20 protein is a membrane protein of HSV-1 that is not glycosylated.  The 
ORF for this protein sits between the UL19 and UL20.5 genes and the expressed form is 
situated on the complementary strand of the viral genome giving a 222 aa protein.  The 
UL20 protein was originally suspected to have two or three membrane spanning domains, 
however, it was more recently predicted to have four membrane spanning domains with 
the amino and carboxyl termini located cytoplasmically (McGeoch, Dalrymple et al. 




Chieng et al. 1998).  Later this form of the protein in the mature virion was partially 
confirmed at the same time that the dependence on UL20 for gK for proper trafficking 
through the cell and maturation was established (Foster, Melancon et al. 2004a; 
Melancon, Foster et al. 2004; Melancon, Fulmer et al. 2007).  The interactions of gK and 
pUL20 were covered in more detail in the above section on gK; the involvement of 
pUL20 will be covered more briefly in this section.  
During infection, gK and pUL20 are interdependent for proper processing and 
localization of the proteins.  The lack of either of these proteins causes the entrapment of 
the other in the endoplasmic reticulum, while expression of both proteins together results 
in these proteins being present in the TGN, cell membrane and on the surface of released 
mature virions (Foster, Melancon et al. 2004b; Melancon, Fulmer et al. 2007). 
Furthermore, these proteins generally colocalize in these areas, suggesting a functional 
and physical linkage for these proteins (Foster, Melancon et al. 2004b; Melancon, Fulmer 
et al. 2007). In the virus life-cycle, pUL20 appears to regulate virus induced fusion since 
syncytia can be prevented in viruses with syncytial mutations in gB or gK if pUL20 is not 
also expressed (Foster, Melancon et al. 2004b; Melancon, Fulmer et al. 2007).  
 
Epidemiology of Herpes Simplex Virus 
Typical infection of a healthy, not immunosuppressed, individual extremely rarely 
results in a primarily fatal infection or contributes to a secondary infection that results in 
death.  This course of infection more typically results in a short duration of 
mucocutaneous lesions, generally around the mouth, with latent disease established in the 




with the age of the virus, likely a human (or human predecessor) pathogen for at least 8-
10 million, contribute to the distribution of HSV-1 as endemic in developed and 
underdeveloped countries worldwide (Black, Hierholzer et al. 1974; Black 1975; 
McGeoch, Dolan et al. 1985; Gentry, Rana et al. 1988).  Infection with HSV requires 
intimate contact of mucosal surfaces or damaged skin in a susceptible individual with 
someone who is shedding virus.  Being an enveloped virus, HSV usually must be 
transmitted directly or with little exposure to the environment.  Enveloped viruses are 
generally more susceptible to degradation of their infectiousness by interactions with the 
environment (e.g.: UV radiation, dehydration, lipids, solvents, etc).  Although some new 
and old world monkeys can be infected with HSV-1 and some animals can be 
experimentally infected, there are no known animal reservoirs or carriers of the virus. 
There have, however, been reports of new world primates being naturally infected; 
however, these are rapidly severe courses of disease and have not been established as a 
true reservoir or reliable source of infection back into the human population (Costa, 
Luppi et al. 2011). 
 New world primates are far more susceptible to HSV-1 infection than old world 
primates. Reports of infection in primates, such as the gorilla (Gorilla gorilla), 
chimpanzee (Pan troglodytes), bonobo (Pan paniscus), and white-handed gibbon 
(Hylobates lar), indicate that the infection in old world primates usually follows the 
typical course of infection similar to that found in immunocompetent humans with 
lesions remaining on mucocutaneous tissues and not progressing to systemic infection 
(Matz-Rensing, Jentsch et al. 2003).  In new world primates and prosimians, the infection 




(Schrenzel, Osborn et al. 2003).  Although old world primates are generally less 
susceptible, fatal systemic infections have been reported in the following new and old 
world primates: marmosets (Callithrix penincillata), white-faced saki (Pithecia pithecia), 
the common marmoset (Callithrix jacchus), the white-handed gibbon (Hylobates lar) and 
the orangutan (Pongo pygmaeus) (Huemer, Larcher et al. 2002; Schmutzhard, Merete 
Riedel et al. 2004; Kik, Bos et al. 2005; Landolfi, Wellehan et al. 2005).  Most infections 
in primates have occurred in pet, zoo, or research settings where primates have a greater 
risk of exposure to a shedding human, however, naturally occurring infections can occur 
in wild populations and are suspected to be the result of exposure to contaminated food 
(Bruno, Liebhold et al. 1997; Juan-Salles, Ramos-Vara et al. 1997; Huemer, Larcher et 
al. 2002; Matz-Rensing, Jentsch et al. 2003; Lefaux, Duprez et al. 2004; Costa, Luppi et 
al. 2011).  For HSV-1, humans are considered the reservoir for primate infections and 
due to the nature of transmission, primate transmission to a human is extremely unlikely 
and therefore, humans are considered the sole source of infection for other humans 
(Whitley and Roizman 2001).  
 
Mucocutaneous Infection 
The frequency and duration of contact contributes significantly to the chance of 
infection for a person (Whitley and Miller 2001).  HSV-1 infection most often occurs by 
5 years of age and is often fairly asymptomatic.  The most common site of primary 
infection is the mucosa of the lips and mucocutaneous junction around the mouth 
(Whitley and Miller 2001; Whitley and Roizman 2001).  After infection, virus is shed 




Fecal shedding is likely due to swallowed virus, as replication of HSV-1 in the 
epithelium of the digestive tract has not been reported as a prominent feature of the virus. 
By 4 to 7 days after neutralizing antibodies can be detected in the serum and these 
antibodies peak at about 3 weeks after infection (Buddingh, Schrum et al. 1953). 
Dissemination of HSV is often correlated with socioeconomic status with in some 
underdeveloped countries having as much as 95% seroprevalence by age 15 (Black, 
Hierholzer et al. 1974; Bader, Crumpacker et al. 1978).  By 10 years of age the estimated 
seroprevalence in the United States is about 50% and about 70% in Europe and at 60 
years of age both populations are at 70% to 85% depending on the study (Nahmias, Lee 
et al. 1990; Looker and Garnett 2005; Fatahzadeh and Schwartz 2007).  
Due to the nature of HSV-1 being primarily acquired orally and HSV-2 primarily 
acquired genitally, seroprevalence to HSV-1 is found in greater numbers and at an earlier 
age than HSV-2, in which the seroprevalence increases after the age of the onset of 
sexual activity (Nahmias, Lee et al. 1990; Fleming, McQuillan et al. 1997).  While HSV-
1 is usually an oral infection and HSV-2 is a genital infection, there are increasing reports 
of both viruses at the alternate sites, however, genital infections with HSV-1 tend to be 
less severe and have a lower frequency of recurrence (Kalinyak, Fleagle et al. 1977; 
Reeves, Corey et al. 1981; Corey, Adams et al. 1983).  
The hallmark of HSV-lifecycle is infection of sensory neurons where the virus 
establishes a latent infection for the life of the host (Whitley, Kimberlin et al. 1998a). 
However, alternate forms of a herpes simplex infection include: neonatal infection, 






Neonatal infections with HSV occur at a rate of 1 in 3000 deliveries and 1500 
cases per year in the United States (Nahmias 1983; Nahmias 1989; Brown, Wald et al. 
2003).  Neonatal infections may occur via in utero, intrapartum or postnatally with 
intrapartum the most common and postnatal infection occurring in 10% of cases (Whitley 
1994; Fatahzadeh and Schwartz 2007).  Congenital infection with herpes simplex is rare 
and often results in myriad developmental abnormalities in the brain (Jones 1996; 
Whitley and Roizman 2001).  Perinatal infection is much more common and may result 
in isolated disease and clearance or systemic disease and encephalitis (NoAuthor 1998; 
Fatahzadeh and Schwartz 2007).  Neonatal herpes was shown to involve the skin, eye, 
and mouth in approximately 42% of cases and generally a treated infant will resolve the 
disease and recover normally (Whitley, Corey et al. 1988; Kimberlin, Lin et al. 2001).  
Neonatal infections that result in encephalitis and/or disseminated disease and are 
often fatal with disseminated disease reaching 60% mortality even in treated infants 
(Fatahzadeh and Schwartz 2007).  In the case of neonatal herpes encephalitis, mortality is 
lower than for disseminated disease, but the brain develops normally in less than half of 
these infants following recovery (Thompson and Whitley 2011).  
 
Disseminated Infection 
Disseminated herpes simplex infection is the result of either neonatal infection or 
immunosuppression in an adult.  The immunosuppressed state has a greater risk for virus 
reactivation with aberrant spread of the virus to the internal organs including; the brain, 




spread is severe and the disease can be fatal even with therapy (Meyers, Flournoy et al. 
1980; Siegal, Lopez et al. 1981; Ramsey, Fife et al. 1982).  
 
Herpes Gladiatorum 
Herpes gladiatorum is infection through damaged or abraded skin in a location 
that is not the typical mucocutaneous exposure (Fatahzadeh and Schwartz 2007).  The 
incidence of this type of herpes infection is directly related to the potential for exposure 
in a shedding individual, with wrestlers, or athletes of similar unprotected contact sports, 
being especially susceptible (Fatahzadeh and Schwartz 2007).  
 
Herpetic Encephalitis 
The encephalitic form of disease with herpes simplex viruses is more attributable 
to the state of the patient rather than the strain of the virus.  When compared to 
mucocutaneous infection, herpes simplex encephalitis is a rare event in the 
immunocompetent person, however, in neonates the primary infection may result in 
encephalitis and in immunocompromised adolescents and adults, the primary or recurrent 
infection can result in encephalitis (Fatahzadeh and Schwartz 2007).  While rare in the 
healthy adult, herpes simplex encephalitis is still a significant cause of encephalitis in 
humans, as the most common cause of infectious encephalitis world wide and responsible 
for over 10% of the 7.3 million hospitalizations for encephalitis from 1979-1988 in the 
US (Stahl, Mailles et al. 2011).  
HSV encephalitis usually causes fever, headache, neurologic deficits, and 




Corey 2007).  When untreated, surviving patients rarely return to a fully normal 
neurologic state and even some treated patients have persistent neurologic deficits (Wald 
and Corey 2007).  HSV or inflammation resulting from HSV has also been implicated in 
the development of Alzheimer’s disease (Honjo, van Reekum et al. 2009).  
 
Ocular Infection 
Whether through primary ocular infection, such as may occur with herpes 
gladiatorum or intimate contact, or recurrence resulting in spread through the trigeminal 
ganglia, HSV may cause ocular disease as well.  Ocular HSV is one of the most common 
infectious causes of blindness in developed countries, with estimates of the incidence of 
herpes ocular disease ranging from 4.1 to 20.7 cases per 100,000 in developed 
countries(Liesegang, Melton et al. 1989b; Liesegang 2001).  An estimated 400,000 
people in the United States have had herpes simplex ocular disease, with about 50,000 
new or recurrent cases occurring yearly (NoAuthor 1998). 
 
Pathogenesis of Herpes Simplex Virus 
Herpes simplex virus is an enveloped, double-stranded DNA virus that must 
infect a target cell and replicate in that cells nucleus to complete its life cycle. Other than 
research settings, HSV is nearly entirely a human pathogen, with person-to-person 
contact responsible for the spread of the virus (Whitley 2001a).  Herpes simplex virus is 
unable to penetrate heavily keratinized layers of the skin, therefore, initial infection 
occurs at mucous membranes, such as the lips or oral cavity, or at areas of abraded skin 




HSV-1, the initial infection and first round of virus replication typically occurs in the 
orolabial mucosa (Roizman, Knipe et al. 2007).  After this initial round of infection, the 
virus spreads in subsequent rounds of infection, through this tissue and into sensory 
neurons innervating the infected tissue.  For HSV-2 this is the dorsal root ganglia in the 
sacral spinal area and for HSV-1 this is typically in the trigeminal ganglia (Bastian, 
Rabson et al. 1972; Baringer and Swoveland 1973; Whitley 2001a).  
The most common clinical form of the disease consists of a short to moderate 
duration of lesions at the initial site of infection, possibly with fever and generalized 
symptoms.  Following this, the virus having infected sensory neurons, establishes a latent 
infection for the life of the host that results in periodic recurrences at or near the site of 
initial infection with generally reduced severity from the initial infection (Bastian, 
Rabson et al. 1972; Baringer and Swoveland 1973; Roizman, Knipe et al. 2007). 
Alternate, and less common, sequelae to the initial infection include the development of 
ocular disease, disseminated disease and neurologic disease.  With the exception of those 
arising from neonatal infections; disseminated, neurologic, and ocular disease are more 
common for HSV-1 than HSV-2 (Roizman, Knipe et al. 2007).  Individuals with reduced 
immune capability, such as neonates, people concurrently infected with HIV, or people 
with other causes of immune suppression are at greater risk for these alternate 
manifestations of the infection (Fatahzadeh and Schwartz 2007).  
 At the site of initial mucosal infection, infected cells exhibit enlargement of the 
cell with condensation of the chromatin in the nucleus.  Sometimes cellular chromatin is 
visibly moved to the periphery of the nucleus with formation of intranuclear inclusion 




degradation and fragmentation of the nucleus and disruption of the plasma membrane. 
Occasionally cells will fuse the plasma membranes forming multinucleated giant cells 
(Pugh, Dudgeon et al. 1955; Wheeler and Abele 1966; Terezhalmy, Tyler et al. 1979).  In 
the infected dermis there is an intense inflammatory response that may be complicated by 
secondary bacterial or fungal opportunistic infection.  Immune cellular response due to 
the erosion of the mucosal surface and surface bacteria and fungi is often mixed with 
polymorphonuclear cells, macrophages, lymphocytes and plasma cells (Pugh, Dudgeon et 
al. 1955; Wheeler and Abele 1966; Terezhalmy, Tyler et al. 1979).  If infected neurons 
enter the lytic phase of infection, they appear similar to infected epithelial cells although 
multinucleate giant cells are very rare (Dudgeon 1969).  Neurons that enter the latently 
infected state may appear normal.  In neuronal tissues, the immune reaction is generally 
restricted to lymphocytes and plasma cells with some macrophages.  In mucosal tissues, 
usually the intensity and duration of the cellular destruction and inflammation decreases 
with recurrent infections (Whitley 2001a).  
 
Mucocutaneous Infection 
 As stated above, primary infection with HSV-1 usually occurs in the orolabial, 
glossal, gingival or buccal mucosa.  This infection is often accompanied by one or more 
of the following symptoms: vesicular or ulcerative lesions, localized pain and edema, 
fever, and sore throat (Amir, Nussinovitch et al. 1997).  The primary infection can 
frequently be asymptomatic or of insufficient clinical significance to be reported as well 
(Whitley and Roizman 2001).  When symptomatic in children, the clinical course is 




adults, the primary infection can produce pharyngitis at the initial stage of the oral 
infection and tonsillectomy is often the treatment of choice when this occurs 
(Langenberg, Corey et al. 1999).  Occasionally the primary infection is complicated by 
dehydration, likely due to an unwillingness to drink due to pain, and secondary bacterial 
infection (Langenberg, Corey et al. 1999).   
With HSV-1, recurrent disease is frequently more noticeable with marked pain, 
burning, tingling or itching as a prodromal event (Spruance, Overall et al. 1977; Spruance 
and Crumpacker 1982; Spruance 1984).  These symptoms are usually short, six hours or 
less, and are followed by formation of vesicles and the typical cold sore within 24-48 
hours (Spruance, Overall et al. 1977; Spruance and Crumpacker 1982; Spruance 1984). 
Pain is generally most intense at the beginning of the cold sore formation with the pain 
resolving over 4-5 days and lesions resolving in approximately 7 days (Segal, Katcher et 
al. 1974; Ship, Miller et al. 1977).  Reactivation can occur for a number of reasons 
including: trauma to the local area of initial infection, fever, exposure to UV radiation 
and stress (Segal, Katcher et al. 1974; Ship, Miller et al. 1977; Spruance, Freeman et al. 
1991).  The frequency of reactivation varies greatly among individuals, with a study 
reporting that approximately 30% of seropositive individuals experience recurrent 
infections with 40% of these having at least one recurrence per year (Wald and Corey 
2007).  HSV-1 can also be detected on the orolabial mucosa of seropositive individuals 
even without clinical disease, suggesting that recurrence, shedding, and possibly 
transmission, can occur as an asymptomatic, subclinical, event (Koelle and Wald 2000; 





 In HSV-2 the primary infection usually occurs in the genital epithelial or mucosal 
tissues.  Generally with HSV-2, the most severe symptoms are associated with the 
primary infection and are characterized by macules and papules that turn into pustules 
and ulcers with lesions and viral secretion lasting about three week (Corey 1982; Corey, 
Adams et al. 1983).  It appears that previous exposure and immunity to HSV-1 may 
mitigate HSV-2 infection, by decreasing the severity of the primary infection (Kaufman, 
Gardner et al. 1973; Corey 1981; Allen and Rapp 1982).  
Clinical recurrence in HSV-2, unlike HSV-1, is typically less severe than the 
initial infection with asymptomatic shedding or milder pain, the development of vesicles, 
and shedding of the virus lasting less than 10 days total (Adams, Benson et al. 1976). 
However, with HSV-2 recurrence seems to be more frequent with several recurrences 
occurring per year and the possibility of transmission during asymptomatic or 
symptomatic disease (Corey 1982; Corey, Adams et al. 1983). 
 
Neonatal Infection 
Neonatal HSV infections occur at a rate of approximately 1 in 3000 births with an 
estimated 1500 cases of neonatal HSV per year in the United States (Nahmias 1983; 
Nahmias 1989; Brown, Wald et al. 2003).  Neonatal infections may occur in utero, 
intrapartum or postnatally with intrapartum the most common and postnatal infection 
occurring in 10% of cases (Whitley 1994; Fatahzadeh and Schwartz 2007).  Congenital, 
in utero, infection is rare with HSV but is often severe when it occurs (Jones 1996; 
Whitley and Roizman 2001).  In utero infection causes cutaneous lesions, scars and 




microcephaly, lissencephaly, hydranencphaly and microphthalmia (Hutto, Arvin et al. 
1987).  Intrapartum infection accounts for 75-80% of cases (Whitley 2001a). HSV-2 is 
often the culprit in intrapartum infection, although HSV-1 infection may also occur, when 
the fetus is exposed to maternal genital secretions during delivery or in the post-natal 
period from the mother or other infected individuals (Whitley 2001a; Wald and Corey 
2007).  
In cases of herpes encephalitis in the neonate, HSV-1 usually has a better 
prognosis than HSV-2 (Toth, Harder et al. 2003).  The risk of fetal infection is directly 
related to the type of maternal genital infection at the time of delivery, with a 
transmission risk of approximately 30% if the mother has a primary infection and 3% or 
less risk of transmission to the fetus if the mother has a recurrent infection at the time of 
delivery (Brown, Benedetti et al. 1991).  Risk of fetal infection is increased in the 
intrapartum period with closer proximity of a primary maternal infection to the time of 
delivery and with increased disruption or trauma to the mucocutaneous tissues (Nahmias, 
Josey et al. 1971; Parvey and Ch'ien 1980; Brown, Wald et al. 2003).  Risk of 
transmission is reduced with maternal seroconversion prior to delivery and with 
caesarean delivery (Brown, Wald et al. 2003; Johnston, Magaret et al. 2008).  
 HSV infection in newborns can result in disseminated disease, central nervous 
system disease, or cutaneous disease.  The type of disease is a result of the site and extent 
of viral replication.  Infection of the newborn may result in isolated cutaneous disease, 
systemic (disseminated) disease, or encephalitis (NoAuthor 1998; Fatahzadeh and 
Schwartz 2007).  Neonatal herpes was shown to involve the skin, eye, and mouth in 




recover normally (Whitley, Corey et al. 1988; Kimberlin, Lin et al. 2001).  Without 
antiviral therapy, 25% of infants with only cutaneous disease still had neurologic 
developmental delays (Whitley, Nahmias et al. 1980; Kimberlin, Lin et al. 2001). 
Neonatal infections resulting in disseminated disease or encephalitis are much more 
severe.  Even with antiviral therapy, in one study there was 57% mortality for cases of 
disseminated disease and 15% mortality for cases of encephalitis in infants (Whitley, 
Arvin et al. 1991).  In this same study none of the infants with cutaneous disease died and 
94% developed normally neurologically (Whitley, Arvin et al. 1991).  While mortality is 
less in cases of infant with encephalitis versus disseminated disease, there are 
developmental abnormalities in more than half of these infants following recovery 
(Thompson and Whitley 2011).  In the previously mentioned study, one year following 
recovery 36% of infants that had encephalitis and 59% of the infants surviving 
disseminated disease were developing normally (Whitley, Arvin et al. 1991).  
 Infants with cutaneous or disseminated disease usually present within the first 10-
12 days of life (Kimberlin, Lin et al. 2001).  Cases of encephalitis in neonates usually 
present slightly later, at 2-3 weeks after birth (Kimberlin, Lin et al. 2001).  Cutaneous 
vesicles may be seen with all presentations of neonatal HSV infection but are frequently 
resolved by the time of presentation with more severe disseminated or encephalitic 
disease (Kimberlin, Lin et al. 2001; Thompson and Whitley 2011).  With central nervous 
system infection and disseminated disease the initial symptoms are often non-specific, 
including fever or fluctuating temperature, respiratory distress, lethargy, inappetance, 
hypotension, shock, disseminated intravascular coagulation, apnea, and shock (Thompson 




including lungs, liver, adrenal glands, skin, eyes, and often the brain (Thompson and 
Whitley 2011).  Severe pneumonitis, hepatitis, and coagulopathy are common 
complications of disseminated disease in neonates (Thompson and Whitley 2011). 
Lesions in the central nervous system of infected neonates are similar to those described 
later for adults with the exception that brainstem involvement appears to be less common 
in the neonate (Chu, Kang et al. 2002; Pelligra, Lynch et al. 2007).  In the cerebrospinal 
fluid, there is mild to moderate pleocytosis, consisting predominantly of mononuclear 
inflammatory cells and normal to decreased protein levels (Koskiniemi, Vaheri et al. 
1980; Cinque, Cleator et al. 1996).  
 
Ocular Infection 
 A less frequent, however, very serious manifestation of HSV infection is herpetic 
ocular disease.  Ocular disease with herpes simplex virus is usually due to HSV-1. Even 
at a prevalence of 149 cases per 100,000 people per year, corresponding to less than 1% 
of people exposed to the virus, HSV is the leading infectious cause of blindness in the 
United States with an estimated 400,000 people in the United States with herpes simplex 
ocular disease and approximately 50,000 new or recurrent cases occurring yearly  
 (Liesegang, Melton et al. 1989b; NoAuthor 1998; Liesegang 2001; Tullo 2003).  
The ocular manifestation of HSV is usually a result of spread of primary disease 
through the branches of the trigeminal ganglion rather than primary infection of the 
ocular area (Tullo, Easty et al. 1982; Theil, Derfuss et al. 2003; Tullo 2003; Pepose, 
Keadle et al. 2006).  While a primary ocular infection could result from mechanical 




accurately multiple recurrences, following a primary infection in the normal route. 
Superinfection, or infection with a second strain after previous exposure to the virus and 
incomplete immune protection, may account for some of the cases of ocular disease and 
recent studies suggest that this phenomenon may be more common than previously 
thought (Remeijer, Maertzdorf et al. 2002).  In either case, after superinfection or 
multiple recurrences or reactivation events, the tissues of the eye, including the cornea 
and adjacent epithelial tissues, become infected and subsequent reactivations can cause a 
progressive degeneration of the cornea eventually leading to blindness (NoAuthor 1998; 
Liesegang 2001).  
 More rare causes of herpetic ocular disease can occur with primary or recurrent 
infection that involves the innervation of alternate structures in the eye; e.g.: those 
structures innervated by a nerve that is not part of the trigeminal.  Reactivation of latent 
HSV, possibly from earlier localized or CNS infection, from the ciliary or superior 
cervical ganglion or Edinger-Westphal-nucleus can result in herpes infection in the iris 
(Pepose, Leib et al. 1996; Labetoulle, Kucera et al. 2000).  Furthermore, reactivation of 
HSV from the suprachiasmatic or paraventricular nuclei or any other 
infection/reactivation event causing encephalitis can result in retinitis or retinal necrosis 
and spread of infection to the surrounding tissues (Gentry, Lowe et al. 1988; Atherton 
2001).  Following this round of replication, the trigeminal ganglion, which innervates the 
sensory structures around the eye can be infected and contribute to later bouts of more 
traditional recurrent herpetic eye disease.  
With recurrent bouts of herpes keratitis, the cornea can become opaque leading to 




spread from the patient’s latently infected trigeminal ganglia to the new cornea and can 
even cause primary graft failure (Cockerham, Krafft et al. 1997; De Kesel, Koppen et al. 
2001; Tullo 2003).  Less commonly, a person without herpes keratitis may receive a 
transplant cornea that is harboring latent or persistent HSV and following a flourishing 
infection in the transplant, the patients previously naïve trigeminal ganglia (Easty, 
Shimeld et al. 1987; Gordon, Romanowski et al. 1991; Kaye, Lynas et al. 1991).  This 
has recently lead to investigations into the possibility of non-neuronal sources of latency 
for HSV (Farooq and Shukla 2011). 
 Primary infection or recurrent shedding causes herpetic ocular disease in one or 
both eyes.  The lesions of ocular infection with HSV include: blepharitis, conjunctivitis, 
dendritic or epithelial keratitis (superficial infection of the cornea), stromal keratitis (deep 
infection of the cornea), anterior uveitis, iridocyclitis, and retinitis (NoAuthor 1998; 
Liesegang 2001).  These conditions can cause blindness through progressive 
inflammation and opacity of the cornea or more directly through destruction of the retina 
(NoAuthor 1998; Liesegang 2001).  On the surface of the cornea, the infection usually 
begins as focal point that spreads to a web-like (dendritic) pattern (Maudgal and 
Missotten 1978).  Pathologically, on the surface of the cornea, there are erosions and 
ulcerations of the epithelium with necrosis and inflammation by polymorphonuclear 
inflammatory cells, lymphocytes and plasma cell, sometimes with syncytial cells and 
intranuclear inclusions (Maudgal and Missotten 1978; Metcalf and Reichert 1979).  






As the lesions progress deeper to stromal keratitis, there is inflammation of the 
corneal stroma by polymorphonuclear inflammatory cells, lymphocytes, plasma cells and 
macrophages (Metcalf and Reichert 1979).  Necrosis, neovascularization, fibroplasia and 
full-thickness penetration may also be observed (Metcalf and Reichert 1979).  The 
infection can progress to deeper eye tissues and cause infection and inflammation of the 
anterior chamber, iris and retina (Holland, Togni et al. 1987; Liesegang 2001; David, 
Baghian et al. 2008).  Lesions can even progress to full-thickness necrosis of the retina 
with mixed inflammatory infiltrates and herpes particles detectable in the cell layers of 
the retina, including the retinal pigment epithelium (Holland, Togni et al. 1987; 
Liesegang 2001).  Acute necrosis of the retina in people is rare but more frequently 
observed in young patients when it occurs (Liesegang 2001).  
Another possible consequence of herpetic ocular disease is hypoesthesia, or loss 
of sensation, in the cornea due to destruction or degeneration of sensory trigeminal nerves 
(Keijser, van Best et al. 2002).  This can cause a decrease in tear production and resulting 
dry eye with increased chances for corneal abrasion, inflammation, secondary infection 
and even stimulation of additional herpetic recurrence (Keijser, van Best et al. 2002; 
Tullo 2003).  
 
Central Nervous System Infection 
 Central nervous system (CNS) infection with herpes simplex virus encephalitis is 
a rare event in the immunocompetent adult, however, in neonates the primary infection 
may result in encephalitis and in immunocompromised adolescents and adults, the 




Schwartz 2007). Although rare compared to oral mucosal infection, HSV-1 is one of the 
most common and potentially severe causes of sporadic encephalitis in adults (Lakeman 
and Whitley 1995). Herpes simplex encephalitis can happen to any age person, has no 
seasonal variability and is one of the most common causes of infectious encephalitis with 
an estimated incidence of 1 in 250,000 to 1 in 1 million people per year (Skoldenberg, 
Forsgren et al. 1984; Whitley and Schlitt 1991). From 1979-1988, herpes simplex 
encephalitis was the most common cause of infectious encephalitis in the US and was 
responsible for over 10% of the 7.3 mission hospitalizations for encephalitis (Khetsuriani, 
Holman et al. 2007; Stahl, Mailles et al. 2011). HSV-2 is a more common cause of 
encephalitis in neonates, but HSV-1 is a far more common cause of herpes encephalitis in 
older age groups, accounting for 90% of cases (Ito, Watanabe et al. 2000).  
Infection of the central nervous system most likely occurs via spread of the virus 
from the primary site of infection, usually mucous membranes, through the nerves that 
innervate these tissues, usually the trigeminal or olfactory nerves (Arduino and Porter 
2008).  This spread can occur following the primary infection or more frequently during a 
recurrence, after latency has been established. HSV encephalitis usually causes fever, 
headache, neurologic deficits, and personality and cognitive disorders and has a 70% 
fatality rate when untreated (Wald and Corey 2007).  Herpes encephalitis has also been 
associated with senile-plaque-like beta amyloid deposits in the brain that are associated 
with the development of dementia and Alzheimer’s disease (Honjo, van Reekum et al. 
2009; Miklossy 2011). 
 Clinically, herpes encephalitis can present with altered consciousness, non-




or behavior changes (Cinque, Cleator et al. 1996).  These lesions generally refer to the 
areas of the brain involved; however, there is no specific pattern for herpes encephalitis 
(Cinque, Cleator et al. 1996).  Prior to full onset of symptoms, there is often a prodromal 
phase consisting of aphasia, fever, headache, nausea, and visual deficits that may 
continue until presentation (Cinque, Cleator et al. 1996).  In the most severe, or untreated, 
cases, the disease can be rapidly progressive with severe cerebral edema, necrosis of vital 
brain structures, and death within 7 to 14 days (Cinque, Cleator et al. 1996).  
CNS lesions of herpetic encephalitis include aseptic meningitis and acute 
encephalomyelitis either with or without necrosis (Dudgeon 1969).  Herpes cases 
involving solely aseptic meningitis appear to be rare (Dudgeon 1969).  Cases with aseptic 
meningitis often have few lesions with only infiltration of the meninges infiltrated by 
mononuclear inflammatory cells and a slight increase of mononuclear inflammatory cells 
in the cerebrospinal fluid (CSF) (Dudgeon 1969; Koskiniemi, Vaheri et al. 1980; 
Skoldenberg, Forsgren et al. 1984).  Cases with encephalitis or encephalomyelitis range 
from moderate to severe with possible extensive cortical necrosis (Stahl, Mailles et al. 
2011).  Generally the temporal lobes are the most frequently affected in a bilateral, 
random, asymmetrical pattern (Dudgeon 1969; Stahl, Mailles et al. 2011).  The frontal 
and parietal cortices are less commonly involved, however, all the brain can become 
involved (Stahl, Mailles et al. 2011).  In cases of encephalitis/encephalomyelitis, the early 
CSF shows a mild to moderate increase in mononuclear cells with normal or slight 
increases in protein (Dudgeon 1969; Koskiniemi, Vaheri et al. 1980; Skoldenberg, 
Forsgren et al. 1984).  Later, especially with necrosis, the CSF can show markedly 




Microscopically, herpes encephalitis lesions are characterized by focal to massive 
necrosis with hemorrhage and edema of the gray matter sometimes with intranuclar 
inclusions (Dudgeon 1969; Booss and Kim 1984).  Neutrophils may be present in areas 
of necrosis and microglial infiltration, microglial nodules and perivascular cuffing is 
observed (Dudgeon 1969).  Although lesions are often confined to the cortex, lesions can 
progress to the basal ganglia, lobar white matter, and the brainstem (Chu, Kang et al. 
2002; Ueda, Miyasaki et al. 2003; Ono, Manabe et al. 2009).  In the end stages there is 
gliosis and astrocytosis and there may be persistent post infectious encephalomyelitis, 
movement disorders, atypical pain syndromes, neurologic deficits and epilepsy 
(Schmutzhard 2001; Simmons 2002).  HSV encephalitis may be diagnosed via PCR of 
brain biopsy tissue or CSF, ELISA of CSF, or viral isolation from brain biopsy tissue 
(Cinque, Cleator et al. 1996).  
 
Infection in an Immunocompromised Host 
 Rather than being a distinct clinical appearance, primary or recurrent infection of 
an immunocompromised person follows pattern similar to those observed in healthy 
individuals with the exception that the infections are more severe, more common, have 
greater spread, and are more likely to develop into serious illness (Fatahzadeh and 
Schwartz 2007).  Immune suppression may be due to immunotherapy, metabolic 
disturbances, malnutrition, or concurrent disease, such as acquired immunodeficiency 
syndrome (AIDS) or immune system neoplasia.  In these patients, HSV infections may 
develop progression from the oral mucosa to severe disease involving the esophagus, 




Korsager, Spencer et al. 1975).  In the case of recurrence of oral mucosal disease, the 
disease may spread extensively in the mouth, on the tongue and along the GI tract 
resulting in a disease that is more painful and takes significantly longer to heal, up to 6 
weeks or more (Whitley, Levin et al. 1984; Cohen and Greenberg 1985; Epstein, 
Sherlock et al. 1990; Woo, Sonis et al. 1990).  The incidence of reactivation can range 
from 60-95% in seropositive patients that receive immunosuppressive therapy for bone 
marrow transplant (Arduino and Porter 2008).  The most common complication in 
immunosuppressed patients is severe, progressive, chronic mucocutaneous infection with 
recurrent infection leading to disseminated disease or CNS infection occurring rarely 
(Whitley, Levin et al. 1984; Whitley and Roizman 2001).  When disseminated disease or 
CNS infection occurs it is similar to the conditions previously described. In the 
immunocompromised patient, HSV-1 is the prominent culprit, however, HSV-2 has been 
reported to cause meningoencephalitis in immunocompromised patients (Linnemann, 
First et al. 1976; Gateley, Gander et al. 1990). 
 
Treatment and Prevention of HSV Infection 
Generally the two broad strategies for control of an infectious agent are some type 
of preventative measure and then treatment of infected individuals.  In the case of HSV, 
whether type 1 or 2, prevention has been difficult to accomplish.  The ideal mechanism 
for prevention would be a vaccine that prevents the development of infection past a mild 
mucocutaneous course of infection, eliminating spread to the nervous system and 
possible recurrence.  No vaccine has produced this level of protection to date (Roizman, 




prophylactic sense to prime the immune system to limit the severity and duration of  
clinical symptoms in primary or recurrent infection (Stanberry 2004).  
 
Vaccines 
Attenuated live strains, killed virus, viral subunits, and genetically modified, 
attenuated viruses have all been attempted.  Attenuated live strains tended to produce 
infection at the site of infection as well as recurrent disease later (Roizman, Knipe et al. 
2007).  Killed virus vaccines have been unreliable at producing a decrease in the 
symptoms of recurrent infection versus placebo (Whitley 2001a).  These vaccines have 
also been unable to provide substantial increases in neutralizing antibody titers or 
complement fixation of virus to defend against primary infection (Roizman, Knipe et al. 
2007).  Subunit vaccines utilize viral proteins without the DNA component to prevent the 
vaccine from causing an infection.  Typically subunit vaccines have provided little 
mitigation of symptoms in the already infected and no definitive protection for the 
unexposed (Roizman, Knipe et al. 2007).  A recent subunit vaccine has had some success 
with the mitigation of symptoms and prevention of primary infection.  
Two somewhat similar HSV-2 based vaccines have recently been used in large, 
well controlled studies (Roizman, Knipe et al. 2007).  They both contain a modified 
recombinant form of glycoprotein D, while one also contains a modified glycoprotein B 
(Wilson, Fakioglu et al. 2009).  The vaccine containing only the gD modification has 
been shown to be protective versus primary infection as well as able to mitigate 
symptoms of recurrence in latently infected women, however, no discernable effect was 




similarity in the two vaccines, the difference may lie in the adjuvant, which in the more 
efficacious vaccine induced T helper-1 rather than T helper-2 immune responses 
(Roizman, Knipe et al. 2007; Wilson, Fakioglu et al. 2009).  The gender difference in this 
vaccine needs to be examined to provide a more efficacious vaccine; however, given the 
poor status of HSV vaccines to date this progress is promising.  
Construction of a recombinant (genetically modified), attenuated, live vaccine 
strain of the virus is the most likely method to produce a vaccine that both limits the 
course of recurrent disease in the latently infected and prevents primary infection. 
Currently some strains with limited replication characteristics have been attempted as 
possible vaccine strains, however, limited replication can have negative consequences on 
the development of a robust immune response (Dudek and Knipe 2006; Roizman, Knipe 
et al. 2007).  Development of vaccine strains that allow sufficient replication to induce an 
immune response while preventing the establishment of latency are likely the best 




Another prevention strategy is to eliminate contact with seronegative individuals 
when seropositive individuals are shedding virus.  Prevention using this strategy is 
difficult due to asymptomatic shedding.  Asymptomatic shedding has been reported for 
HSV-2 and one study found that 33% of people were asymptomatic at the time of 
infection of their partner (Mertz, Schmidt et al. 1985; Barton, Wright et al. 1986). For 




70% of the population may shed HSV-1 at least once per month with many of these 
shedding six times per month without symptoms (Miller and Danaher 2008).  Amounts of 
viral DNA that can be detected decrease during antiviral therapy, however, detectable 
DNA is still shed without symptoms during this therapy (Koelle and Wald 2000).  
Clearly the virus can be transmitted to a seronegative individual without the knowledge 
of the carrier.  
 
Therapeutics 
Therapeutic antivirals that can reduce the symptoms and duration of primary and 
recurrent infection are available for HSV.  The nucleoside analogs such as acyclovir, 
ganciclovir, famciclovir and valacyclovir have specific activity against HSV.  The first 
nucleoside analog used effectively to treat HSV was acyclovir (Elion 1977).  In general 
these are analogs of the nucleoside guanosine, or are converted by cellular or viral 
enzymes to analogs of guanosine, that can substitute for guanosine in DNA replication 
(Wilson, Fakioglu et al. 2009).  In these cases the deoxyribose sugar ring is altered or 
replaced by another molecular structure.  For acyclovir this is specifically a non-ring, 
linear structure.  Acyclovir enters the cell in this form and is phosphorylated to 
acycloguanosine-monophosphate by viral thymidine kinase (Coen and Richman 2007).  It 
is then converted to the tri-phosphate form by cellular kinases and acycloguanosine-3P 
competes with GTP in DNA synthesis (Coen and Richman 2007).  It inhibits the viral 
DNA polymerase and since the sugar end of acyclovir cannot be used to link the next 
nucleotide, it terminates the DNA strand replication (Furman, St Clair et al. 1984).  Viral 




reading/removal of the acyclovir.  This is because the HSV DNA polymerase is 
irreversibly inactivated when it attempts to use the acyclovir-triphosphate (Furman, St 
Clair et al. 1984).  Acyclovir and the other guanosine analogs appear to have a higher 
affinity for viral kinases and viral DNA polymerase thereby making them have a more 
potent anti-viral effect than an anti-cellular enzyme effect (Fyfe, Keller et al. 1978).  The 
oral bioavailability of acyclovir is low, therefore other forms of guanosine analogs and 
pro-drugs, such as famciclovir and ganciclovir were created with greater flexibility in 
dosing (Coen and Richman 2007).  Acyclovir and related compounds are fairly 
efficacious in limiting the severity of herpetic disease, however, resistant strains have 
developed (Bacon, Levin et al. 2003; Coen and Richman 2007).  In cell culture, acyclovir 
can be used to establish a quiescent/latent infection state, therefore, it is likely that drugs 
like acyclovir may provide some measure of help in maintaining the latent state in 
sensory neurons (Danaher, Jacob et al. 1999).  
Another inhibitor of DNA replication, and HSV antiviral compound, is foscarnet. 
This is a pyrophosphate mimic that can directly inhibit the action of the DNA polymerase 
by substituting for pyrophosphate (Coen and Richman 2007).  This compound will also 
inhibit RNA polymerase.  Foscarnet does not require the viral thymidine kinase for 
activation and is therefore active versus acyclovir resistant viruses (Wilson, Fakioglu et 
al. 2009).  Since this compound is not as specific for HSV, it also possesses action 
against cellular polymerases and is more toxic (Wilson, Fakioglu et al. 2009).  Cidofovir 
is a nucleoside analog, similar to acyclovir, however it uses cellular enzymes to be 
phosphorylated to an active form and, therefore, can be used versus acyclovir resistant 




and effective against acyclovir resistant viruses, these are generally administered only in 
cases of resistance (Wilson, Fakioglu et al. 2009).  
 
 
The Host Neuron and its Role in HSV Infection 
 
Basic Neuron Structure 
The anatomic structure of a typical neuron is composed of the cell body (soma) 
that contains the nucleus, an axon (which is the long tubular process that traverses the 
distance between the soma and the axon terminals, dendrites (which are multiple web-
like projections of processes and synaptic bulbs (King 1994).  Most neurons are 
multipolar with axons and dendrites projecting in multiple directions and dendrites 
coming directly off the soma.  Sensory neurons, the primary neuronal target of HSV, are 
pseudounipolar with a single process that bifurcates to make the axon running to the 
receptors at one end and axonal termini at the other with the soma situated in the middle 
(King 1994).  In a sensory pseudounipolar neuron, the dendrite extends to the innervated 
site and acts electrophysiologically like a dendrite bringing sensory stimuli toward the 
cell body (Zaichick, Bohannon et al. 2011).  However, in other respects the structural 
composition, functional elements, and directionality of microtubules of this structure are 
more similar to an axon (Enquist, Husak et al. 1998; Zaichick, Bohannon et al. 2011). 
The synapse is formed from a synaptic bulb (a bulge in the axon terminus), the synaptic 
cleft and the post-synaptic structure being acted upon (dendrites, other axons or neuron 
cell bodies).  The synaptic cleft is lined by the pre-synaptic membrane (part of the bulb 
which releases neurotransmitters) and the post-synaptic membrane (where 




attractive target for entry of a virus as there is abundant turn-over of membranes due to 
the vast recycling associated with release and reuptake of neurotransmitters (Salinas, 
Schiavo et al. 2010).  For HSV specifically, nectin-1 is located at the synaptic junction 
for sensory neurons (Salinas, Schiavo et al. 2010).  
 
Retrograde and Anterograde Transport 
To discuss neuronal axonal biology and transport functions a few terms must first 
be defined.  First directionality of transport within a neuron must be considered. 
Retrograde transport is defined as transport from the axon terminus/ends of dendritic 
processes toward the nucleus/cell body.  Anterograde transport is the opposite, transport 
from the nucleus/cell body to the axon terminus/ends of dendritic processes.  When 
referring to a single neuron, this system is fairly straightforward.  However, occasionally 
these terms are used to refer to the overall direction of travel from the point of a whole 
system that contains arcs of multiple neurons.  In this case, retrograde transport refers to 
the overall movement toward the central nervous system (CNS), the brain or spinal cord. 
In this context, anterograde transport refers to movement from the CNS toward the 
peripheral tissues of the animal.  Therefore, due to the architecture of neuronal pathways 
and individual neurons, retrograde transport at the level of the overall animal may require 
brief anterograde transport on an individual neuron level.  
The axon is a long, tubular structure in which the majority of transport within 
neurons occurs.  The axon is made predominantly of microtubules surrounded by the 
plasma membrane and contains abundant transport molecules, proteins, enzymes, and 




glial cel) in the peripheral nervous system (PNS) and by oligodendroglial cells in the 
CNS with unmyelinated axons being supported and surrounded in groups in the PNS 
(King 1994).  The axon structure is vital to the function of transport of molecules within 
the neuron. 
Interestingly, intracellular transport is highly conserved among neurons and non-
neuronal cells.  Transport along axons occurs primarily along a scaffold of microtubule 
rails.  These are made of heterodimers of alpha and beta tubulins and are approximately 
25 nm in diameter (Hirokawa 1998; Hirokawa and Takemura 2005).  Although, transport 
mechanisms are conserved, microtubules have polarity and in axons they run in the same 
direction while in dendrites and other cell types they may run in multiple directions.  In 
axons, the plus end is directed to the periphery; which means that in axons anterograde 
transport is always directed toward the plus end and retrograde transport toward the 
minus end (Baas, Deitch et al. 1988; Burton 1988; Sharp, Yu et al. 1995).  In epithelial 
cells the minus ends are oriented toward the apical surface of the cell and in fibroblasts 
they radiate around the nucleus in various directions (Hirokawa, Noda et al. 2009). 
Transport within axons is accomplished by two types of molecular motors.  One is the 
kinesin superfamily of proteins (KIFs) and the other is dynein.  Both of these proteins 
transport a large variety of molecules and, although they use different mechanisms to 
specify what molecules are transported, they both use ATP hydrolysis to drive transport 
(Hirokawa, Noda et al. 2009).  Dynein forms a dynactin complex with multiple subunits 
to bind various molecules while KIFs use a wide variety of proteins in the family to 
accomplish binding and transport of varied proteins, enzymes and organelles (Vallee, 




Comprehensive analysis of mammalian genomes have found 45 KIF genes with 
38 expressed in the brains of mice (Miki, Setou et al. 2001).  There are 3 broad catagories 
of KIFs; N-kinesins with the motor domain near the amino terminus, M-kinesins with the 
motor near the middle and C-kinesins with the motor near the carboxy terminus 
(Hirokawa and Noda 2008; Hirokawa, Noda et al. 2009).  N-kinesins have plus directed 
motor activity and C-kinesins have minus motor activity.  The majority of kinesins are N-
kinesins with KIFs responsible for all anterograde transport currently identified (other 
than diffusion) and dynein responsible for the majority of retrograde transport (Miki, 
Setou et al. 2001; Gennerich and Vale 2009; Hirokawa, Noda et al. 2009).  A few of the 
best characterized kinesin superfamily proteins and their known cargos will be listed. 
KIF1A has been shown to transport synaptic vesicle precursors containing 
synaptophysin, synaptotagmin and Rab-3A and binds its cargo through a pleckstrin-
homology domain (Okada, Yamazaki et al. 1995; Klopfenstein, Tomishige et al. 2002). 
KIF1Bbeta seems to share many functions with KIF1A and this was not a unique instance 
of some redundancy in these proteins (Hirokawa and Noda 2008).  KIF1Balpha is a 
monomer used for transport of mitochondria (Nangaku, Sato-Yoshitake et al. 1994). 
KIF5 is a dimeric motor that consists of 3 subtypes (A, B, and C) that can form tetramers 
with KIF light chains. KIF5 has been shown to transport mitochondria, neurofilaments, 
syntaxin, syntabulin, GAP-43, synapsin and likely c-jun NH2-terminal kinase interacting 
proteins (which serve as scaffolds for MAP kinases (Hirokawa and Noda 2008).  KIF5 
can also play a role in retrograde transport (Hirokawa and Noda 2008).  
The previous examples are of fast axonal transport, however, there is a second set 




transport carries structural proteins, like tubulins and neurofilaments, or glycolytic 
enzymes (Hirokawa and Noda 2008).  KIF5 is the primary currently identified mediator 
of slow anterograde transport (Hirokawa and Noda 2008).  There is increasing evidence 
that slow and fast transport actually occur at similar rates of forward progress, just that 
slow anterograde movement has pauses of significantly greater duration than in fast 
transport (Brown 2003).  The determinants of what causes a pause, allows a return to 
movement or determines the length of pauses are not well known (Brown 2003; 
Hirokawa and Noda 2008).  However, it appears that in slow axonal transport, there is a 
distinct on- or off-track state and in the off-track state, neurofilaments pause for 
prolonged periods of time without forward movement (Brown, Wang et al. 2005). 
Furthermore, myosin Va may play a role in the length of pauses in the delivery of 
neurofilaments by reducing time off-track (Alami, Jung et al. 2009). 
 Most of the retrograde transport that occurs in neurons, occurs via dynein. Less 
specific details are known about dynein in axonal transport compared to the kinesin 
superfamily.  Dynein is a very large protein complex, 1.2 MegaDaltons (MDa), and is 
composed of two heavy chains and multiple light chains (Gennerich and Vale 2009).  The 
motor action of dynein is performed by the heavy chains and the intermediate and light 
chains perform cargo attachment functions (Hall, Song et al. 2010).  The heavy chains of 
dynein are encoded by a single gene and as few as two genes may encode the possible 
dynein light chains (Pfister, Shah et al. 2006; Ha, Lo et al. 2008).  These may be arranged 
as isoforms to provide diversity of cargo binding domains.  The intermediate chain of 
dynein has at least 6 splice variants that appear to be preferentially expressed in various 




TrK B) (Pfister, Shah et al. 2006; Lo, Kogoy et al. 2007; Myers, Lo et al. 2007; Ha, Lo et 
al. 2008).  When considered simply, this disparity in complexity is likely due in part to 
the vast amounts of molecular material that must be transported to the axon terminus 
versus the much lower amount of material that needs to be transported back from the 
terminus to the cell body.  Cellular components and neurotransmitters that must be 
recycled at the level of the cell body, must be transported in the retrograde direction. 
However, there is substantial evidence that protein synthesis occurs at the nerve termini 
and that there may be glial-neuronal cell signaling at protein and RNA levels at the axon 
terminus (Giuditta, Chun et al. 2008).  This is interesting in that it would provide a faster 
response mechanism for the neuron to react at a local level, especially in long axons. 
Neurons would need to react at the cell body level to signals for axonal growth and 
development/regeneration.  It is known that signaling endosomes do transport in a 
retrograde fashion (Ha, Lo et al. 2008).  Signaling endosomes are created and transported 
when growth factors (such as neural growth factor NGF) or neurotrophic factors (such as 
brain-derived neurotrophic factor BDNF) activate tyrosine kinases at the ends of neuronal 
processes (Bhattacharyya, Watson et al. 2002; Delcroix, Valletta et al. 2003; Huang and 
Reichardt 2003; Heerssen, Pazyra et al. 2004).  Other cellular constituents such as 
organelles are transported by the dynein motor complex as well (Vallee, Williams et al. 
2004).  Retrograde transport is also necessary for neuron survival and the plasticity of 
axons (Ha, Lo et al. 2008).  
 One of the prime functions of anterograde transport is the delivery of 
neurotransmitters/neurotransmitter precursors and synaptic vesicle constituents to the 




neurotransmitters are released), the synaptic cleft, and the post-synaptic membrane 
(where neurotransmitter receptors reside).  Neurotransmitters are released in response to 
the arrival of an action potential. The arrival of this action potential causes voltage gated 
calcium channels to open.  Ca2+ floods into the synaptic bulb (some release from stored 
intracellular calcium storage may contribute) and this causes pre-synaptic vesicles to 
release their neurotransmitter into the synaptic cleft (King 1994).  Then the transmitter 
binds to its receptor and causes its particular action.   
 Classically defined neurotransmitters include GABA (gamma aminobutyric acid) 
(considered an inhibitory transmitter), glutamate (considered excitatory), acetylcholine 
(functioning at the neuromuscular junctions), and dopamine and serotonin (which have 
more complex functions in the central and peripheral nervous systems) (Kawaguchi 
1997; Lee, Schmidt et al. 2001; Chase and Koelle 2007; Wang, Van Bockstaele et al. 
2008; Dave and Bordey 2009).  Neurotransmitters can also be classified as monoamines 
(serotonin, dopamine, norepinephrine, epinephrine etc), amino acids (glutamate, GABA, 
etc) and neuropeptides  (endorphins, enkephalins, etc) (Kawaguchi 1997; Lee, Schmidt et 
al. 2001; Chase and Koelle 2007; Wang, Van Bockstaele et al. 2008; Dave and Bordey 
2009).  Once the excitatory and/or inhibitory neurotransmitters are released, an action 
potential is generated if a threshold of excitation is reached.  This propagates as an 
electrical signal along the axon.  Once an action potential threshold is reached, these are 
generally considered an all or none phenomenon with the action potential propagating the 
entire length of the axon(King 1994).  In many instances these neurotransmitters have 
channels for reuptake and recycling at the synapse, which reduces the demand for novel 




Effects of Action Potentials on Transport 
Action potentials are primarily a membrane effect, while axonal transport occurs 
in the axonal cytoplasm.  The majority of research appears to cover how axonal damage 
alters impulses, delivery of molecules via axonal transport or neurotransmitter release or 
recycling.  However, there was some evidence that the mere generation of action 
potentials may have an effect on the transport of molecules through the axon.  It appears 
that nerve impulse firing significantly reduced the retrograde transport of dynein in both 
velocity and total distance traveled (Lardong, Maas et al. 2009).  Also, firing of action 
potentials altered the anterograde transport in axons.  In one study of bullfrog dorsal root 
ganglia, nerve stimulation decreased the overall fast axonal transport temporally, but did 
not result in ultrastructural changes (Hammerschlag and Bobinski 1992).  This was 
interpreted as neurons increase transport when conduction is not occurring to replenish 
the axon terminus (Hammerschlag and Bobinski 1992).  Interestingly in neither study did 
tetrodotoxin (which blocks action potentials by blocking ion channels) have an effect on 
axonal transport (Hammerschlag and Bobinski 1992; Lardong, Maas et al. 2009). 
 
Neuronal Transport as it Relates to HSV Infection 
For HSV to complete its infectious cycle for a neuron, it must first come into 
contact with the axonal processes of a neuron.  Then the virus enters the neuronal cell via 
pH-independent fusion of the viral envelope to the axonal process membrane (Qie, 
Marcellino et al. 1999; Nicola, Hou et al. 2005).  Viral fusion and entry are thought to 
operate similarly to described earlier for non-neuronal cells using the coordinated 




Desai, Schaffer et al. 1988; Ligas and Johnson 1988; Hutchinson, Browne et al. 1992). 
Some neurotropic viruses enter the neuron via endocytotic or clathrin mediated pathways, 
including Canine Adenovirus type-2 (CAdV-2) and Rabies virus, and through neuron 
specific sorting of endosomes can directly begin retrograde transport (Salinas, Schiavo et 
al. 2010).  Rabies virus transport has been demonstrated in an enveloped state and CAdV-
2 has been shown to be transported in intact endosomes (Salinas, Schiavo et al. 2010). 
This may suggest a possible alternate, as yet undescribed, pathway for HSV that would 
have implications for glycoproteins and the tegument proteins potential involvement in 
early infection.  After entry, the virus must be transported along the axon to the cell body 
and eventually the nucleus.  HSV has been shown to rely on the dynein/dynactin 
molecular motor system using the microtubule network for retrograde transport in 
fluorescence studies of viral transport in neurons and in studies using inhibitors or 
destabilizers of dynein and the microtubule network (Topp, Meade et al. 1994; Bearer, 
Breakefield et al. 2000; Dohner, Wolfstein et al. 2002).  The exact interaction remains to 
be determined for retrograde transport.  Some proteins have been shown to bind dynein in 
vitro including pUL34 and pUL9 (Diefenbach, Miranda-Saksena et al. 2008b).  These 
proteins are not present in the mature virion however, and may be used by the virus for 
transport of materials during assembly (Diefenbach, Miranda-Saksena et al. 2008b).  
Viruses lacking the pUL35 protein, or the capsid protein VP26, have been shown to have 
greatly decreased retrograde transport in vivo, but in vitro retrograde transport to the 
nucleus is retained, suggesting that functional redundancies or more complex interactions 
may exist in this system (Desai, DeLuca et al. 1998; Antinone, Shubeita et al. 2006; 




it is assumed that interacting proteins will come from the capsid or tegument proteins 
closely associated with the capsid.  However, if the virus were to enter the neuron via 
endocytosis it is unknown what role envelope proteins may play or if multiple pathways 
exist to instigate retrograde transport.  
Once the virus reaches the nucleus, the virus is likely to go latent, as discussed 
earlier.  During the reactivation of a latent infection or immediately if the virus stays in 
the lytic phase, the viral components must be created and assembled to produce progeny 
virus.  This progeny virus is then transported in the anterograde direction to the axon 
termini to be released and infect epithelial cells at the initial site of infection.  The vast 
majority of this process is considered to occur in the same manner as previously 
described for non-neuronal cells.  The mechanism of transport and the character of the 
virion during transport in the anterograde direction is a highly controversial issue.  Two 
competing theories predominate, these are: 1) transport of the capsid containing the DNA 
separate from the glycoproteins with final assembly occurring at the plasma membrane of 
the neuron at the axon terminus, sometimes called the “unmarried model”; 2) transport of 
a fully formed, enveloped virus that is created by budding through the TGN described 
earlier, sometimes called the “married model” (Enquist, Husak et al. 1998).  These two 
models are in contention in large part due to disparate results from studies in two 
alphaherpesviruses, Pseudorabies virus (PRV) and HSV-1 (Diefenbach, Miranda-Saksena 
et al. 2008a; Liu, Goodhouse et al. 2008; Mettenleiter 2008; Mettenleiter, Klupp et al. 
2009; Antinone and Smith 2010; Antinone, Zaichick et al. 2010; Maresch, Granzow et al. 




Since the N-kinesin members of the KIF superfamily (such as the prominent 
members KIF1, KIF3, and KIF5) are the primary anterograde transporters in neurons, it is 
likely that one of these molecules is the major molecular motor to transport herpes 
viruses (Diefenbach, Miranda-Saksena et al. 2008b). Notably, since the exact character of 
transport is unknown, little is also known about what components of the described 
neuronal anterograde transport system are involved in the transport of herpes virions. 
Although many viral glycoproteins have been implicated in efficient egress of virions 
from epitheilal cells, the role of these proteins in neuronal egress has not been studied 
extensively (Mettenleiter, Klupp et al. 2009).  In PRV glycoproteins gE and gI are 
required for anterograde transport, but not retrograde transport (Card, Whealy et al. 
1992a; Jacobs, Mulder et al. 1993b; Babic, Klupp et al. 1996a; Johnson, Webb et al. 
2001a; Brittle, Reynolds et al. 2004; Ch'ng and Enquist 2005).  HSV-1 gE has been 
reported to function in both retrograde and virus spread from epithelial cells to neurites 
but it is not necessary for direct infection of neurites or retrograde transport in axons 
(Balan, Davis-Poynter et al. 1994b; Saldanha, Lubinski et al. 2000; Wang, Tang et al. 
2005; Brittle, Wang et al. 2008; McGraw and Friedman 2009).  
Recently, the role of actin in herpes virus infection in neurons has been under 
increased scrutiny.  In the growing axon, actin directs the growth of the axon by 
maintaining polarity in axonal growth cones (Roberts and Baines 2011).  In the mature 
neuron, actin still plays a role in maintaining polarity at the axon hillock, where it acts as 
a buffer between the endoplasmic reticulum and cargoes that are destined for transport 
along the axon (Roberts and Baines 2011).  This would suggest that HSV necessarily 




nucleus for anterograde transport during a reactivation.  Very recent work has suggested 
that myosin Va, a molecular motor that interacts with actin, may bridge the gaps between 
axonal transport and the nuclear membrane, but these models are early in development 
and more work is necessary to confirm the hypothesis (Roberts and Baines 2011).  
 
Latent Infection with HSV 
While much is known about herpes viral latency, even more remains a mystery 
regarding the exact mechanisms of latency and reactivation.  Latent infection must first 
be distinguished from chronic infection.  In a chronic infection, a virus will express 
proteins and produce a low level of infectious progeny that is shed continuously albeit in 
amounts that may significantly wax and wane.  In a true latent state, as defined for herpes 
viruses, the viral DNA is held in a circular episome within the host cell nucleus and a 
very slight level of DNA transcription occurs, however, there is no protein production 
(Roizman, Knipe et al. 2007).  During latency, HSV creates a latency-associated 
transcript (LAT) from the viral DNA.  The promoter for the encoded LAT is maintained 
in acetylated histones, or active areas, of the host DNA (Kubat, Amelio et al. 2004).  In 
the latent stage of the infection, the lytic, or active infection, genes of HSV are 
maintained in areas of heterochromatin, which are regions of host cell DNA that are 
inactivated (Wang, Zhou et al. 2005).  HSV DNA also avoids methylation by the host 
nucleus that could inactivate the virus (Roizman, Knipe et al. 2007).  During the latent 
infection, the LAT is the only transcript expressed in abundance, however, very sensitive 
assays can detect small amounts of transcription of lytic genes (Kramer and Coen 1995; 




leakiness or abortive attempts at reactivation (Bloom, Giordani et al. 2010).  The exact 
reason for this expression is unknown.  The LAT is an 8.3 kb sequence with several 
splice variants, of which a 2.0 kb sequence is the most common (Farrell, Dobson et al. 
1991).  Through evaluation of mutant viruses, the LAT is associated with efficient 
establishment of latency, reactivation, and blocking apoptosis (Farrell, Dobson et al. 
1991).  LAT deficient mutants have more significant pathology in the trigeminal ganglion 
with more necrosis of neurons and greater mortality in mouse studies (Roizman, Knipe et 
al. 2007).  The LAT actually appears to have a protective effect for neurons that become 
infected.  
In the normal course of HSV infection, the virus replicates at the initial site of 
epithelial infection and then infects the innervating sensory neurons.  The virus travels in 
the anterograde direction through the axon of the neuron to the nucleus and establishes a 
latent infection.  During the first 24-72 hours after infection of the ganglionic neurons, 
expression of lytic genes and the LAT are observed, however, the lytic genes must be 
rapidly suppressed to prevent a lytic infection, since neurons do not have an intrinsic 
invulnerability to lytic infection (Kosz-Vnenchak, Coen et al. 1990; Kramer, Chen et al. 
1998).  Although an exact mechanism is unknown, it appears that CD8+ T cells play a 
role in regulating infection in nervous tissue and there is a distinct lack of alpha gene 
expression as latency is established (Roizman, Knipe et al. 2007).  Furthermore, once the 
latent state is established, less is known about the mechanism of maintenance of this 
state.  During latency, the LAT expression is maintained and HSV specific T cells are 




Once latency has occurred, the final characteristic of the virus is to reactivate out 
of the latent state and cause a recurrent infection at the site of mucosal innervation via 
retrograde transport.  The mechanism of reactivation is not clearly defined.  The 
conditions that can cause reactivation have been described and include: any source of 
local or systemic stress, such as UV radiation, trauma, surgery, excessive heat, another 
infection, emotional stress, and hormonal imbalance (Roizman, Knipe et al. 2007).  Once 
this stress occurs, the lytic genes are moved from areas of heterochromatin to acetylated 
histones, become active and begin a recurrent infection (Amelio, Giordani et al. 2006). 
Viral proteins are created, viral DNA is replicated, and virions are assembled which can 
then be transported to the site of initial infection (Roizman, Knipe et al. 2007).  These 
progeny virions can also move in the anterograde direction to second and third order 
neurons progressing deeper into the central nervous system, although this is less common 
(Roizman, Knipe et al. 2007).  The final fate of the reactivated neuron is not clear. 
Guaranteed destruction seems unlikely since areas of mucosal infection do not always 
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THE HERPES SIMPLEX VIRUS TYPE-1 (HSV-1) GLYCOPROTEIN K(gK) IS 





Herpes simplex virus type 1 (HSV-1) is an enveloped, double-stranded DNA 
virus that is a ubiquitous pathogen of humans.  When symptomatic, HSV-1 commonly 
causes mucocutaneous lesions with acute encephalitis and ocular pathology occurring 
less frequently (Whitley 2001).  Although a less frequent manifestation of disease, ocular 
HSV is one of the most common infectious causes of blindness in developed countries 
with estimates of the incidence of herpes ocular disease episodes ranging from 4.1 to 20.7 
cases per 100,000 in developed countries (Liesegang, Melton et al. 1989; Liesegang 
2001).  An estimated 400,000 people in the United States have had herpes simplex ocular 
disease with about 50,000 new or recurrent cases occurring yearly (NoAuthor 1998).  
Herpesvirus infection usually begins at a mucosal surface and from this site the virus 
invades the ganglionic sensory neurons and can establish a latent infection for the life of 
the host (Whitley, Kimberlin et al. 1998).  
 HSV-1 specifies at least 11 glycoproteins that are expressed in the infected cells 
(Roizman and Knipe 2001).  Glycoproteins B and C are primarily involved in initial 
attachment of the virion to cell surface glycosaminoglycans by binding to heparan sulfate 
(Laquerre, Argnani et al. 1998).  Attachment is followed by fusion of the viral envelope  
_______________________ 
* Material reprinted from Current Eye Research, 2008 May;33(5):455-467, The herpes 
simplex virus type 1 (HSV-1) glycoprotein K (gK) is essential for viral corneal spread 
and neuroinvasiveness,; David AT, Baghian A, Foster TP, Chouljenko VN, Kousoulas 




with cellular membrane receptors and viral glycoproteins B (gB), D (gD), H (gH) and 
L(gL) (Furth, Whitbeck et al. 1997; Whitbeck, Peng et al. 1997; Warner, Geraghty et al. 
1998; Krummenacher, Rux et al. 1999; Whitbeck, Muggeridge et al. 1999).  These 
glycoproteins have also been shown to be essential for viral entry and infectious virus 
production (Wanas, Efler et al. 1999).  Virus spread, a priori, occurs by either infectious 
virions produced by cells that can then infect adjacent cells, or via inter-cellular 
transmission of fully infectious virions facilitated by virus-induced cell fusion (syncytia 
formation). Virus-induced cell fusion is mediated by viral glycoproteins expressed on 
cell-surfaces, while gB, gD, gH and gL are necessary and sufficient to cause cell fusion in 
the absence of virus replication (Davis-Poynter, Bell et al. 1994; Turner, Bruun et al. 
1998; Muggeridge 2000; Pertel, Fridberg et al. 2001).  Glycoprotein E (gE) may also 
function to transport virions between cellular membranes by other than cell fusion 
mechanisms (Dingwell and Johnson 1998; Wisner, Brunetti et al. 2000; Johnson, Webb 
et al. 2001). 
 HSV-1 gK is essential for cytoplasmic virion envelopment, virion egress and 
virus-induced cell fusion (Hutchinson and Johnson 1995).  Recently, we have 
demonstrated that gK physically binds to the UL20 membrane protein (Foster and 
Kousoulas 2008).  Furthermore, UL20/gK interactions are essential for their intracellular 
transport, cell-surface expression and functions in cytoplasmic virion envelopment and 
virus-induced cell fusion (Foster, Alvarez et al. 2003; Foster, Melancon et al. 2004a; 
Foster, Melancon et al. 2004b; Melancon, Fulmer et al. 2007; Foster and Kousoulas 
2008).  HSV-1 gK is of particular importance to eye infections, because it has been 




anti-gK humoral and cellular immune responses (Osorio, Cai et al. 2004; Mott, Osorio et 
al. 2007; Mott, Perng et al. 2007; Osorio, Mott et al. 2007).  Deletion of the gK gene 
encoded by the pseudorabies virus (PRV) appeared to attenuate the virus, but did not alter 
the ability of the gK-null virus to invade the central nervous system and cause clinical 
eye disease (Flamand, Bennardo et al. 2001; Schwartz, Brittle et al. 2006; Ch'ng, Spear et 
al. 2007).  These results prompted the present work to assess the role of HSV-1 gK in 
corneal spread and neuroinvasiveness.  In contrast to previous findings with PRV gK, 
work presented here, shows that HSV-1gK is essential for virus spread in the cornea of 
mice and neuroinvasiveness.  
 
MATERIALS AND METHODS 
 
Cells and Viruses 
 The ocular and neural virulent McKrae strain of HSV-1 was obtained from Dr. 
J.M. Hill (Louisiana State University Health Sciences Center, New Orleans, La). The UL 
53 (gK) gene of HSV-1 McKrae was replaced with an EGFP gene cassette from plasmid 
pEGFP-1 (Clontech, Pala Alto, Ca) under control of the human cytomegalovirus 
immediate early gene promoter as described previously for the KOS ∆gK/GFP (Foster, 
Rybachuk et al. 1998).  Briefly, plasmid PTF9201 contains an EGFP gene cassette under 
the human cytomegalovirus immediate early promoter control (HCMV-IE) within a DNA 
fragment spanning the UL52-UL54 genomic region that lacks the UL53 gene (Foster, 
Rybachuk et al. 1998).  Plasmid PTF9201 was used in transfection followed by infection 




small fluorescent viral plaques under the fluorescence microscope.  Individual viral 
plaques were plaque-purified six-times before viral stocks were prepared in Vero or 
VK302 cells.  The resulting HSV-1 McKrae UL53 null virus is referred to as MK∆gK.   
A rescued virus that was positive for both gK and GFP (MKgK) was constructed from 
the MK∆gK, as described previously (Foster and Kousoulas 1999).  See map of viral 
mutations in Fig 2.1. African green monkey kidney (Vero) cells were obtained from 
ATCC (Rockville, MD) and grown in Dulbecco’s modified Eagle Medium (DMEM) 
supplemented with 7% fetal bovine serum (FBS) and antibiotics.  The gK complementing 
VK302 cell line (generously provided by Dr. David Johnson, Oregon Health Sciences 
University) was maintained in Dulbecco’s modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and antibiotics (penicillin and 
streptomycin).  This cell line was used for generation of high titer MKΔgK viral stocks.  
The properties of all virus recombinants were validated as described previously (Foster, 
Rybachuk et al. 1998; Foster and Kousoulas 1999).  
 
Mice 
 6-10 week old, female, Balb/c mice were used for all experiments and were 
handled in accordance with the ARVO statement for the use of animals in ophthalmic and 








Figure 2.1:  Schematic of recombinant virus construction. (A) The top line represents 
the prototypic arrangement of the HSV-1 (McKrae) genome with the unique long (UL) 
and unique short (US) regions flanked by the terminal repeat (TR) and internal repeat 
(IR) regions. (B) HSV-1 genomic map in relative map units. (C) An expanded genomic 
region between map units 0.7 and 0.8 containing the UL52, UL53, and UL54 open 
reading frames. (D) Diagram of the pSJ1723 plasmid (Jayachandra, Baghian et al. 1997), 
which contains the UL52, UL53 and UL54 region of HSV-1 (KOS). (E) Plasmid PTF901 
(Foster, Rybachuk et al. 1998) containing the CMV-IE-EGFP gene cassette in-place of 
the gK gene, which was used to delete the gK gene and insert the EGFP gene cassette 













Plaque Morphology and Virus Replication Characteristics 
 For plaque morphology, confluent monolayers of Vero and VK302 cells were 
infected at multiplicity of infection (MOI) of 0.001 with the MKgK and MK∆gK viruses 
and were visualized by immunohistochemistry at 48 and 72 hours post infection (hpi).  At 
48 or 72 hpi, cells were fixed with ice-cold methanol.  Immunohistochemistry was 
performed with horseradish peroxidase-conjugated anti-HSV antibodies (Dako) and the 
reactions were developed with NovaRed substrate (VectorLabs; Burlingame, CA). 
 To determine the kinetics of viral replication, cells were infected with the 
MKΔgK, MKgK or the McKrae parental strain at MOI’s of 0.1 and 5.  For McKrae 
parental strain and the rescue strain, plates of Vero cells were used and for the MKΔgK 
virus Vero and VK302 cells were used.  Plates were prepared in triplicate and infections 
were halted by freezing at 0, 3, 6, 9, 12, 24, 36, 48 and 72 hours post infection (hpi).  
Plates were frozen, thawed and viral titers were determined for each time point by 
standard plaque assay on VK302 cells (for the MKΔgK virus) or Vero cells (for the 
parental and MKgK strains). Plaques were stained with crystal violet and visualized by 
dissecting microscope. Growth curves show the result of the average of the triplicate 
plates. 
 
Mouse Eye Infections 
 Ocular infection with the rescued virus (MKgK) and wild type virus produced 
similar results in terms of clinical and laboratory findings (data not shown); therefore, the 
rescued strain data is presented since it serves as a better comparison to the gK null 




mice each cornea was scarified by four strokes vertically and four strokes horizontally of 
a 25 gauge needle in a grid pattern.  Then the designated viral inoculum, in 5 µl of 
DMEM, was applied to the eyes with a micropipetter and the eyelids were gently held 
shut for 30 seconds.  For all studies, either 1.0 x 106 PFU of MKΔgK was inoculated into 
each cornea or 2.5 x 104 PFU of MKgK was inoculated into each cornea. If not scarified, 
mouse eyes were gently abraded by rubbing with sterile cotton swabs 10 times in 
different directions.  
 For clinical lesion studies, mice were monitored daily for survival and the 
degree of blepharitis, hyperemia and ocular discharge were recorded.  These symptoms 
were scored on the scale of 0-3, with 0 representing no symptoms and using the most 
severe lesions in the group infected with the rescued McKrae strain as the scale of 3.  For 
direct observation of viral infection and spread in the eye, 2 groups of mice were 
similarly inoculated (5 mice/group/time point).  Mice were sacrificed at 12, 24, 48 and 72 
hpi as well as 5, 7, 10 and 14 days post inoculation (dpi).  The eyes of the mice were 
excised and viral spread was tracked by direct observation under a Zeiss Stereo Lumar 
fluorescence microscope and digitally photographed with an Axiocam color camera (Carl 
Zeiss Inc, USA.).  The extent of fluorescent plaques on the eye were scored on the 
following 0-3 scale:  0 (No fluorescent foci observed), 1 (One or few (<12) pinpoint 
plaques covering less than 5% of total visual surface or peripheral rim of connective 
tissue), 2 (One or more plaques larger than pinpoint, or numerous pinpoint plaques, 
covering 5-20% of the total visual surface or peripheral rim of connective tissue, 3 




involvement).  Iris involvement was determined by fluorescent highlighting of iris tissue 
structure.  
 
Detection of Latent Virus in Trigeminal Ganglia Using PCR and In Vitro Tissue 
Explants Cultures 
 
 Mice that survived the initial infection were sacrificed at 30-35 days post-
infection.  Mice were sacrificed via CO2 asphyxiation followed by thoracotomy.  Then 
trigeminal ganglia (TG) of the mice were excised.  For determination of culture 
reactivation, excised trigeminal ganglia were cultured as a whole for 5 days in six-well 
plates in DMEM containing 10% bovine serum and antibiotics in a humidified incubator 
at 37 degrees Celsius with 5% CO2 and 95% filtered room air.  After 5 days, the TG were 
triturated with a glass pipet and ganglion cells and media were placed on the Vero or 
VK302 cell monolayers.  Wells were monitored to study evidence of cytopathic effects 
(CPE) indicative of virus reactivation.  Every other day, half the media in each well was 
passed to new plates with fresh monolayers and these were also monitored for CPE.  This 
process was repeated until a well had demonstrated CPE or for 12 days following plating 
of the initial ganglion cells.  
 For viral DNA detection, a nested PCR methodology was used targeting the 
UL30 gene.  Mice surviving the clinical infection to 30 dpi were euthanized and the 
trigeminal ganglia (TG) were harvested and frozen at -80C.  TG’s were thawed and total 
DNA from the TG was extracted using the Qiagen DNeasy blood and tissue kit (Qiagen, 
CA, USA) per the manufacturer’s instructions.  For non-scarified mice, TG DNA from 




or both ganglia was considered positive.  For scarified mice, the right and left TG were 
pooled for extraction.  
 The individual primers for the primary PCR reaction were :  A) 5’-
CCTGGACAAG CAGCAGGCCGCCATC-3’; and B) 5’-
GCGCACCAGATCCACGCCCTTG-3’. The second step PCR utilized primers C) 5’-
CTCGGTGTACGGGTTCACGGGAGT-3’; and D)5’-
GATGGAGTCCGTGTCCCCGTAGATG-3’.  The PCR product of A, B primers was 
452bp, while the secondary PCR with primers C, D produced a 207bp DNA fragment.  
These primers are HSV-1-specific diagnostic primers based on previously published 
degenerate diagnostic UL30 primers (VanDevanter, Warrener et al. 1996). The 
authenticity of individual PCR fragments was confirmed by DNA sequencing.  The 
FailSafe enzyme system with PCR premix E was used for all PCR reactions (Epicentre 
Biotechnologies, Madison, WI, USA). Specifically, 1-10µl of extracted DNA was used 
for the first step reaction and 1-10µl of the first step product was used in the second step. 
The PCR products were then subjected to electrophoresis and stained with ethidium 
bromide. 
 The positive control consisted of DNA extracted from McKrae virus stock. 
Negative controls were TG DNA from mock infected mice as well as no template 
controls.  To determine the lower limit of sensitivity, serial dilutions of extracted viral 
DNA mixed with equal volumes of negative mouse TG DNA were used.  The lower limit 








 All following statistical analyses in this chapter were performed using 





Recombinant Virus Construction and Characterization 
The construction of a HSV (KOS) recombinant virus in which the gK gene was 
replaced with an EGFP gene cassette was described previously (Foster, Rybachuk et al. 
1998).  A similar strategy was utilized to construct the recombinant virus MK∆gK with 
the gK gene deleted and replaced with a EGFP gene cassette (Fig. 2.1).  In addition, the 
rescued virus MKgK was constructed, in which the missing gK gene was replaced with 
the wild-type gK gene, without affecting the adjacent CMV-IE-EGFP gene cassette.  
Both viruses were extensively characterized by PCR diagnostics to ensure the absence of 
any wild-type gK sequences from the MK∆gK virus and the restoration of the gK gene in 
the MKgK virus (not shown).  As expected, the MKΔgK virus formed extremely small 
plaques on Vero cells composed of a maximum of 5-10 cells, while the MKgK virus 
formed large plaques, which were indistinguishable from the prototypic McKrae virus. 
MKΔgK virus plaques on the gK complementing cell line VK302 were rescued to nearly 




The replication kinetics of the MK∆gK and MKgK viruses was investigated in 
Vero cells, as well as in VK302 cells that constitutively express gK at different MOI. The 
MKgK virus appeared to replicate slightly slower than the wild-type McKrae virus, 
however, both approached similar titers at late times post infection.  The MK∆gK virus 
exhibited approximately two logs (one hundred times) lower replication in comparison to 
the McKrae and MKgK viruses.  Replication of MK∆gK virus in the VK302 
complementing cell line produced virus titers similar to those observed with the McKrae 
and MKgK viruses (Fig. 2.3). 
 
 
Figure 2.2:  MK∆gK and MKgK plaque morphology. Confluent Vero (A, B, D, E) or 
gK complementing VK302 cells monolayers (C, F) were infected with either the MKgK-
rescued virus, or the MK∆gK (gK-null) virus at an MOI of 0.001, and viral plaques were 
visualized by immunohistochemistry at 48 (A, B, C) or 72 (D, E, F) hpi. All images are 








Figure 2.3:  Virus replication kinetics. Vero or VK302 cell monolayers were infected 
with either MK∆gK, MKgK or McKrae viruses at MOI of 0.1 and virus titers were 
obtained at different times post infection on either Vero or VK302 cells. 
 
In Vivo Phenotypes and Clinical Disease Patterns of MKgK and MK∆gK Viruses in 
the Mouse Eye Model System 
 
Corneas are composed principally of a fairly thin epithelial layer resting on a 
much thicker stromal layer composed primarily of collagen fibers.  Corneas are typically 
highly innervated tissues. To ensure that viral infections could access nerve endings 
within the cornea, infections were performed with mild or more extensive scarification 
(see Materials and Methods).  MKgK viral infections produced viral plaques, which were 
first visible by stereoscopic fluorescence microscopy at 12 hpi appearing as streaks of 
multiple viral plaques. By 24 hpi viral plaques were spread substantially, and by 72 hours 
viruses appeared to have spread to the iris.  In mice infected after swab abrasion of their 
corneas, fluorescent viral plaques were less numerous on the visual surface, but 




infected after needle scarification.  In addition, at late times post infection, the iris of 
mice infected after cotton swab scarification appeared to have less pronounced infection, 
as evidenced by the substantial reduction in the number of fluorescent viral plaques (data 
not shown). 
Infected mice were monitored daily for clinical indicators of eye infection, such 
as blepharitis, hyperemia and ocular discharge for 30 days post infection and the intensity 
of the infection indicators were recorded on scale of 0-3.  Typically, mouse eyes infected 
with viruses after scarification were scored 0 when there were no symptoms of clinical 
disease (Fig. 2.4: A).  Eyes scored with a score of 1exhibited minimum blepharitis, 
hyperemia, and ocular discharges at the medial canthus (Fig. 2.4: B).  Eyes scored 2-3 
exhibited progressively more severe clinical symptoms outlined above producing 
ultimately crusting and complete occlusion of the eye (Fig. 2.4: C-E).  The MKgK virus 
produced severe disease in most mouse eyes (score 2-3), while few eyes were scored at 
lower scores (score 1).  The MK∆gK virus produced no significant clinical disease (score 
0) in infection experiments even though approximately two logs higher virus titers of 
M∆gK (1.0 x 106 PFU) were used than the MKgK virus (2.5 x 104 PFU) (Fig. 2.5: A). 
Similar experiments were performed with the exception that mice eyes were abraded with 
cotton swabs as opposed to needle scarified.  Overall, peak clinical disease observed in 
the unscarified mouse experiments was similar to that of the scarified experiments with 
disease peaking within 7-9 dpi.  Again, clinical disease was pronounced with the MKgK 
virus, while the MK∆gK virus produced no disease symptoms.  The only apparent 
differences between the abrasion versus the more severe scarification results, were that in 




return to normal conditions at approximately 14-16 dpi.  In the more extensively scarified 
eyes, many mice exhibited grade 1 lesions at much later times post infection (greater than 
20 dpi) (Fig. 2.5: A, B).  
 
 
Figure 2.4:  Clinical disease progression. Mouse eyes were monitored for clinical signs 
of disease as detailed in Materials and Methods. (A) Clinically normal mouse. (B) Lesion 
with a score of 1 characterized by mild hyperemia, blepharitis and ocular discharge. (C) 
Lesion with a score of 2 characterized by moderate hyperemia, blepharitis and ocular 
discharge. (D and E) Lesion with a score of 3. (D) Picture shows severe hyperemia and 
blepharitis. (E) The arrow indicates the position of the eye, which is completely covered 
by a crust of ocular discharge. In figures B and C, arrows indicate accumulation of ocular 






Figure 2.5:  Clinical lesion scores. Mice were infected ocularly with MKgK or MK∆gK 
viruses. Ocular disease was based on a 0 to 3 scale for the parameters blepharitis, 
hyperemia, and ocular discharge as described in the Material and Methods section.  (A) 
Graph shows the average clinical lesion scores in scarified mice on representative days 1, 
2, 4, 7, 9, 11 and 14 following infection. (B) Graph shows the average clinical lesion 
scores in non-scarified mice on the same days. Data are presented as the group mean of at 
least 12 mice per group with error bars indicating the standard error.  Bars denoted by an 
* represent an average lesion score of 0 (The small positive bar is presented for visual 




Mice were also monitored for survival for 30 days following inoculation.  
Regardless of scarification status, all mice inoculated with the MKΔgK strain survived to 
30 dpi (Fig 2.6: A, B).  In scarified mice, 10 of the 30 mice inoculated with the rescued 
virus died during the study with deaths occurring between 6 and 12 dpi (Fig 2.6 A).  In 
non-scarified mice, 8 of the 20 mice inoculated with the rescued virus died during the 
study with deaths occurring between 4 and 15 dpi (Fig 2.6: B).  Kaplan-Meier survival 
curve analysis revealed a statistically significant difference in death rate for both scarified 
and unscarified groups at a P=.001 (Fig 2.6: A, B).  However there was no statistical 
significance in the survival when comparing the mildly scarified with the more 
extensively scarified groups that were inoculated with the rescue strain (Fig 2.6: C). 
 
Figure 2.6: Mouse survival data after infection with recombinant viruses. (A-C) In 
clinical lesion studies, mice were also monitored daily for survival to 30 days post 
infection. (A) In scarified mice, 10 of the 30 mice inoculated with the rescued virus died 
during the study with deaths occurring between days 6 and 12 post inoculation. All mice 
inoculated with the gK-null strain survived. (B): In non-scarified mice, 8 of the 20 mice 
inoculated with the rescued virus died during the study with deaths occurring between 
days 4 and 15 post inoculation. All mice inoculated with the gK-null strain survived.  
(C) There is no statistical difference between scarified or non-scarified groups when 
inoculated with MKgK. (A, B) This shows a stastically significant difference in death 
rate for both scarified and unscarified groups at a P=.001 (Fig 2.6: A, B) by Kaplan-


















Visualization of Viral Plaque Formation in Mouse Eyes 
To study the degree of invasiveness and spread of viruses from the site of initial 
ocular infection, mice were infected, following corneal scarification, with the MKΔgK or 
MKgK viruses.  All mice in each group were sacrificed at 12, 24, 48 and 72 hpi and 5, 7, 
10 and 14 dpi.  The eyes were excised intact and observed directly under an inverted 
fluorescence microscope. 5 mice (10 eyes) /group/time point were examined and 
representative pictures of the spread of fluorescent viral plaques at various time points are 
shown (Fig. 2.7).  MKgK produced viral plaques in mouse corneas that were easily 
visible through direct observation of tissues using a fluorescent microscope as early as 12 
hpi.  These viral plaques increased substantially over time and appeared to spread to 
mouse iris by 3-4 dpi (Fig. 2.7: F-J).  In contrast, the MK∆gK virus, produced very small 
plaques at 12 hours post infection, with an increasing number of viral plaques appearing 
at 24 hpi.  However, these viral plaques were substantially less visible at 48 hpi and all 
mice in this group were devoid of viral plaques by four dpi (Fig. 2.7: A-E).  These results 
were consistent with virus isolation from eye swabs that revealed less than 10 viruses per 
MK∆gK-infected eye, while MKgK-infected eyes yielded more that 1,000 plaque 
forming units (PFU) per eye (not shown).  The fluorescent plaques produced in mouse 
eyes were also scored on a 0-3 point scale, average scores by day are shown (Fig. 2.8).  
This graph and the previous pictures show that virus spread was markedly impaired in the 
MK∆gK virus, with minimal plaque formation, smaller plaques and more rapid resolution 








Figure 2.7:  Virus spread in mouse corneas. Spread and replication of MKgK versus 
MKΔgK was studied in ocular infection of mice.  The infected eyes in each group were 
directly examined under an inverted fluorescence microscope.  (A-E) Mouse eyes 
infected with MK∆gK at 12hpi (A), 24hpi (B), 48hpi (C), 72hpi (D) and 5dpi (E).  (A, C) 
White arrows point to small plaques in these eyes. (F-J) Mouse eyes infected with MKgK 
at 12hpi (F), 24hpi (G), 48hpi (H), 72hpi (I) and 5dpi (J).  Figures are representative of 5 









Figure 2.8:  Graphical representation of virus spread. Mice were infected after 
corneal scarification with the MK∆gK or MKgK viruses.  Then the eyes of the mice were 
excised and viral spread was tracked by direct observation under a fluorescence 
microscope. Fluorescent plaque lesions were scored using a 0-3 scale described in 
materials and methods. Bars represent the mean of 5 mice (10eyes)/group/time point.  
Mice were sacrificed at 12, 24, 48 and 72 hpi and 5, 7, 10 and 14 dpi.  Bars denoted by an 
* represent an average lesion score of 0 (The small positive bar is presented for visual 
reference only). Error bars are not present on these bars since standard error is also 0. 
 
Determination of Virus Spread to the Trigeminal Ganglia 
Typically, infection of mouse corneas with wild-type HSV-1 leads to transport of 
virions in a retrograde fashion within neuronal axons and establishment of latency in 
trigeminal ganglia.  To determine the relative efficiency by which MKgK and MK∆gK 
viruses reached the trigeminal ganglia, extracted ganglia were tested for the presence of 
infectious virus by co-culture in Vero or VK302 cells.  In these studies, mice were used at 
least 10 days post complete resolution of clinical symptoms.  In the scarified groups, 19 
of 20 mice in the MKgK virus infected group had trigeminal ganglia that produced 




produced infectious virus (Table 2.1).  In the non-scarified mice inoculated with the 
MKΔgK virus, 0/12 trigeminal ganglia produced infectious virus after co-culture with 
VK302 cells (Table 2.1).  In contrast, 5/12 non-scarified mice that were inoculated with 
MKgK virus produced infectious virus after co-culture with Vero cells (Table 2.1).  
Additional testing was performed to detect the presence of viral DNA within 
trigeminal ganglia of infected mice.  In mice inoculated with MKgK without 
scarification, HSV DNA was detected by PCR in 14/24 (58.3%) TG’s, corresponding to 
9/12 (75%) mice (Fig 2.9, Table 2.1), while MKΔgK infections identified 0/24 TG 
ganglia as PCR-positive corresponding to 0/12 mice (Table 2.1).  In mice inoculated with 
MKgK after scarification, HSV DNA was detected in the pooled TG by PCR in 19 out of 
20 mice.  In mice inoculated ocularly after scarification with MKΔgK, 3 of 20 mice were 
PCR-positive for HSV-1 viral DNA (Table 2.1). 
 
 
Figure 2.9:  Nested PCR detection of viral DNA within mouse ganglia. Total DNA 
was extracted from mouse ganglia and viral DNA was detected using a nested PCR 
protocol (see Materials and Methods). Lanes 1-18 and 20-25 correspond to the right and 
left TG, respectively, of 12 unscarified and MKgK-infected mice (24 lanes). Lanes 19 
and 33 contain 2-Log DNA molecular mass ladder.  Lanes 26, 27, 31 and 32 contain 





Table 2.1:  Rates of Viral Latency, Reactivation, and Mouse Survival Data 
 
Table 2.1:  (* and +) There is a stastically significant difference between the two groups 
at P<0.05.  (#, **, ++, ##) There is a stastically significant difference between the two 
identified groups at P<0.001.  Fishers exact test for each pairing was performed using 
GraphPad Prism version 4.0 for Windows. 
 
DISCUSSION 
We have shown previously that HSV-1 glycoprotein K (gK) is not essential for 
viral entry into cells, but is essential for virus spread in cell culture, inasmuch as gK-null 
viruses form very small viral plaques typically consisting of less than 10 infected cells 
per plaque (Jayachandra, Baghian et al. 1997; Melancon, Luna et al. 2005).  This viral 
phenotype is produced because lack of gK drastically inhibits cytoplasmic virion 
envelopment presumably occurring at trans-Golgi network (TGN) membranes (Foster, 
Melancon et al. 2004a; Foster, Melancon et al. 2004b; Foster and Kousoulas 2008).  A 
similar viral phenotype has been also described for pseudorabies virus (PRV) indicating 
that HSV-1 and PRV gK function in a similar fashion in viral morphogenesis and egress 
in tissue culture (Klupp, Baumeister et al. 1998).  In vivo work with PRV indicated that 




neuroinvasiveness (Flamand, Bennardo et al. 2001).  Therefore, we undertook this study 
to investigate whether HSV-1 gK was essential for neuronal infection and disease 
causation in the mouse model system.  We found that HSV-1 gK is essential for corneal 
spread in the mouse eye, subsequent transmission and infection of the central nervous 
system, and disease causation.  
HSV-1 McKrae was isolated from a human ocular herpes infection (Kaufman, 
Ellison et al. 1969) and it is highly virulent in mice and rabbits (Perng, Thompson et al. 
1995; Perng, Chokephaibulkit et al. 1996; Halford, Balliet et al. 2004).  The recombinant 
virus MK∆gK was constructed to have a deletion of the gK gene, while at the same time 
carrying a HCMV-IE driven EGFP gene cassette that enabled tracking of viral infection 
using a fluorescence microscope.  The rescued virus, MKgK was produced by rescuing 
the gK gene, while leaving the EGFP gene cassette intact.  The MKgK virus titers at 48 
hours post infection were similar to the wild-type McKrae virus indicating that the 
presence of the EGFP gene cassette constitutively expressing EGFP did not adversely 
affect virus replication.  However, it was noted that the MKgK virus appeared to replicate 
slightly slower than the MKgK virus at earlier times post infection suggesting that EGFP 
expression may had a mild negative effect on virus replication at early times post 
infection. 
HSV-1 virulent strains including HSV-1 McKrae can readily infect the mouse eye 
via the cornea leading to efficient transmission to the central nervous system and 
establishment of viral latency in the trigeminal ganglia.  Following infection of murine 
eyes with HSV-1, viral replication occurs initially in the corneal epithelium, and 




Virions are thought to move in the retrograde direction within neuronal axons to neuronal 
bodies where they establish latency (Cunningham, Diefenbach et al. 2006; Diefenbach, 
Miranda-Saksena et al. 2008).  Infection of the CNS via the ocular route is very efficient 
because the cornea is a highly innervated tissue with a high density of nociceptors per 
square millimeter.  Specifically, the human cornea is estimated to have more than 7,000 
nociceptors per square millimeter (Muller, Marfurt et al. 2003).  Thus, direct inoculation 
of HSV-1 in the eyes of mice was predicted to have ample access to sensory neuronal 
fiber endings innervating the cornea.  Mild abrasion of the cornea with cotton swabs was 
expected to expose neuronal endings innervating the cornea, while more aggressive 
scarification of the cornea would be expected to give direct access of the virus to nerve 
bundles in the sub-basal plexes underlying the epithelium of the cornea. 
Apparently, constitutive expression of the EGFP gene did not significantly affect 
viral replication in tissue culture.  Similarly, viral plaques in mouse corneas were similar 
to those produced by the wild-type McKrae strain (not shown).  Infection of the mouse 
eyes either with the cotton-swab or needle scarification protocols revealed that, in 
comparision to the MKgK rescued virus, the MK∆gK virus was not able to efficiently 
replicate and spread in mouse corneas despite the fact that a two log higher virus 
inoculum of the MK∆gK virus was used and prepared in the complementing cell line 
VK302.  Specifically, MK∆gK was able to infect cells, as evidenced by the production of 
small viral plaques that appeared to enlarge by 24 hpi; however those plaques were not 
any more visible at later times post infection presumably because infected cells had been 
eliminated.  Clinical disease symptoms absolutely paralleled the observed infection 




following viral infection, while the MKgK rescued virus produced significant eye disease 
by 4 dpi.  This disease was characterized by severe hyperemia, blepharitis (thickening of 
the eyelid), inflammation and ocular discharge.  In addition, the MK∆gK virus did not 
cause any mortality in the infected mice, while the MKgK virus produced significant 
mortality, as well as clear signs of neurological damage characterized by visual 
observation of hunched posture, ataxia, circling and seizures.  
A priori, neuronal infection via the eye route should lead to efficient 
establishment of viral latency in mouse trigeminal ganglia.  Nineteen-of-twenty mice 
infected with the MKgK-rescued virus released infectious virus after cocultivation of 
mouse ganglia with Vero cells, and 19/20 mice contained viral DNA in their ganglia 
detectable by PCR.  Mice infected after cotton swab eye scarification appeared to have a 
lower incidence of viral latency reduced by approximately 25% -50% taking into account 
either PCR detection of viral DNA, or virus isolation, respectively.  Infection of murine 
eyes following either cotton swab or needle scarification revealed that the MK∆gK virus 
was not able to efficiently establish latency as evidenced by the fact that only 3/20 
ganglia were positive for viral DNA by PCR in the scarification model, while none of the 
ganglia were positive in the cotton swab scarification model.  The fact that no virus was 
isolated from any ganglia in coculture experiments may be partly due to the inability of 
gK-null viruses to efficiently egress out of infected cells.  
Overall, these results strongly show that gK is essential for corneal spread, 
neuroinvasion, and infection and establishment of latency in mice infected via the ocular 
route. In this regard, this result is substantially different from those obtained with the 




requirements for neuroinvasion.  In the PRV gK-null virus experiments, mice were 
infected via the intranasal route.  It is possible that infection via this route may access the 
central nervous system more efficiently than the ocular route. However, additional 
experiments in mice have revealed that the MK∆gK virus is also avirulent when 
administered at relatively high titers (greater than 106 PFU) either via the intranasal or 
intramuscular routes (not shown) suggesting that PRV and HSV-1 gK-null viruses use 
substantially different mechanisms for neuroinvasion. 
 HSV-1 gK may be particularly important for the causation of ocular disease in 
humans because it has been reported to exacerbate ocular disease mediated by anti-gK 
humoral and cellular immune responses (Ghiasi, Cai et al. 1996; Ghiasi, Cai et al. 1997; 
Mott, Perng et al. 2007; Osorio, Mott et al. 2007).  Thus, gK is an important determinant 
of both viral infectivity and ocular disease. The high probability that neuronal endings 
were readily accessible in the mouse eyes after extensive scarification and the relative 
lack of viral DNA in mouse ganglia argues for a role of gK in direct neuronal infection as 
well as indirect transmission of virus from corneal epithelial cells to nerve endings. It is 
also possible that the lack of gK may lead to the formation of defective tegumented 
capsids, which are unable to move in a retrograde fashion. Additional in vitro and in vivo 
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A MUTANT HERPES SIMPLEX VIRUS TYPE-1 (HSV-1) MCKRAE LACKING 
THE GLYCOPROTEIN K (GK) GENE IS UNABLE TO BE TRANSPORTED IN 





Herpes simplex virus type 1 (HSV-1) is an important human pathogen that 
typically causes mucocutaneous lesions in facial and genital epithelial/mucosal surfaces.  
The hallmark of HSV-lifecycle is infection of sensory neurons where the virus establishes 
a latent infection for the life of the host (Whitley, Kimberlin et al. 1998).  HSV-1 
neuronal infection can occasionally cause acute encephalitis (Kimberlin, Lin et al. 2001), 
while ocular HSV-associated disease is one of the most common infectious causes of 
blindness in developed countries (Liesegang, Melton et al. 1989; Liesegang 2001). 
HSV-1 enters into neuronal cells via a pH-independent fusion of the viral 
envelope with neuronal plasma membranes  (Qie, Marcellino et al. 1999; Nicola, Hou et 
al. 2005), while it can enter into a wide range of non-neuronal cells via either pH-
independent or pH-dependent endocytosis (Milne, Nicola et al. 2005).  Virus entry into 
all cells involves the coordinated functions of glycoproteins gD, gB, gH, gL and gC (Cai, 
Gu et al. 1988; Desai, Schaffer et al. 1988; Ligas and Johnson 1988; Hutchinson, Browne 
et al. 1992).  Viral glycoprotein gD binds to different cellular receptors including the 
herpesvirus entry mediator (HVEM, or HveA), nectin-1 (HveC), or 3-O-sulfated heparan 
sulfate (Montgomery, Warner et al. 1996; Geraghty, Krummenacher et al. 1998; Shukla, 
Liu et al. 1999).  Apparently, gB can also bind to additional receptors including paired 




IIA (NMHC-IIA), and myelin-associated glycoprotein (MAG) that function in virion 
attachment and virus entry (Satoh, Arii et al. 2008; Arii, Goto et al. 2010; Suenaga, Satoh 
et al. 2010).  Binding of gD and gB to their cognate receptors is thought to trigger 
sequential conformational changes in gH/gL and gB causing fusion of the viral envelope 
with cellular membranes during virus entry, as well as fusion among cellular membranes 
(Heldwein, Lou et al. 2006; Hannah, Heldwein et al. 2007; Connolly, Jackson et al. 
2011). 
Fusion of the viral envelope with cellular membranes causes deposition of the 
viral capsid into the cytoplasm, which is subsequently transported to the cell nucleus 
(Morrison, Stevenson et al. 1998; Morrison, Wang et al. 1998; Ojala, Sodeik et al. 2000).  
This retrograde transport of capsids to the neurons is highly dependent on the cellular 
microtubule network and mediated via, most likely, direct interactions by one or more 
tegument and capsid proteins with the dynein motor and the dynein cofactor dynactin 
(Kristensson, Lycke et al. 1986; Topp, Meade et al. 1994; Sodeik, Ebersold et al. 1997; 
Dohner, Wolfstein et al. 2002), reviewed in (Diefenbach, Miranda-Saksena et al. 2008).  
Infectious virus production is initiated in the nucleus of cells where capsids 
assemble.  The virus acquires an initial viral envelope by budding of capsids into 
perinuclear spaces (Diefenbach, Miranda-Saksena et al. 2008; Mettenleiter, Klupp et al. 
2009).  Fusion of the viral envelope with the outer nuclear membrane is thought to 
deliver partially tegumented capsids into the cytoplasm.  These capsids acquire additional 
tegument proteins before acquiring their final envelopes by budding into intracellular 
vesicles, most likely, originating from the trans-Golgi network (TGN) (Mettenleiter 2002; 




process that appears to involve the kinesin family of microtubular network-associated 
motors reviewed in (Diefenbach, Miranda-Saksena et al. 2008; Mettenleiter, Klupp et al. 
2009). 
The mechanism of anterograde transport of alphaherpesvirus in neuronal cells is 
highly controversial to a large extent because of disparate results obtained with 
pseudorabies virus (PRV) and HSV-1.  Two principle mechanisms of axonal transport 
have been proposed:  1) independent axonal transport of viral glycoproteins and capsids 
and assembly of the enveloped virions in the plasma membrane; 2) transport of  fully 
enveloped virions that have formed via budding of capsids into TGN-derived membranes 
(Diefenbach, Miranda-Saksena et al. 2008; Liu, Goodhouse et al. 2008; Mettenleiter 
2008; Mettenleiter, Klupp et al. 2009; Antinone and Smith 2010; Antinone, Zaichick et 
al. 2010; Maresch, Granzow et al. 2010; Osakada and Cui 2011b). 
A number of viral glycoproteins have been implicated in efficient egress of 
virions from infected non-neuronal cells (Mettenleiter, Klupp et al. 2009).  However, the 
role of viral glycoproteins in both retrograde and anterograde neuronal transport has not 
been extensively studied.   PRV glycoproteins gE and gI are required for anterograde 
transport, but not retrograde transport (Card, Whealy et al. 1992; Jacobs, Mulder et al. 
1993; Babic, Klupp et al. 1996; Johnson, Webb et al. 2001; Brittle, Reynolds et al. 2004; 
Ch'ng and Enquist 2005).  HSV-1 gE has been reported to function in both retrograde and 
virus spread from epithelial cells to neurites (Balan, Davis-Poynter et al. 1994; Saldanha, 
Lubinski et al. 2000; Wang, Tang et al. 2005; Brittle, Wang et al. 2008).  Experiments 
with neuronal cultures in microfluidic chambers revealed that HSV-1 (gE) was not 




epithelial cells to neurites.  In addition, gE-null virions that entered into neurites did not 
exhibit any defect in retrograde axonal transport (McGraw and Friedman 2009). 
HSV-1 gK is a structural component of the virion particle and functions in virus 
entry into epithelial cells (Foster, Rybachuk et al. 2001; Jambunathan, Chowdhury et al. 
2011), cytoplasmic virion envelopment, virion egress and virus-induced cell fusion  
(Hutchinson, Roop-Beauchamp et al. 1995).  In infected cells, gK is found in a functional 
complex with the membrane protein UL20 (Foster and Kousoulas 2008). UL20/gK 
interactions are essential for their intracellular transport, cell-surface expression, and 
functions in cytoplasmic virion envelopment and virus-induced cell fusion (Foster, 
Alvarez et al. 2003; Foster, Melancon et al. 2004a; Foster, Melancon et al. 2004b; 
Melancon, Fulmer et al. 2007; Foster and Kousoulas 2008). Recently, we showed that 
HSV-1 gK and UL20 physically bind to gB and gH and modulate gB-mediated 
membrane fusion (Chouljenko, Iyer et al. 2009; Chouljenko, Iyer et al. 2010). Also, we 
reported that gK was essential for virus spread in the cornea of mice, neuroinvasiveness 
and establishment of latency into ganglionic neurons (David, Baghian et al. 2008).  In 
this report, we utilize a microfluidic chamber to show that gK is required for infection of 
neurites and retrograde and anterograde transport in neurons. 
 
MATERIALS AND METHODS 
Cells and Viruses 
African green monkey kidney (Vero) cells were obtained from the American 
Type Culture Collection (Rockville, MD, USA) and grown and propagated in Dulbecco’s 




antibiotics.  The gK complementing VK302 cell line (generously provided by Dr. David 
Johnson, Oregon Health Sciences University, Portland, OR, USA) was maintained in 
Dulbecco’s modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and antibiotics.  This cell line was used for generation and maintenance of 
McKrae ∆gK viral stocks. Vero and VK302 cells were used to determine the replication 
characteristics (plaque morphology) for parental McKrae virus and all recombinant 
viruses used in these experiments.  The clinical ocular isolate and neuroinvasive strain of 
HSV-1 (the parental wild-type), McKrae strain, was obtained from Dr. J. M. Hill 
(Louisiana State University Health Sciences Center, New Orleans, LA, USA) (Fig 3.1:A).   
 
Construction of Recombinant Viruses 
 The construction methodology of mutant viruses for this experiment is essentially 
similar to the techniques that were previously described to create KOS strain mutants 
(Jayachandra, Baghian et al. 1997; Foster, Rybachuk et al. 1998; Foster and Kousoulas 
1999; David, Baghian et al. 2008).  McKrae virus with deleted UL53 (gK) gene (∆gK; 
(Fig 3.1: B)) was constructed using the ICP27-null (d27-1) virus and plasmid pSJ1724, as 
described previously for the HSV-1 (KOS) ∆gK virus (Jayachandra, Baghian et al. 1997).  
The ICP27-null virus has 1627 base pair (bp) of UL54 gene deleted, but contains a 
complete UL53 gene.  Plasmid pSJ1724 has a 1068 bp deletion in UL53, but has an intact 
UL54.  Recombination between homologous regions of d27-1 virus and plasmid pSJ1724 
resulted in the ∆gK virus.  This virus does not contain an EGFP cassette and is designated 
in this paper as ΔgK/GFP-.  This ∆gK virus was rescued (R/GFP-) (Fig 3.1: C) by 




HSV-1 (KOS) strain followed by infection with the ∆gK virus (Jayachandra, Baghian et 
al. 1997).  The UL 53 (gK) gene of HSV-1 McKrae was replaced with an enhanced green 
fluorescence protein (EGFP) gene cassette under control of the human cytomegalovirus 
immediate early gene promoter (CMV-EGFP) (Foster, Rybachuk et al. 1998).  Briefly, 
The CMV-EGFP cassette was cloned into the plasmid pSJ1723 to create plasmid 
pTF9201 as described previously (Foster, Rybachuk et al. 1998; David, Baghian et al. 
2008).   Plasmid PTF9201 contains an EGFP gene cassette under the human 
cytomegalovirus immediate early promoter control (HCMV-IE) within a DNA fragment 
spanning the UL52–UL54 genomic region that lacks the UL53 gene.  Plasmid PTF9201 
was used in transfection followed by infection with HSV-1 (McKrae) to isolate the 
McKrae-∆gK/EGFP virus (Fig. 3.1: D) designated ∆gK/GFP+, appearing as small 
fluorescent viral plaques under the fluorescence microscope (Foster, Rybachuk et al. 
1998; David, Baghian et al. 2008).  The McK ∆gK/EGFP virus was rescued using 
plasmid pTF9105, which contains a complete UL53 gene from the HSV-1 (KOS) strain 
creating the virus designated R/GFP+ (Fig. 3.1: E) (Foster and Kousoulas 1999). 
 
Animals 
 Adult female Sprague-Dawley rats, 15-18 days pregnant, were used (Charles 
River, Wilmington, MA).  All procedures were approved by the Louisiana State 







Figure 3.1: Schematic representation of mutant viruses.  The top line represents the 
prototypic arrangement of the HSV-1 genome with the unique long (UL) and unique 
short (US) regions flanked by the terminal repeat (TR) and internal repeat (IR) regions. 
(A) McKrae wild type.  (B) McKrae parental strain with deletion mutation of gK and 
without the EGFP cassette (ΔgK/GFP-).  (C) Rescue of the gK deletion in the virus (B) 
without the EGFP cassette (R/GFP-).  (D) McKrae parental strain with deletion of the gK 
gene by replacement with an EGFP cassette (ΔgK/GFP+).  (E) Rescue of the virus in (D) 












Dorsal Root Ganglion Primary Neuron Culture 
 Dorsal root ganglia (DRG) neurons were cultured under conditions that were 
adapted from those described previously for culturing sympathetic superior cervical 
ganglia-derived neurons (Liu, Goodhouse et al. 2008).  Additional modifications were 
adapted from previously 
described culture conditions for dorsal root ganglia (Osakada and Cui 2011b; Osakada 
and Cui 2011a).  Specifically, ganglia were dissected from fetal Sprague-Dawley rats at 
embryonic day 
15-18. DRG were incubated at 37° C for 30 min in 250 mg/ml of trypsin (Worthington 
Biochemical Corp., Lakewood, NJ).  Trypsin was neutralized by incubating ganglia in 
neuron culture media with 10% fetal bovine serum (FBS) and 1 mg/ml trypsin inhibitor 
(Sigma Aldrich, St. Louis, MO) for 2 min.  Ganglia were rinsed with fresh neuron culture 
media and ganglionic neurons were gently triturated into a single-cell suspension using a 
pulled-glass Pasteur pipette. Then cells were plated into one side of the microfluidic 
neuron devices (Cat. number: SND450; Xona Microfluidics, LLC, Temecula, CA) 
adhered to glass coverslips or the surface of 35mm plastic petri dishes.  Glass coverslips 
or 35mm plastic petri dishes were prepared for neurons by coating with Poly-D-Lysine, 
molecular weight 75,000 to 150,000 Daltons, (Sigma Aldrich) dissolved in borate buffer 
at 0.2mg/ml, incubated at 37° C for 48 hours prior to plating of neurons.  Neuronal 
devices were assembled by placing a standard neuronal microfluidic device firmly onto 
the coverslip or petri dish to ensure a sealed barrier.  Maintenance neuron culture media 
consists of Neural Basal Media with B-27 supplement, at manufacturer’s recommended 




neural growth factor 2.5s (Invitrogen), 2% normal rat serum (Invitrogen), 1X Glutamax 
(Invitrogen) and 0.2% Primocin (Invivogen, San Diego, CA).  Once plated, neurons were 
maintained in a humidified incubator at 37° C and 5% CO2 for the duration of all 
experiments.  To eliminate non-neuronal cells, 1 and 3 days post-plating, neuronal 
cultures were treated with 4 mM cytosine β-d-arabinofuranoside (CAB) (Sigma-Aldrich) 
in neuronal media for 24 hours.  Neuronal culture media was changed every 48-72 hours 
during the course of the experiment.  
 
Infection of Neuron Devices 
 Neurons were allowed to grow for 10-14 days post plating until robust axonal 
processes with abundant branching were observed on the axon side of neuron devices. 
Once present, the neuronal devices were prepared for infection.  For retrograde 
infections, media was completely depleted from the wells of the axonal side of 
microfluidic devices. Then on the neuron-soma-side of the devices, wells were filled to 
maximum fluid capacity until a small meniscus formed in the neuronal culture media. 
After establishment of the fluid pressure gradient, axonal side wells would be inoculated 
with the virus at the concentration indicated in the results.  Then, approximately 100 
microliters of neuron culture media was placed in the infected wells to ensure mixing of 
the virus into the central chamber containing the axons. Once the fluid pressure gradient 
had been established media was only added to the soma side if necessary to combat 
dehydration and maintain an obvious fluid level difference. In the case of anterograde 
neuronal infection studies, the axonal side was co-plated with a monolayer of VK302 or 




neutralized using 100% FBS, and an abundance of cells were plated on the axon side of 
the microfluidic neuron devices using a media consisting of a 1:1 mixture of DMEM with 
10% FBS and neuronal culture media.  VK302 or Vero cells were seeded in devices and 
allowed to grow for 24-48 hours to ensure a nearly confluent monolayer for experiments. 
For anterograde infections, media was completely depleted from the wells of the neuron 
soma side of microfluidic devices. Then on the axon/reporter cell side of the devices, 
wells were filled to maximum fluid capacity. After establishment of the fluid pressure 
gradient, soma side wells were inoculated with the virus at the concentration indicated in 
the results.  Then approximately 100 ml of neuron culture media was placed in the 
infected wells to ensure mixing of the virus into the central chamber containing the 
axons.  Again, after establishment of the gradient, media was only added to the high side 
(axon/reporter cell side in this case) to replace any loss due to dehydration. 
 
Growth Curves on Neurons 
To determine the kinetics of viral replication on ganglionic neurons, 24-well 
plastic plates were plated with 175,000 ganglionic cells using the above described 
harvesting protocol. Ganglionic neurons were infected with approximately a multiplicity 
of infection (MOI) of 0.1 with each of the viruses. Plates were prepared in triplicate and 
infections were halted by freezing at 0, 12, 24, 48 and 72 hpi. Plates were frozen, thawed 
and viral titers were determined for each time point by standard plaque assay on VK302 
cells (for the ΔgK viruses) or Vero cells (for the parental and rescue strains). Plaques 
were stained with crystal violet and visualized with a dissecting microscope. Growth 





For fluorescent plaque morphology, confluent monolayers of Vero and VK302 
cells were infected at MOI of 0.001 with the indicated viruses.  EGFP fluorescence of 
representative plaques was visualized and photographed at 72 hpi with a fluorescence 
microscope (Olympus, Tokyo, Japan). For immunohistochemical plaque morphology, 
cells were fixed with 10% formalin at 72 hpi (Melancon, Foster et al. 2004; David, 
Baghian et al. 2008). Immunohistochemistry was performed with primary rabbit anti-
HSV antibodies (1:1000) (Dako, Carpinteria, CA) and the reactions were developed with 
NovaRed substrate (VectorLabs; Burlingame, CA).  Images were taken with an inverted 
light microscope (Olympus) using relief contrast.  
 
Visualization of Retrograde and Anterograde Infections 
 For direct observation by phase contrast of the viral infection, neuronal soma 
sides and axon/reporter cell sides of devices were observed and imaged using an inverted 
microscope (Olympus) and relief contrast.  EGFP fluorescence was observed using the 
same inverted microscope set for fluorescence.  For immunofluorescent antibody analysis 
of anterograde infections, microfluidic devices were fixed with cold 10% formalin.  Then 
the devices were incubated with blocking buffer (PBS containing 4% BSA and 2% goat 
serum) for 1 hour at room temperature.  Next the primary antibodies were added and 
devices were incubated overnight at 4°C.  Primary antibodies used were mouse 
monoclonal anti-HSV glycoprotein C IgG2a (Virusys Corp., Taneytown, MD) diluted 
1:3000 and mouse monoclonal anti-neurofilament IgG1 (Invitrogen) diluted 1:1000.  




anti-mouse IgG2a conjugated to Alexafluor 594 (Invitrogen), both diluted to 1:1000 were 
applied.  All antibodies were diluted in PBS containing 2% BSA and 1% goat serum.  
After 30 minutes devices were washed 5 times with PBS.  The microfluidic neuron 
devices were placed on ice and removed from the glass coverslips (per the 
manufacturer’s instructions).  Prolong Gold with DAPI (Invitrogen) was added to the 
coverslips and cells were photographed with an inverted fluorescence microscope.  
 
Sample Collection for PFU and Quantitative PCR (qPCR) Studies 
 For studies of viral DNA transmission and virus/viral DNA production neuronal 
devices were sampled in the following manner.  The low side (axonal side in retrograde 
studies and somal side in anterograde studies) was always aspirated first.  At the 
appropriate time points, the media present in the low side wells was aspirated and 
collected.  Then, the sampled side was flushed with a small amount of media. Following 
that, media from the higher side was collected and that side was flushed with a small 
amount of media.  Subsequently, the high side wells were filled with media and the 
devices were frozen overnight.  Devices were then thawed and the low side was flushed 
with a small amount of media and this media was collected.  Finally, the high side was 
flushed and collected.  This procedure allowed for maintenance of the fluid pressure 
gradient by always keeping the gradient and allowed for collection of cell-associated 
virus as well as any free virus in the media.  At this point all samples were frozen.  Later 






Detection of PFU from Anterograde and Retrograde Infections 
 Samples of media collected from the neuronal devices were thawed and plated in 
serial dilutions.  The number of infectious virions in the media was determined by plaque 
assay on appropriate (Vero or VK302) monolayers visualized with anti-HSV-1 rabbit 
polyclonal antibody (Dako) developed with Nova Red (Vector Labs).  
 
QPCR 
For quantitative PCR, once thawed, samples were processed using the Qiagen 
DNeasy blood and tissue kit (Qiagen, Valencia, CA) per the manufacturer’s instructions 
to isolate DNA. qPCR was performed as described previously for Kaposi’s sarcoma 
herpesvirus (KSHV) (Subramanian, D'Auvergne et al. 2008; Subramanian, Sehgal et al. 
2010).  Specifically, the primers and probe (6-carboxytetramethylrhodamine (TAMRA)) 
for the real-time PCR were designed to detect HSV-1 US6 (gD).  Equal volumes of viral 
DNA were used for TaqMan PCR 196 analysis.  Purified plasmid containing the gD gene 
was initially used to generate the standard curve.  Samples were also tested and genome 
numbers were determined using validated standards provided by the Path-HSV1-genesig 
real-time PCR  detection kit for Human Herpes Virus 1 (Herpes simplex type 1) 











Replication Characteristics of Recombinant Viruses on Rat Dorsal Root Ganglionic 
Neurons 
 
We have previously described the construction of recombinant HSV-1 
(McKrae) viruses constitutively expressing the enhanced green fluorescence protein 
(EGFP) under the human cytomegalovirus immediate early promoter (HCMV-IE) 
(David, Baghian et al. 2008).  To determine the role of glycoprotein K (gK) in neuronal 
replication, a complete set of recombinant viruses with intact or deleted gK genes were 
constructed and studied.  This set of viruses include: 1) the wild-type McKrae strain 
compared to a mutant virus lacking the gK gene (∆gK/GFP-) and a virus in which the 
deleted gK gene was rescued to wild-type (R/GFP-) (Fig. 3.1: A, B, C, respectively); 2) a 
set of McKrae derived viruses that have a HCMV-IE-EGFP gene cassette replacing the 
gK gene sequence (∆gK/GFP+) and a derivative virus that replaced the missing gK gene 
and retained the HCMV-IE-GFP gene cassette adjacent to the gK gene (R/GFP+) (Fig. 
3.1: D, E, respectively).  
Infection of dorsal root ganglionic neurons with wild-type McKrae virus 
resulted in rapid cytopathic effects exhibited as early as 12 hpi.  Typically, neurons 
appeared rounded up, swollen, while the overall number and length of axons present 
before infection, appeared to be markedly reduced at early times after infection (not 
shown).  Wild-type-like McKrae virus as well, as wild-type-like virus produced after 
rescue of the deleted gK gene, replicated with approximately equal efficiencies in the 




the gK gene grown on either Vero, or the gK complementing cell line VK302 replicated 
1-2 logs less efficiently than the parental McKrae viruses at late times post infection (Fig. 
3.2: A, B).  
All wild-type-like viruses (wild-type and gK-rescued virus) produced on 
average similar size plaques on both Vero and VK302 cells (Fig. 3.3) (David, Baghian et 
al. 2008).  In contrast, gK-null viruses prepared in either Vero or VK302 cells produced 
on average drastically smaller viral plaques on Vero cells.  The gK-null defects were 
efficiently complemented on VK302 cells, where gK-null viruses produced viral plaques 
similar in size to the wild-type like viruses (Fig. 3.3).  Examination of individual viral 
plaques by fluorescence microscopy revealed that all viruses containing the GFP gene 
cassette readily expressed EGFP (Fig. 3.3). 
 
Microfluidic Multi-Chamber Device for Neuronal Transport Studies 
A commercially available microfluidic device was used for neuronal transport 
studies (see materials and methods).  This device enables the physical separation of 
neuronal somas and axon termini under virion impermeable conditions (Fig. 3.4: A).  To 
ensure that virions could not be passively transmitted from one chamber to the other, 
control experiments were performed as follows: Vero cells were plated in wells on both 
sides of the microfluidic chamber.  Wells of one side were infected with R/GFP+ virus at 
an MOI of 10.  A hydrostatic pressure differential between the infected and uninfected 
chambers was maintained by ensuring that the uninfected fluid levels were substantially 
higher than those in the infected wells.  The infected cells exhibited extensive 




exhibit any cytopathic effects, or fluorescence at 5 days post infection suggesting that 





Figure 3.2: Growth curves of HSV-1 (McKrae) and mutants on DRG neurons.  
Approximately 175,000 ganglionic cells plated in 24 well plates were infected with the 
parental McKrae strain, R/GFP+, ∆gK/GFP+ (Vero), ∆gK/GFP+ (VK302), R/GFP-, 
∆gK/GFP- (Vero), or ∆gK/GFP- at an MOI of approximately 0.1.  (A) Curves for the 
three GFP+ viruses with the parental McKrae strain for comparisson.  (B) Curves for the 
three GFP- viruses with the parental McKrae strain for comparisson.  Viral titers were 
obtained at indicated time points post infection by standard titration plaque assay on Vero 
or VK302 cells.  PFU totals represent the mean of triplicate experiments and error bars 







Figure 3.3: Representative plaque morphologies of HSV-1 (McKrae) strain and 
mutants on Vero and VK302 cells.  Confluent Vero or gK complementing VK302 cells 
monolayers were infected with the R/GFP+, ∆gK/GFP+ (Vero), ∆gK/GFP+ (VK302), 
R/GFP-, ∆gK/GFP- (Vero), or ∆gK/GFP- at an MOI of approximately 0.001.  Viral 
plaques were visualized by immunohistochemistry at 72 hpi using rabbit anti-HSV-1 
developed with Nova Red (Vector Labs) with contrast microscopy.  Fluorescent plaques 
from viruses with EGFP were observed using a fluorescence microscope at 72 hpi. 
Plaques shown are representative of average plaque size observed.  All images are taken 







Figure 3.4: Microfluidic Neuron Device System.  (A) Photograph of the neuron device 
(Xona Microfluidics) that maintains a fluid pressure (left panel).  Virus impermeable 
barrier containing axons (middle panel).  Side view schematic showing wells, main 
central channel and microgroove barrier showing the maintenance of a fluid pressure 
gradient (right panel).  (B) Control experiment to test for system integrity.  Phase contrast 
and GFP fluorescence of infected Vero cells at 3 days post infection, and uninfected Vero 
cells at 5 days post infection.  During all 5 days the uninfected side wells were 
maintained at a higher fluid level than the infected side wells.  
 
Retrograde Transport of Virions  
Retrograde transport of virions from infected neuronal endings to neuronal 
somata was investigated.  For retrograde studies, microfluidic chambers were seeded with 
rat dorsal root ganglionic neurons on one side of the chamber.  Neurons were allowed to 
propagate axons across the microgroove barrier for 10-15 days, or until axons and 
neuronal endings were visibly present across the barrier and the apposed chamber, 
respectively (see Materials and Methods).  The neuronal endings chambers were infected 




infection on the neuronal soma side of the microfluidic device was monitored daily using 
a fluorescence microscope to detect EGFP expression. EGFP expression was readily 
detected as early as 24 hpi in the R/GFP+, while infection with the ∆gK/GFP+ virus 
failed to produce any EGFP expression, as late as 5 days post infection (Fig. 3.5).  
Surprisingly, ∆gK/GFP+ virus grown on the VK302, gK complementing, cells failed to 
be transmitted to the neuronal soma side of the microfluidic device, although an 
occasional fluorescent cell was infrequently detected (approximately 100-1000-fold less 
than the R/GFP+ ) (Fig. 3.5 F).  
 To determine whether infectious virions and/or viral DNA were transported in a 
retrograde manner, neuronal termini chambers were infected with an MOI of 
approximately 5.  The number of viral genomes was obtained by quantitative PCR, while 
the presence of infectious virus was assessed by determining viral titers on VK302 cells 
as detailed in Materials and Methods. Generally, all virus stocks appeared to have a 
genome to PFU ratio of less than 10 suggesting that most viral genomes were contained 
within infectious virion particles (Fig. 3.6).  The number of viral genomes detected on the 
neuronal termini side of the device decreased by approximately 35% at 48 hpi and 45% at 
72 hpi, respectively, while it did not decrease in wells infected with either the 
∆gK/EGFP+ or ∆gK/EGFP+ produced in VK302 cells suggesting that the gK-null 
viruses failed to enter into neuronal endings, unlike the wild-type-like virus.  Comparison 
of total PFU numbers revealed a time-dependent decrease of PFU remaining within the 
neuronal endings chambers for all viruses.  This PFU reduction was similar to decreases 
in PFU obtained when viral samples were incubated for similar time periods at 37C 




Examination of the number of viral genomes and PFU obtained from samples derived 
from the soma side of the devices revealed that the R/GFP+ virus efficiently transported 
and replicated in soma chambers producing maximum viral genomes and PFU at 72 hpi.  
In contrast, both the ∆gK/EGFP+ and ∆gK/EGFP+ grown on VK302 cells failed to be 




Figure 3.5: Infection of neuron cell bodies (Soma) via retrograde transport.  Phase 
contrast (A-C) and GFP fluorescence (D-F) of neurons.  Axonal side of chambers (not 
shown) were infected with ΔgK/GFP+ (VK302), ΔgK/GFP+ (Vero) and R/GFP+. 
Neurons potentially infected with ΔgK/GFP+ (VK302 or Vero) were photographed, 
using phase and fluorescence microscopy, at 5 dpi to allow ample time for retrograde 
transport.  Neurons infected with R/GFP+ were photographed, using phase and 
fluorescence microscopy, at 2 dpi due to the presence of ample infected neurons.  All 








Figure 3.6: Determination of PFU and viral genomes recovered in retrograde virus 
transport experiments.  Viral DNA copy number determined by QPCR, and PFU, 
determined by serial titration plaque assay are shown for samples recovered from the 
axon and soma sides of devices infected in retrograde manner.  Bars represent the mean 
of 6 (DNA) or 4 (PFU) samples taken from devices at 2, 48, and 72 hpi as well as 
corresponding volume samples of innocula taken at the time of infection (input).  (A, B) 
R/GFP+ infected. (C, D) ∆gK/GFP+ (Vero) infected. (E, F) ∆gK/GFP+ (VK302) 
infected.  Input bars are black.  Bars representing the axon side (white) and soma side 





Anterograde Transport of Virions  
For anterograde studies, after seeding of microfluidic chambers and propagation 
of axons, axonal side wells were co-plated with a monolayer of VK302 cells.  Then, 
neuronal somata were infected as described in the retrograde studies. Infection of the 
neuronal side of the microfluidic chambers was also monitored daily by visualizing 
EGFP fluorescence.  All three viruses, R/EFP+, ∆gK/GFP+(Vero) and 
∆gK/GFP+(VK302) infected neuronal somas efficiently, as evidenced by the strong 
EGFP fluorescence (Fig. 3.7).  However, only the R/GFP+ virus was transported in an 
anterograde manner to the Vero reporter cells on the microfluidic chambers (Fig. 3.7).  
Similar virus axonal transport experiments were performed, but this time the cells within 
the soma and reporter sides of the microfluidic chambers were fixed and immune-stained 
with antibodies specific for viral glycoprotein C (gC), nuclei, and neurofilament (neuron-
specific stain) and viruses not expressing GFP were utilized (to allow multicolor 
immunofluorescence). Cells in both the soma and reporter sides of the chambers 
expressed relatively high levels of gC only when infected R/GFP- virus, while both 
∆gK/GFP- (Vero) and ∆gK/GFP- (VK302) viruses expressed in gC in cells in the soma 
side of the chambers, while no gC expression was detected on the reporter side of the 
chambers (Fig. 3.8). 
 Anterograde transport of virions was also monitored by determining the number of 
infectious viruses produced on the reporter side of the microfluidic chamber (Vero cells) 
after infection of the neuronal soma sides, as well as determining the number of viral 
genomes transmitted axonally to the reporter sides using QPCR. Infectious virions were 




virions present at 72 hpi in somas appeared to decrease in comparison to input virus, 
while the total number of viral genomes appeared to increase reflecting continued viral 




Figure 3.7: Anterograde infection and transmission.   Anterograde infection and 
transmission demonstrated by phase and fluorescence microscopy of the infected 
neuronal side and uninfected reporter cell/axon side.  Only the rescued virus was 







Figure 3.8: Anterograde infection and transmission via immunofluorescence of viral 
proteins.  Anterograde infection and transmission demonstrated by fluorescent 
antibodies.  Images are stained with anti-neurofilament antibody with Alexafluor 488 
secondary (green), anti-HSV-1 gC with Alexafluor 594 secondary (red) and DAPI (blue). 
Neuron sides of the microfluidic devices were infected with R/GFP-, ΔgK/GFP- (vero) 
and ΔgK/GFP- (VK302).  Only the rescued virus was observed spreading in the 
anterograde direction to reporter cells as demonstrated by red staining indicating the 







Figure 3.9: Determination of PFU and viral genomes recovered in anterograde virus 
transport experiments.  Viral genome and PFU numbers from the axon/reporter cell and 
soma sides of devices infected in the anterograde manner.  Bars represent the mean of 6 
(DNA) or 4 (PFU) samples taken from devices at 72 hpi as well as corresponding volume 
samples of innocula taken at the time of infection (input).  (A, B) R/GFP+ infected. (C, 
D) ∆gK/GFP+ (Vero) infected. (E, F) ∆gK/GFP+ (VK302) infected.  Input bars are 
black.  Bars representing the soma side (white) and reporter cell side (gray) are shaded to 






HSV-1 gK functions as a protein complex with the membrane protein UL20 in 
membrane fusion phenomena during virus entry and virus-induced cell fusion enabling 
virions to enter into cells and spread into adjacent uninfected cells, respectively 
(Jayachandra, Baghian et al. 1997; Melancon, Luna et al. 2005; Foster and Kousoulas 
2008; Chouljenko, Iyer et al. 2009; Chouljenko, Iyer et al. 2010; Jambunathan, 
Chowdhury et al. 2011).  Previously, we showed that lack of gK prevented corneal spread 
in mice, transmission of the gK-null virions to the central nervous system, and 
establishment of latency.  Here, we show that gK is essential for infection of free 
neurites, and retrograde and anterograde transport in rat dorsal root ganglionic neurons in 
culture, in agreement with the previous in vivo studies (David, Baghian et al. 2008). 
Herein, we have chosen to work with the HSV-1 McKrae strain because this 
virus was isolated from a human ocular herpes infection (Kaufman, Ellison et al. 1969) 
and shown to be highly virulent in mice and rabbits (Perng, Thompson et al. 1995; Perng, 
Chokephaibulkit et al. 1996; Halford, Balliet et al. 2004).  In these studies we utilized a 
set of recombinant viruses lacking gK gene expression in the presence or absence of 
EGFP expression for comparative purposes, because constitutive expression of the EGFP 
gene may alter viral replication characteristics (DeWire, Money et al. 2003).  Wild-type-
like viruses replicated to similar levels in the presence or absence of GFP expression in 
ganglionic neurons.  In contrast, gK-null virions reached maximum viral titers that were 
1-2 logs lower than their corresponding wild-type-like viruses, while EGFP expression 
did not adversely affect viral growth.  These experiments indicated that EGFP expression 




The relative size of viral plaques is an indication of the ability of the virus to 
spread from infected to uninfected cells.  Consistent with previous findings, the lack of 
gK caused the production of substantially smaller viral plaques indicating a severe defect 
in virus spread.  EGFP expression did not have any effect on the gK-null defect in virus 
spread. 
Microfluidic devices separating axonal termini from neuronal somata have been 
extensively used in herpes viral experiments to investigate the contribution of individual 
genes in retrograde and anterograde axonal transport (Ch'ng, Flood et al. 2005; Feierbach, 
Bisher et al. 2007; Liu, Goodhouse et al. 2008; Curanovic and Enquist 2009).  We 
exclusively utilized a commercially available microfluidic device (Xona Microfluidics, 
LLC) originally developed from a collaboration between the Enquist laboratory 
(Princeton Univ.) and the Jeon laboratory (Univ. of CA Irvine) (Liu, Goodhouse et al. 
2008).  It is particularly important in all studies using these devices that control 
experiments are performed carefully to ensure that there is no leakage of fluids between 
the device and the cover slip on which the device is placed.  Therefore, methods utilized 
in these studies were validated for obtaining appropriate sealed chambers prior to the 
onset of each experiment.  Furthermore, chambers were inspected to ensure that axons 
were exclusively appearing within the device microgrooves.  
Infections of chambers containing axonal termini showed that the wild-type-like 
virus (R/GFP+) was readily transported to the somata containing chamber, while the gK-
null virus ∆gK/GFP+ failed to be transported.  Surprisingly, ∆gK/GFP+ virus grown on 
the complementing cell line VK302 was also largely unable to be transported to the 




gK gene in VK302 cells may complement for infectious virus production in Vero, 
however virions produced in VK302 cells may not be able to infect neuronal axons.  We 
have shown that the amino terminus of gK interacts with the amino terminus of gB, most 
likely affecting the ability of gB to mediate fusion of the viral envelope with cellular 
membranes during virus entry (Chouljenko, Iyer et al. 2009; Chouljenko, Iyer et al. 2010; 
Jambunathan, Chowdhury et al. 2011).  Comparison of the predicted amino acid 
sequences of KOS and McKrae gB and gK reveal a number of amino acid differences 
including amino acid changes within the amino termini of gB and gK.  Furthermore, lack 
of gK prevented entry via fusion of the viral envelope with cellular membranes 
(Chowdhury, Naderi et al. 2012).  Thus, it is conceivable that KOS gK cannot efficiently 
complement the McKrae gK-null virus for entry into neuronal axons via fusion of the 
viral envelope with neurites, because of altered interactions between KOS gK and 
McKrae gB.  It is important to note these experiments cannot differentiate whether 
virions entered into neurons but were subsequently unable to be either transported or 
replicated within somatas, since only GFP expression was monitored. In an attempt to 
address this issue, the total viral genomes and infectious virions remaining within the 
axonal termini-containing chambers were determined. In the inoculated chambers, viral 
genome numbers appeared to decrease by up to 45% in the wild-type-like infections with 
no comparable decrease observed with gK-null infections, possibly suggesting that the 
gK-null virions were unable to enter into axons and be removed from the inoculated side.  
This result was not corroborated by the PFU counts, most likely, because of the natural 
decay of infectious virions at prolonged incubation at 37C.  Despite the consistent 




somata, there were no infectious virions recovered from these chambers even at 72 hpi.  
Collectively these results indicate that EGFP expression may be due to transport of DNA 
fragments containing the EGFP gene cassette.  These gene fragments may exist in the 
original virus stocks used for infections, or produced after degradation of endocytosed 
virions into neurons. 
UL20 and gK are required for cytoplasmic virion envelopment and egress in 
epithelial cells (Hutchinson, Roop-Beauchamp et al. 1995; Jayachandra, Baghian et al. 
1997; Melancon, Luna et al. 2005).  Furthermore, direct comparison of the role of gK and 
UL20 in cytoplasmic envelopment, virion egress and infectious virus production with 
similar functions provided by the carboxyl terminus of gD, gE, UL11, or gM have 
revealed that gK and UL20 are more important than each of these proteins alone or in 
combination (Chouljenko, Kim et al. 2012).  In agreement with these known functions of 
gK, lack of gK drastically inhibited transmission of virus from somata-containing 
chambers to axonal termini embedded within VK302 cell monolayers.  Neurons, unlike 
epithelial or fibroblasts have an intricate distribution of cytoplasmic organelles within 
somata and axons.  Specifically, TGN derived-membrane vesicles migrate to synapses 
and play important roles in synapse formation among neurons (Sytnyk, Leshchyns'ka et 
al. 2004).  Therefore, it is conceivable that cytoplasmic envelopment of virions occur 
within both somata and via budding into TGN-derived vesicles proximal to synaptic 
membranes. 
Apparently, both ∆gK virions grown on Vero or VK302 cells appeared to infect 
somata with approximately similar efficiencies indicating that lack of gK does not 




Neurons are known to express nectin-1, which binds gD and functions in virus entry 
(Richart, Simpson et al. 2003; Simpson, Manchak et al. 2005).  In agreement with these 
published results, we readily detected nectin-1 expression in neuronal termini, axons and 
somata (not shown).  Thus, an altered distribution of nectin-1 between neurites and somas 
are probably not responsible for the lack of gK-null virus infection of neuronal termini.  
Nectin-1 is known to primarily mediate endocytosis of virions rather than fusion of the 
viral envelope with cellular membranes (Milne, Nicola et al. 2005).  Thus, it is possible 
that virions enter into neurites primarily via membrane fusion suggesting that gK 
functions in virus-cell membrane fusion utilizing cellular receptors other than nectin-1.  
Herpes simplex virions have evolved a highly complex system for optimum 
infection of neurons, the ultimate destination of the virus in the human host.  It is 
conceivable that virus entry into neuronal synapses via transmission of virus through 
epithelial neuronal synapses, or via infection of axonal termini requires the presence of 
gK.  We hypothesize that gK, known to interact with the amino terminus of gB, may 
modulate fusogenic activity of gB via specific gB cellular receptors.  Lack of gK may 
result in loss of critical regulatory functions provided by gK on gB to mediate fusion of 
the viral envelope with synaptic membranes resulting in inability to enter into axons, or 
entry and subsequent degradation of virions within lysosomal compartments.  Direct 
visualization of fluorescent virions via specially equipped fluorescent microscopes may 
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 Earlier work in our laboratory has shown that HSV-1 glycoprotein K (gK) is not 
essential for virus entry into cells, but is essential for virus spread in cell culture. 
Glycoprotein K-null mutant viruses form very small viral plaques typically consisting of 
less than 10 infected cells per plaque (Jayachandra, Baghian et al. 1997; Melancon, Luna 
et al. 2005).  This phenotype is the result of gK’s critical role in cytoplasmic virion 
envelopment presumably occurring at trans-Golgi network (TGN) membranes (Foster, 
Melancon et al. 2004a; Foster, Melancon et al. 2004b; Foster, Chouljenko et al. 2008).  A 
similar viral phenotype had been described for pseudorabies virus (PRV) indicating that 
HSV-1 and PRV gK function in a similar fashion in viral morphogenesis and egress in 
tissue culture (Klupp, Baumeister et al. 1998).   
 In vivo work with PRV indicated that gK was essential for virus spread in cell 
culture, but it was not essential for neuroinvasiveness (Flamand, Bennardo et al. 2001).  
To investigate whether HSV-1 gK was essential for neuroinvasiveness and disease 
causation, we performed the experiments detailed in chapter 2 of this dissertation.  Using 
a mouse eye model, we established that HSV-1 gK is essential for spread in the cornea 
during primary infection.  No clinical symptoms and very low levels of virus were found 
in gK-null virus infected mouse eyes, which correlated well with data from cell culture, 
in that HSV-1 can infect without gK but the infection is scant at best with no ability to 
spread.  For our studies, we used the McKrae strain of HSV-1.  This strain was initially 




highly virulent in the eyes and neural tissues of mice and rabbits and, therefore, served as 
an excellent standard to judge manipulations that resulted in reduced pathology (Perng, 
Thompson et al. 1995; Perng, Chokephaibulkit et al. 1996; Halford, Balliet et al. 2004).   
 Following infection of mouse eyes with HSV-1, virus replication occurs initially 
in the corneal epithelium, and subsequently the virus is transmitted via epithelial-
neuronal interfaces to neurons.  Virions are thought to move in the retrograde direction 
within axons to neuronal soma where they establish latency (Cunningham, Diefenbach et 
al. 2006; Diefenbach, Miranda-Saksena et al. 2008).  To determine the neuroinvasiveness 
of the gK-null mutant virus, mice that were infected in the corneas were monitored for 
survival and symptoms of neurologic disease.  The eye is a good model for neural 
transmission because the eye cornea is a highly innervated tissue with a high density of 
nociceptors per square millimeter and thus, efficient, ready access to the nervous system 
(Muller, Marfurt et al. 2003).  Clinical disease symptoms absolutely paralleled the 
observed infection patterns with the MK∆gK infected eyes exhibiting no clinical signs at 
any time point following viral infection, while the rescued virus produced significant eye 
disease by day 4 post infection.  Furthermore, neuroinvasion was confirmed due to the 
development of severe neurologic symptoms and death in rescue inoculated mice.  
Significantly no clinical eye disease or neurologic symptoms were observed in the gK-
null inoculated mice.   
 The final test of virulence and transmission was to determine whether the gK-null 
viruses could cause retrograde spread to the sensory ganglia and establish latent infection 
in the periphereal nervous system. With the efficiency of neuronal infection and 




infection should result in latent infection.  Thirty days after infection of the eyes, 
trigeminal ganglia from infected mice were cultured to isolate reativated HSV-1.  No 
reactivation could be found in mice infected with the gK-null virus, but mice infected 
with the rescue strain had abundant reactivation.  To provide greater certainty, the 
ganglionic tissues were also examined by PCR for HSV-1 DNA.  HSV-1 DNA was very 
rarely present in the ganglia of gK-null infected mice.   
 These results taken together, provide stong evidence for gK as a critical 
determinant of spread, pathogenesis, neuroinvasion, and the establishment of latency.  
These results are substantially different from the results reported for PRV. To better 
characterize these disparate results, it was decided that this infection process should be 
evaluated in a primary neuron cell culture system to eliminate confounding factors that 
are present in animal models.  To that end, a primary neuronal culture system was 
developed.  This system was developed using dorsal root ganglionic neurons from rats.  
These ganglia provide sensory neurons, which are the primary neuronal target of HSV-1.  
Use of neurons, allowed us to separate the phenomena of retrograde and anterograde 
transport in a more definite way than is possible in a live animal model.  This was 
important because PRV glycoproteins gE and gI are required for anterograde transport, 
but not retrograde transport (Card, Whealy et al. 1992; Jacobs, Mulder et al. 1993; Babic, 
Klupp et al. 1996; Johnson, Webb et al. 2001; Brittle, Reynolds et al. 2004; Ch'ng and 
Enquist 2005).  And HSV-1 gE has been reported to function in both retrograde and virus 
spread from epithelial cells to neurites but was not required for direct infection of neurites 




Wang, Tang et al. 2005; Brittle, Wang et al. 2008; McGraw and Friedman 2009).  Clearly 
these processes have different interacting proteins. 
 The experiments contained in chapter 3 use the primary neuronal culture system and our 
gK-null mutant viruses to demonstrate that gK is a critical determinant in infection at the level of 
the neurite/axonal process.  Viruses without gK could infect and apparently replicate in neurons 
that were infected at the level of the cell body, however, this virus could not be transported in the 
anterograde direction or be released to infect adjacent cells.  Although a number of viral 
glycoproteins have been implicated in efficient egress of virions from non-neuronal cells, their 
role in neuronal transport has not been studied extensively (Mettenleiter, Klupp et al. 2009).  The 
findings of this dissertation suggest a possible similarity between the role of gK in neurons and 
non-neuronal cells.  The infection phenotype observed in neurons recapitulates in many ways the 
infection observed in non-neuronal cultures.  Herpes simplex virions have evolved a highly 
complex system for optimum infection of neurons, the ultimate destination of the virus. It is 
conceivable that virus entry via transmission of virus through epithelial neuronal synapses, or 
direct infection of axonal termini requires the presence of gK.   
 UL20 and gK are required for cytoplasmic virion envelopment and egress in 
epithelial cells (Hutchinson, Roop-Beauchamp et al. 1995; Jayachandra, Baghian et al. 
1997; Melancon, Luna et al. 2005).  Lack of gK drastically inhibited transmission of 
virus from somata-containing chambers to axonal termini embedded within VK302 cell 
monolayers.  Neurons, unlike epithelial or fibroblasts have an intricate distribution of 
cytoplasmic organelles within somata and axons.  Specifically, TGN derived-membrane 
vesicles migrate to synapses and play important roles in synapse formation among 




envelopment of virions occur within both somata and via budding into TGN-derived 
vesicles proximal to synaptic membranes. 
 
CURRENT AND FUTURE WORK 
Neurons are known to express nectin-1, which binds gD and functions in virus entry 
(Richart, Simpson et al. 2003; Simpson, Manchak et al. 2005).  In agreement with these 
published results, we have readily detected nectin-1 expression in neuronal termini, axons and 
somata. In particular, nectin-1 appears to be expressed at or near the synapse of sensory neurons 
(Salinas, Schiavo et al. 2010).  Nectin-1 is known to primarily mediate endocytosis of virions 
rather than fusion of the viral envelope with cellular membranes (Milne, Nicola et al. 2005). 
However, HSV-1 is thought to enter the neuron via viral membrane fusion with the neuron 
plasma membrane (Salinas, Schiavo et al. 2010).  Therefore one area of interest is determining 
the receptor constituents used by HSV-1 as it enters the neuron and the exact entry mechanism; 
e.g. fusion versus endocytosis.  The entry mechanism may have a significant impact on what 
viral proteins accompany the capsid as it enters the neuron cytoplasm and eventually axon.   
Following other work in this lab, this may require extensive investigation in the gB, gK, 
UL20 interactions.  Another area of interest for further investigation is a further refinement of the 
exact domains that influence the virus’ ability to infect and be transported in neurons.  These 
domains may provide additional insights to the complex interactions of the envelope proteins the 
domains responsible for neuroinvasiveness, morphogenesis, egress, and fusion are examined for 
simultaneous functions and higher order interactions with other proteins.  
  As these properties of the virus are determined, this research may bring great advances 




tumor therapy.  The identification of the exact determinants of neuronal infection, transport and 
eventual latency, if combined with the determinant for a robust immune reaction would enhance 
the efficacy and safety of herpes viruses used for therapies or preventative vaccines.  
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DEVELOPMENT OF PRIMARY NEURON CULTURE 
 
CELL SOURCES 
 I attempted to use a variety of different cells as sources for the primary neuronal 
culture system.  These included harvested cerebral cortical cells from mice, commercial 
frozen cortical and ganglionic cells from mice and rats, harvested cortical cells from rats, 
and harvested dorsal root ganglionic neurons from rats.  In addition to the primary cells, 
redifferentiation of neuroblastoma cell lines to a primary cell was attempted.  The 
greatest and most easily reproduced success was with the dorsal root ganglionic neurons 
from the rat. 
When evaluating these potential systems, three main factors were necessary for a 
usable system for our experiments.  The first factor was survival of the neurons in 
sufficient quantity and density to provide a reasonable population for experimentation 
and microscopic visualization.  The second factor was the growth of axons of sufficient 
length to allow the use of a culture system that could physically separate the neuron cell 
body (soma) from the termini of axons (neurites) so we could separate anterograde and 
retrograde transport.  In practice this required an axon to grow to a length of at least 450 
microns before the neuron would die from senescence in prolonged cell culture.  The 
third factor was the development of a robust network of axons and neurites on the axonal 
side of the culture system that would provide a reasonable substrate for infection and 




Redifferentiation of neuroblastoma cell lines is accomplished using retinoic acid 
in varying doses to force the cells to go from an undifferentiated, tumor state to a 
differentiated neuron.  Using this system, we could get the neuroblastoma cells to achieve 
a morphology more similar to a primary neuron rather than a tumor cell-line; however, 
these were unsuitable for our experiments because the axons produced were not 
consistently long enough to be placed in a chamber system that could isolate the axonal 
processes from the cell bodies.  In fact, the morphology of these neurons usually more 
closely resembled the morphology of a cortical neuron with many short dendrites 
surrounding the soma and very rare, short axons when they were present.  Cultures of 
cortical neurons, in all cases, were unsuitable for the same reasons.  Although cortical 
neurons consistently produce dense, hearty neurons the processes are uniformly of 
insufficient length for the purposes of our proposed experiments.  This was found with all 
cortical neuron types, including: commercial, primary harvested, frozen and shipped rat 
or mouse neurons as well as on-site harvested rat and mouse cortical neurons.  
Ganglionic neurons harvested from mice in our lab were also unsatisfactory.  This 
is likely a technical problem that may be overcome; however, in my experience yields 
were insufficient for our experiments.  This is likely due to the extreme difficulty of 
harvesting ganglionic neurons from the neonatal mouse, as the ganglia are very small and 
difficult to visualize.  Using the commercial, primary, frozen rat and mouse ganglionic 
neurons was initially promising with decent density of neurons at plating.  These neurons 
seemed to lack viability as the duration of cultures progressed.  Axonal growth was slow 
and by the time axonal processes were nearing sufficient length, the density of neurons 




By far the most suitable cultures came from dorsal root ganglia of rats.  These 
ganglia are challenging to dissect for primary culture, but not prohibitively difficult like 
mouse ganglia.  One particular challenge to the harvest of a primary cell such as a 
neuron; is that there is significant time lapse from euthanasia of the animal to removal of 
the neural tissue and placement of this tissue in a media that will prevent cell death.  In 
these systems, animals are generally euthanized and then dissection proceeds to the 
ganglia.  After dissection, the ganglia must be enzymatically treated to achieve a single 
cell suspension before addition to a growth medium for plating in a culture system.  I 
found two things to significantly enhance neuron survival, and therefore plating density, 
during this stage.  The use of a dissecting solution, composed of phosphate buffered 
saline supplemented with 3.5 grams per liter of sucrose and 7 grams per liter of glucose, 
for all stages of dissection and enzymatic dissociation greatly influenced neuron survival. 
Also, whenever possible keeping the tissues to be dissected and the dissected ganglia 
cold, as situated in a Petri dish over ice, was helpful.  The method used to produce 
consistent, robust cultures of rat dorsal root ganglia will be covered in more detail next.  
 
PRIMARY RAT DORSAL ROOT GANGLIONIC NEURON HARVEST 
 
Rats 
 Harvesting the ganglia of varying ages of rats was attempted.  All attempts were 
made ranging from embryonic to 7 days after birth.  Neurons harvested from rats between 
3 and 7 days after birth may give initial robust plating densities; however, these neurons 




very poor neuron densities by the time neurons are ready for experimentation.  For our 
experiments we used Sprague-Dawley rats that had a gestation of 21-22 days.  Dorsal 
root ganglia (DRG) neurons from rats ranging from embryonic day 17 (E17) to 48 hours, 
2 days, after birth (P2) provide suitable neurons for abundant plating densities and 
sufficient survival times to allow for axon growth and experimentation.  The only 
difficulty with this age for harvest is that the spinal column has mineralized to a more 
significant degree making removal of the ganglia more time consuming, which can 
contribute to loss of cells if the dissector is not proficient.  For my harvests, the ideal age 
was day 15-16 of gestation (identified as E15-E16 pups).  Any earlier and the tissues 
were too soft to handle without major structural disruption.  At E15-16, once the vertebral 
column is dissected from the spinal cord, the spinal cord can be removed with the DRG 
maintaining their attachment.  Later than E16, the dissection of the vertebrae is easier due 
to greater size and structure of the tissues but the DRG will separate from the spinal cord 
unless careful and time-consuming dissection is performed.  The DRG must be 
individually separated from connections that hold them against the remaining spine. 
 
Dissection and Processing 
 My preferred technique is as follows. First a pregnant rat is euthanized at day 15-
16 of gestation.  The rat is rapidly dissected along the abdominal midline and the uterine 
horns containing the E15-16 pups are placed in conical tubes containing dissecting 
solution that are situated in an ice bath.  The rat pups are dissected from the uterus as 
needed and are otherwise left in the solution in the ice bath.  Using a dissecting 




with sharp-tipped micro-dissection forceps.  These forceps are used to remove all the 
thoracic and abdominal viscera from the pup.  Then micro-dissection, spring scissors are 
used to remove the tail at the pelvis.  Then from the caudal to the cranial end of the pup, 
one tip of the scissors is inserted into the spinal column and the lateral wall of all 
vertebral bodies is cut.  Care must be taken to avoid traumatizing the spinal cord 
excessively.  The best cut is made with the flat cutting axis of the scissors running 
parallel to ribs and the scissors as low as possible to the level of the rib attachments, 
without actually cutting the ribs.  This will usually take several snips to travel the full 
length of the spine.  After making this cut from the tail to the cervical spine near the base 
of the skull, the ventral floor of the vertebral bodies can be removed.  During this process 
rib attachments have usually separated from vertebrae.   At this point, the spinal cord can 
be visualized and the DRG should be visible as small, oval, lumps lying next to the spinal 
cord between and alternating with the remnants of the vertebral bodies or ribs (Fig A.1). 
For the next cut, the cutting axis of the scissors is directed perpendicularly to the 
direction of the ribs.  From the tail to the head, a cut is made longitudinally just lateral to 
the spinal cord on both sides.  The longitudinal cuts should run from the caudal to the 
cranial extremity of the pup, cutting soft tissues and rib attachments just slightly lateral to 
the vertebrae, where the DRG are situated, but leaving the DRG with the spinal cord. 
Then the head is cut from the cervical spine with the scissors.  Using two sets of micro-
dissection forceps, the dorsal remnant of the spine is stabilized against the dissecting 
surface with one hand while the spinal cord is gently pulled up using the other hand. 




 At this point, the spinal cord with the attached DRG, is placed in a Petri dish 
containing dissection solution that is on ice (Fig A.1).  The dissection process can be 
repeated to increase the number of ganglia.  Care must be taken to balance a large harvest 
with the time taken to remove the ganglia, as the percentage of neurons that will not 
survive increases with increasing time to placement in media.  I usually harvest between 
10 and 15 pups, trying not to take longer than 90 minutes for the harvest step.  Once 
spinal cords with attached ganglia are collected in a petri dish, the individual ganglia are 
dissected from the spinal cords using either micro-dissection scissors or a small scalpel 
blade.  Spinal cords are discarded.  Using a glass pipette, ganglia are suctioned and 
placed in a 15 ml conical tube with approximately 2 ml of dissection solution.  Care must 
be taken to prevent excessive adherence of ganglia to the sides of the glass pipette.  Some 
dissection protocols recommend pre-coating the inside of the glass pipette with serum 
prior to suctioning a tissue that may adhere.  I avoid this because serum is also used to 
inactivate the trypsin that will be used to enzymatically digest the tissues in the next step. 
I have found a quick pre-pipette of dissection solution can help.  Also pipetting quickly in 
multiple batches is preferable to allowing the ganglia to sit in the barrel of the pipette for 





Figure A.1: Pictures of primary neuron harvest from embryonic rat dorsal root 
ganglia.  For all pictures, rats at 4 days post birth were used to enhance visualization of 
pertinent tissues.  A:  The spinal cord can be observed following the removal of the 
ventral segments of the vertebral bodies.  Black arrows designate the positions of the 
DRG interspersed between the remnants of the attachments of the ribs and the remaining 
vertebral body tissue.  B:  Higher magnification of the spinal cord, DRG, and vertebrae.  
The position of the DRG are denoted by black arrows.  Note DRG are slightly less shiny 
and more translucent appearing than the adjacent bone and cartilage.  C:  A 35 mm petri 
dish filled with dissection solution, containing several spinal cords that have been 
removed with the DRG attached.  At this magnification, DRG are just visible as small 
nodules slightly protruding from the sides of the spinal cords.  D:  Higher magnification 
of a segment of a spinal cord with DRG attached.  White arrows demonstrate the DRG as 





 Once ganglia are in the conical tube, trypsin is added at a final concentration of 
0.25 mg/ml.  Ganglia are placed in a 37 degree Celsius water bath for 45 minutes, 
swirling every 5 minutes to agitate.  Trypsin may be diluted to stock concentrations using 
dissection solution and stored for at least 6 months at -80 degrees Celsius.  Once ganglia 
have incubated for 45 minutes, allow to sink to the bottom of the tube by gravity for 1-2 
minutes.  Pipette off excess enzyme solution.  The next step neutralizes trypsin, therefore, 
leaving some is preferable to removing more than a few ganglia when removing the 
enzyme solution.  For neutralization of trypsin and plating of neurons, neuronal media 
(recipe will be included later) supplemented with 10% fetal bovine serum (FBS) is used. 
This will be referred to as plating media.  Add approximately 2 ml of plating media to the 
tube, swirl, and allow ganglia to settle by gravity for 1-2 minutes.  Remove media by 
pipetting and repeat this neutralization step twice more to ensure full rinsing and 
neutralization of trypsin.  Add the plating media to a final volume of 2 ml on the ganglia. 
Using a glass Pasteur pipette, pipette up and down to agitate the ganglia to make a single 
cell suspension.  A fired, pulled pipette may be used for a more narrow diameter that will 
provide greater turbulence and agitation but these are usually not necessary.  The opening 
of the pipette can be placed against the bottom of the tube to restrict flow and give greater 
turbulence as well.  The solution should rapidly become cloudy.  At this stage the tissues 
are very soft and should dissociate fairly easily with 10 or less pipettings.  Neurons are 
also fragile at this point and exceedingly vigorous pipetting can cause cell death.  
 Once a single cell suspension is achieved, a sample should be taken to count the 




the 2 mls of plating media.  While counting cells, centrifuge the neuron suspension to 
form a pellet.  Centrifuge at 400 times gravity or less for 5 minutes.  Remove supernatant 
taking care to not disturb the cell pellet.  Resuspend the cells in a small amount of 
residual media.  Using the cell count obtained earlier, calculate the total number of live 
cells and dilute to the desired plating concentration using plating media.  I usually plate 
between 60,000 and 100,000 cells, with 75,000 cells being a good average to achieve the 
desired plating for our neuronal devices.  It is important to note that not all of these are 
neurons.  Although I have not performed specific counts, I suspect half or less of the total 
cell amount is neurons.  From a harvest of the ganglia from 12 pups, I can usually 
achieve approximately 4 million total live cells.  
 After dilution to the desired concentration, neurons may be plated.  For our 
neuron devices, the SND450 from Xona Microfluidics (more information in Materials 
and Methods section of second data chapter), a pipetting volume of 12-15 microliters is 
necessary for use with the device.  The central chamber of interest only holds 
approximately 1 microliter but it is impossible to pipette a single microliter in a manner 
that fills the chamber without significant and disruptive air bubbles.  Therefore, I plate at 
a concentration of 5,000 cells per microliter.  Allow the neurons to adhere to prepared 
surface (instructions on preparing a substrate to follow) for 15 min to 1 hour, then fill 









Neuron Medias and Maintenance 
 Unless otherwise specified, the neuronal media used is as follows (suppliers and 
more information included in Materials and Methods of the second data chapter):  Neural 
basal media supplemented with 1 X B27 supplement, 1% Glutamax, 2% normal rat 
serum, 2% Primocin and 50 nanograms per milliliter neural growth factor 2.5s.  For the 
plating and neutralizing media used during dissection, this media is further supplemented 
with 10% FBS.  I have found that plating with this media enhances neuron attachment, 
survivability, and axon growth.  Generally neurons grow best using a system of removing 
half the current media and replacing with fresh, not full media changes.  Therefore, the 
only full media changes occur when adding or removing anti-mitotic agents.  Twenty-
four hours after plating, an anti-mitotic agent must be added to the culture.  These agents 
enrich the culture for neurons.  All other cultured cell types will attempt to divide in 
culture.  The addition of these agents inhibits division causing the other cells (namely 
astrocytes and glial cells with some fibroblasts) to die and be removed from the culture 
with successive media changes.  At 24 hours post plating, neuronal media, supplemented 
with 5 micromolar cytosine-β-d-arabinofuranoside (CAB), is added to the culture.  At 48 
hours post plating, this media is removed and replaced with normal neuronal maintenance 
media.  At 72 hours post plating, neuronal media, supplemented with 2 micromolar CAB, 
is added to the culture.  At 4 days post plating, this media is removed and replaced with 
normal neuronal maintenance media.  Successive media changes all occur with 




metabolic state and needs.  Unless necessary to maintain proper pH, only half of the 
media should be changed.  
 With this plating strategy, large numbers of neurons are placed into the central 
chamber (the area of interest) of the neuron devices.  Primary neurons in cell culture tend 
to aggregate especially when densely cultured.  Neurons also tend to grow processes in 
an attempt to build a significant network of interconnections with neighboring cells.  A 
serendipitous side effect of the anti-mitotic agents is that they will help prevent this 
somewhat.  Large numbers of neurons are also present in the wells.  These neurons are 
very dense and are more likely to cause aggregation of chamber neurons to the well than 
contribute to the area of interest.  To prevent this, the neurons in the device chambers can 
be vacuumed out during the early media changes as long as care is taken to avoid 
disrupting the central chambers.  In practice, this seems to also stimulate additional 
growth across the microgrooves to the axonal side of the chamber; likely as the neurons 
attempt to find connections that would have been preferentially diverted toward the wells 
if many neuron somata were in the wells.  Once established, neuron cultures are rather 
stable and will grow robust interconnected axons within 1-2 weeks post plating.  At this 
point they are ready for use in an experiment.  
 During the course of developing the culture system, maintenance media and 
plating media went through many permutations.  There are reports of various 
neurotrophic factors enhancing axonal development, particularly in enhancing directional 
growth.  In my experience, the use of brain derived neurotrophic factor, glial cell derived 
neurotrophic factor, and ciliary neurotrophic factor did not provide a substantial benefit 




enhanced directional axonal growth to some degree, however, this was not sufficient to 
overcome the negative effects.  It appeared that the use of these factors in concentrations 
sufficient to stimulate some growth, also stimulated increased migration of cells through 
the microgrooves.  This is highly problematic, since it must be definitively determined 
that these are not neurons or the integrity of the anterograde versus retrograde state of the 
device is suspect.  Some of these devices were tested and I was able to confirm neuron 
migration post plating through the microgrooves (or possibly under the device as a 
whole) as a consequence of this treatment.  We also attempted to use varying 
concentrations of neural growth factor to stimulate growth, as axons will tend to grow 
toward the high side of a gradient.  In the devices we were using this was similarly 
dissapointing.  Once again, there seemed to be minimal increase in directional axonal 
growth with increased cellular migration to the non-plated side.  
 
Reporter Cell Co-Culture 
 If a reporter cell culture is desired, to simulate an epithelial-axonal interface as 
might be found in an animal, cell-line cultures may be co-plated over the axons.  Once 
the axon density on the axon side of the chamber is at the desired level, cells such as 
Vero or VK302 cells may be co-plated.  To plate these over the axons, cells grown to a 
confluent monolayer are trypsinized as normal for splitting of the cells.  Once trypsinized 
and disrupted to a single cell suspension, trypsin is neutralized with 100% FBS.  Then the 
cells in the FBS are centrifuged to produce a cell pellet.  Cells are resuspended, diluted in 
media and plated by filling the wells of the axon side with this media.  For the Vero and 




150 microliters of that used for plating per well (so 300 microliters for a device with two 
wells on the axon side).  The media used for this purpose is a one-to-one ratio of our 
standard Vero cell media and neuronal media supplemented with a final concentration of 
10% FBS.  Our standard Vero or VK302 cell media consists of Dulbecco’s modified 
eagle media supplemented with 20 micromolar HEPES buffer.  Plated cells in the axon 
chamber often do not grow well beyond the initial plating.  To provide more access to 
nutrients, cells in the wells may be suctioned out the day after plating, similar to neurons.  
 
Setting up Neuronal Devices and Substrates for Plating Neurons 
 Neuron devices are commercially available polydimethylsiloxane chips that have 
been shaped using laser lithography.  These devices were described previsously in the 
neuronal transport chapter.  Briefly, when placed on a coverslip or Petri dish, they can 
create a chamber with that allows culture of neurons and growth of axons to a second 
chamber that is functionally impermeable to virus by diffusion.  This type of chamber 
allows the study of retrograde and anterograde transport separate from one another. 
Neurons may be plated on glass coverslips or directly on plastic Petri dishes that will act 
as the floor of these chambers.  In either case neurons grow best with the least clumping 
using a dual coating of poly-D-lysine and laminin.  However, with a laminin coated 
substrate, axonal growth seems more aggressive and neurons are much more likely to 
penetrate under a neuron device.  The virus impermeable barrier can only be guaranteed 
if axons only grow through the device microgrooves and growth under the device as a 
whole disrupts this barrier.  Lysine only coated surfaces seem to have a failure rate of 




 To prepare a substrate, whether glass or plastic, poly-D-lysine, at a concentration 
of 0.1-0.25 milligrams per milliliter in borate buffer, is placed on the substrate and 
incubated at 37 degrees Celsius.  For a lysine only coating, this is best done for 48 hours 
prior to use.  For a dual coating, lysine is allowed to coat the substrate for 24 hours.  Then 
the substrate is washed 5 times with sterile water and laminin, at a concentration of 0.01 
milligrams per milliliter in borate buffer, is placed on the substrate for 24 hours at 37 
degrees Celsius.  After coating with either method, the substrate is washed 5 times with 
sterile water and allowed to dry completely but not excessively.  Ideally the substrate 
should be assembled with the neuron device within 30 minutes of fully drying.  Neuron 
devices are prepared by treating with an ethanol soak followed by rinsing 5 times with 
sterile water and fully drying.  Once substrate and neuron device are dry, a device is 
pressed very firmly onto the substrate to ensure a complete seal.  It is recommended that 
when using glass coverslips a very flat, sterile, surface is used, otherwise coverslips may 
crack from unequal pressure during this step.  Very aggressive pressure can help to make 
laminin coated substrated less likely to fail; and in a recent experiment the failure rate 
with extensive pressure was below 20%.  Once the device and substrate are assembled, 
they should be placed in a humidified incubator to prevent excess dehydration of the 
laminin.  Prepared devices should be plated with neurons the same day as they are 
prepared but lysine coated devices can be used with some success after 1-2 additional 
days if necessary.  When devices are ready for an infection, as determined by sufficient 
axonal growth and branching and reporter cell culture if desired, media levels must be 
adjusted to maintain barrier.  The side being infected should always have a lower fluid 




the “high” side is recommended at this time, since following the addition of virus, only 
addition of media, not removal and change, is recommended to avoid accidental loss of 
fluid pressure gradient.  Media may be added to either side to combat dehydration as long 
as gradient is maintained.  See schematics of neuron devices with fluid pressure gradients 
demonstrated (Fig A.2).  A scale model of a cross section of a single microgroove with 
representations of the sizes for the HSV virion particle, a typical dorsal root ganglionic 
neuronal axon, and a typical dorsal root ganglionic neuronal soma are provided for 







Figure A.2: Microfluidic Neuron Device.  A:  Picture of a microfluidic neuron device 
containing media in a 35mm Petri dish.  B:  Three dimensional wire-frame, side view 
schematic of wells, central chamber and microgrooves of microfluidic device.  The 
microgrooves are 3 microns tall by 10 microns wide and 450 microns long.  The central 
chambers that connect same side wells (only one well from each side shown in this 
schematic) are 100 microns high by 1.5 mm wide and 7 mm long.  Wells are 8 mm in 
diameter.  C:  Color schematic, top view, of a retrograde setup.  D:  Color schematic, top 







Figure A.3: Scale model of the cross section of a microgroove in a microfluidic 
neuron device.  Scale side view schematic of the cross section of a microgroove from a 
microfluidic neuron device. The microgrooves are 10 x 3 microns (width x height) and 
450 microns long.  There are scale appropriate size examples of an average dorsal root 
ganglion cultured axon with a diameter of about 1 micron and the range of the HSV virus 
particle with a reported 120-300 micron diameter.  For comparision, on the bottom: In 
one study, that characterized cultured DRG’s, neuronal cell bodies ranged from 20-50 
microns for the cell body diameter.  The smallest of these soma diameters is represented 
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